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ABSTRACT
Inositol 1,4,5-trisphosphate [Ins(l,4,5)P3] is a well characterised second messenger 
produced by phosphoinositide hydrolysis, which triggers Ins(l,4,5)P3 receptor-mediated 
Ca2+ release from intracellular Ca2+ pools. Ins(l,4,5)P3 is rapidly metabolised in cells by 
various phosphatases and kinases with various inositol phosphates produced as a result. 
The di-equatorial 4,5-bisphosphate structure of the molecule together with the flanking 
position-6 hydroxyl group, are now recognised as necessary features for the productive 
interaction of Ins(l,4,5)P3 with its receptor and metabolic enzymes.
Over the past decade, aberrations at various stages of the signalling pathway resulting in 
alterations in calcium signalling have been increasingly observed in a variety of disease 
states, including various cancers. These findings have prompted interest in the synthesis 
of Ins(l,4,5)P3 analogues designed to intervene the polyphosphoinositide signalling 
pathway as specific enzyme inhibitors and receptor partial antagonists.
The common theme of the work covered in this thesis is the effect of stereochemical 
modification of the Ins(l,4,5)P3 molecule on the interaction with its related proteins, in 
particular the Ins(l,4,5)P3 receptor. The aim is to distinguish an inositol phosphate 
structure which retains the high affinity for the receptor but loses its efficacy as an 
agonist, thus interrupting the signalling process.
The meso compound «eo-inositol-l,3,4,6-tetrakisphosphate was synthesised to 
determine the binding orientation of the previously reported partial agonist myo- 
inositol-l,3,4,6-tetrakisphosphate. Two analogues of the latter tetrakisphosphate, 
namely DL-weo-inositol-1,3,4-trisphosphate and the corresponding trisphosphorothioate 
were synthesised to study the biological effect of stereochemical inversion of the three 
hydroxyl substituents of the Ins(l,4,5)P3 molecule and any differences that 
phosphorothioate substitution together with these configurational inversions may have. 
These compounds were made from the same key intermediate DL-l,4,6-tri-Oallyl-2,3- 
O-isopropylidene-wyo-inositol and are the first neo-inositol phosphates synthesised to 
date. DL-e/?/-inositol-1,3,6-trisphosphate was synthesised via the Swem oxidation and 
subsequent borohydride reduction of the key intermediate DL-1,4,5-tri-(9-allyl-2,3-di-0- 
benzyl-myo-inositol, and can be visualised as Ins(l,4,5)P3 with its position-6 hydroxyl 
group inverted. No reports of an e/?/-inositol phosphate have yet appeared in the 
literature. A new rapid route to a//o-inositol from L-quebrachitol is also described, as is 
the synthesis of DL-tf//o-inositol-l,3,6-trisphosphate, a mimic of Ins(l,4,5)P3 with its 
position-3 and -6 hydroxyl groups inverted.
DL-weo-inositol-1,2,4-trisphosphate and DL-tfy/o-inositol-1,2,5-trisphosphate each 
presents an axial position-5 phosphate and a position-4 phosphate respectively, in place 
of the di-equatorial 4,5-bisphosphate system of Ins(l,4,5)P3. These compounds were 
prepared via the key intermediate DL-1,4-di-O-benzyl-2,3-0-isopropylidene-/?ryo 
inositol which was also resolved to provide the key compound in the synthesis of D- 
my<9-inositol-2,3,5-trisphosphate and D-wyo-inositol-2,3,6-tnsphosphate. These two 
compounds are also mimics of Ins(l,4,5)P3 with inversions of configuration at each of 
the phosphate groups of the 4,5-bisphosphate motif of Ins( 1,4,5 )P3 .
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The fossil records of today suggest that unicellular organisms resembling present day 
bacteria were present on earth 3.5 billion years ago but that it apparently required more 
than another 2.5 billion years for the first multicellular organisms to appear. Why was 
multicellularity so slow to evolve?
Although the answer cannot be known, it may perhaps be related to the need of 
multicellular organisms for elaborate signalling mechanisms that would enable its cells 
to communicate with one another so as to co-ordinate their behaviour for the benefit of 
the organism as a whole. Intercellular signals, interpreted by complex machinery in the 
responding cell, allow each cell to determine its position and specialised role in the 
body and ensure, for example, that each cell divides only when its neighbours dictate 
that it should do so. The importance of such “social controls” on cell division become 
apparent when the controls fail, resulting in cancer, which usually kills the multicellular 
organism.
1.2. First and second messengers
Intercellular communication is carried out by a range of extracellular signalling 
molecules or first messengers, which include hormones, neurotransmitters and local 
mediators. Small hydrophobic signalling molecules, such as steroids and thyroid 
hormones, are able to pass through the cell membrane and activate receptor proteins 
within the cell but the vast majority of signalling molecules are hydrophilic and are 
prevented from entering the cell by the lipid bilayer of the plasma membrane. Instead, 
they bind to receptors on the cell surface and this interaction with the receptor somehow
causes the production or release within the cell of a second messenger which effects a 
cellular response.
lD-7wyoinositol 1,4,5-trisphosphate [Ins(l,4,5)P3], was reported to have a second 
messenger function in 1983.1 Since then, its production, metabolism, and interaction 
with intracellular proteins to release stored calcium have all been extensively 
investigated.2"6 It is through the regulation of intracellular Ca2+, that Ins(l,4,5)P3 
functions to regulate so many cellular processes.
1.3, Ca2+ signalling
Calcium is the most common signal transduction element in cells. Control of muscle 
contraction and neurotransmitter release are now obvious examples, but Ca2+ has been 
implicated in many other processes, including synaptic plasticity, cell proliferation and 
cell death.7
Unlike many other second messenger molecules, Ca2+ cannot be metabolised, so cells 
have developed the mechanics to regulate intracellular levels through numerous binding 
and specialised extrusion proteins. Normal intracellular Ca2+ concentrations are about 
lOnM, which is 20,000 fold lower than the 2mM concentration found extracellularly. 
Why has evolution granted this divalent ion such supremacy? Sea-water magnesium, 
after all, is higher in concentration than Ca2+. One likely argument for the uniqueness of 
Ca2+ is that it must be maintained at low levels since it precipitates phosphate, the 
established energy currency of cells.
Cells evolved strategies for binding Ca2+, perhaps at first simply to reduce their 
cytosolic levels but later for signal transduction. By exploiting these Ca2+ gradients, 
mechanisms developed that could allow small amounts of Ca2+ to flow back into the 
cytosol, either from the outside or from intracellular sequestering compartments, under 
the control of variables such as changes in membrane potential or extracellular stimuli.
Proteins that originally functioned as Ca2+ buffers took on more specialised signal
2+
transduction roles, involving conformational changes triggered by the binding of Ca 
and Ca2+-binding motifs became incorporated into many different proteins.8 
We now know that the mechanisms of influx and efflux of Ca2+ to and from the cytosol 
are organised so as to generate brief pulses of Ca2+ which often recur to give trains of 
repetitive spikes. In addition, each spike can be organised as a wave, in that the Ca2+ 
signal initiates in one region of the cell and spreads in a regenerative manner through a 
process of calcium-induced calcium release.
The full significance of these complex spatiotemporal patterns remains to be 
determined. One intriguing possibility is that the generation of spikes may indicate that
74-Ca signalling is based on a digital system with information being encoded through 
frequency rather than amplitude. Some support for a frequency modulated (FM) system 
has come from numerous observations that the frequency of Ca2+ spiking varies with 
hormone concentration.9’13 A major challenge for the future is to understand first the 
encoding mechanism responsible for generating Ca2+ spikes, and then to find out how 
the cell decodes these digital signals into changes in the activity of specific processes.14 
Perturbations of Ins(l,4,5)P3 levels during agonist- induced Ca2+ oscillations have 
recently been reported.15
1.3.1 Ca2+ Sources
Cells have access to two major sources of Ca2+; extracellular and organellar. Since the 
Ca2+ concentration outside the cell is 20,000-fold greater than inside, there is a large 
electrochemical gradient favouring Ca2+ entry. This gradient is exploited by some small
74 -cell types to drive a rapid influx of Ca .
Additionally, many cells use Ca2+ sequestered within the endoplasmic reticulum (ER) 
or sarcoplasmic reticulum (SR) in muscle cells. These two sources of Ca2+ can be used
4either separately or in combination. The ON mechanisms of Ca2+ signalling depend 
upon the activation of Ca channels that control either the entry of extracellular Ca , 
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Figure 1.1. A summary of the major ON and OFF mechanisms responsible for 
regulating the intracellular [Ca2+].
Stimuli raise the level of Ca2+ by activating the ON mechanisms which promote either 
the entry of external Ca2+, or the release of Ca2+ from intracellular stores (ER/SR). 
Changes in [Ca2+] are damped by buffers located both in the cytoplasm and in the 
ER/SR compartments. The OFF mechanisms restore the low level of Ca2+ by either 
pumping it out of the cell, or back into the stores. The effects of an elevated [Ca2+] are 
mediated by sensors such as calmodulin (CAM) or troponin C (TnC), to regulate a wide 
range of cellular functions.17
51.4. Plasma membrane Ca2+ channels
The plasma membrane contains a variety of channels capable of regulating the influx of
9 +external Ca , which have been named according to the way in which their channel 
activities are controlled.18’19
1.4.1 Voltage operated channels (VOCs)
VOCs are found primarily in excitable cells (nerve, muscle and certain endocrine cells), 
where they open in response to membrane depolarisation and allow extracellular Ca 
to enter the cell.19,20 These channels can be regulated by both receptor mediated and 
intracellular (e.g. cyclic AMP ) systems.21
1.4.2 Receptor operated channels (ROCs)
ROCs are activated by the binding of extracellular agonists, usually neurotransmitters, 
e.g. glutamate and ATP. A classical example of ROCs are the N-methyl-D-aspartic acid 
(NMDA) receptors which open in response to glutamate, to gate Ca2+ entry. The Ca2+ 
entering neurones through NMDA receptors plays an important role in modifying 
synaptic plasticity.
1.4.3 Ca2+-release activated Ca2+ channels (CRACs)
The plasma membrane also contains channels that are controlled indirectly by the state
9 *
of fullness of the ER Ca store, through a mechanism known as capacitative calcium 
entry (CCE).18'22'2^
In this scheme, the ER Ca2+ stores behave like a capacitor in that they inhibit Ca2+ entry 
when they are fully loaded but, as they discharge, they begin to open calcium-release
94 -activated channels. The mechanism by which Ca stores modulate CRACs in the
6plasma membrane is unclear. One suggestion is that the empty Ca2+ stores release a 
messenger, referred to as calcium influx factor (CIF),25 a small phosphorylated anionic 
molecule (Mr<500),which diffuses through the cytoplasm to the plasma membrane and 
opens the CRACs, allowing the flow into the cytoplasm of a calcium-release-activated 
calcium current (1^), and thus replenishing the [Ca24].26 1 ^  has been shown to be 
highly selective for Ca2+, non voltage dependant and linked to the depletion of 
intracellular Ca2+ stores. Neither Ins(l,4,5)P3 or Ins(l,3,4,5)P4 are required for its 
activation.27
A more recent report, however, claims the existence of a highly selective Ins(l,4,5)P3 
activated Ca channel in the plasma membrane of A431 carcinoma cells, whose 
activity is not attributed to store depletion.28 The significance of this finding is awaited 
with interest.
An alternative model by which Ca2+ stores modulate CRACs, known as conformational 
coupling, suggests that Ins(l,4,5)P3 receptors can somehow “sense” the Ca2+ content of 
the ER stores and can transmit this information via a direct protein-protein interaction 
to the channels in the plasma membrane.29,30
1.5. Intracellular Ca2+ channels
There are two main families of intracellular channels responsible for releasing Ca2+ 
from intracellular stores; Ins(l,4,5)P3 receptors (InsP3Rs) and ryanodine receptors 
(RyRs).31 These two receptors probably evolved from a common protein ancestor, as 
they display considerable similarity in primary and secondary structure and share 
several physiological properties. A third type of intracellular Ca2+ channel, gated by 
sphingolipids, has been characterised. It has been suggested that the natural ligand may 
be sphingosine-1-phosphate (SIP).32,33
71.5.1 Ryanodine receptors (RyRs)
RyRs were first identified in muscle cells and were named due to their strong affinity 
for the plant alkaloid, ryanodine. They are now known to function in Ca2+ signalling in 
a wide variety of cell types,34-36 sharing a common functional Ca2+ pool with 
Ins(l,4,5)P3 receptors.37 Molecular studies have identified a family of RyRs which have 
tissue specific expression and activation mechanisms.
Table 1. Ryanodine receptor isoforms. 














The Type-1 isoform ( RyR 1 ), found primarily in skeletal muscles, is activated by 
depolarisation of transverse tubules and is thus important for excitation-contraction 
coupling of skeletal muscle. The bulbous head of the RyR 1 seems to interact through 
conformational coupling with the dihydropyridine receptor, which is the voltage sensor 
of the T-tubule membrane. The RyR 2, found mainly in cardiac muscle can also be
2"bopened by depolarisation of the cell membrane but is stimulated by a pulse of Ca .
2 | 2 jCa thus triggers its own release, in a positive feedback manner. This process of Ca -
2 “b  2 "binduced Ca release (CICR), as already mentioned, is of central importance in Ca
signalling, and is a property of ryanodine receptors and Ins(l,4,5)P3 receptors. A single 
mutation in the RyR 1 (Arg 615 to Cys ) seems to be responsible for malignant
9+hyperthermia, in which over-sensitivity of the receptor to Ca leads to uncontrolled 
CICR, resulting in muscle spasms and potentially fatal overheating.
As the phenomenon of CICR is increasingly seen as fundamental to the whole process
9-4-of Ca signalling, it may be more instructive to regard Ins(l,4,5)P3 receptors and 
ryanodine receptors as two related families of CICR channels, the former of which is 
known to be modulated by Ins(l,4,5)P3 . The latter is modulated by cyclic adenosine 
diphosphate ribose (cADPR),39’40 a metabolite of nicotinamide adenine dinucleotide 
(NAD)+, which triggers Ca2+ release through ryanodine receptors by sensitising them to 
CICR.
Figure 1.2. Cyclic ADP-ribose, a metabolite of nicotinamide adenine dinucleotide.
NH
P— O
This display of CICR is of particular significance to the spatiotemporal aspects of 
calcium signalling. It accounts for the ability of both receptor families to generate 
calcium spikes and waves, as Ca2+ released from one receptor is able to excite its 
neighbours, thereby igniting a regenerative wave capable of sweeping through the 
cytoplasm.8
1.6. The formation of Ins(l,4,5)Pi and DAG.
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In response to many stimuli, such as neurotransmitters, hormones and growth factors, 
Ins(l,4,5)P3 and diacylglycerol (DAG) are formed by hydrolysis of an inositol lipid 
precursor phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2], stored in the plasma 
membrane. This hydrolysis is effected by a phosphodiesterase of the phospholipase C 
(PLC) type.
Figure 1.3. Phospholipase C-catalysed hydrolysis of PtdIns(4,5)P2.










Phospha t idy Iinositol-4,5-bisphosphate inositol-1,4,5-trisphospha te
[PtdIns(4,5)P2] [Ins(l,4,5)P3j
Evidence is now emerging to suggest that the axial 2-OH on the PtdIns(4,5)P2 molecule, 
adjacent to the phospholipid anchor, is an essential intramolecular nucleophile in this 
catalysed hydrolysis.41
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1.6.1 Phospholipase C enzymes
The structural and mechanistic features of the phospholipases C as effectors of inositol
phospholipid-mediated signal transduction has recently been reviewed.42
There are three major PLC family members (p, y,8), and at least ten different isoforms
have been isolated and cioned (PLC-P 1-4, PLC-y 1-2, PLC-5 1-4).42
Two main types of cell surface receptors are capable of initiating the production of
Ins(l,4,5)P3 by activating certain PLC isoforms. These are the G-coupled receptors and
the tyrosine kinase-coupled receptors.17 G-protein and tyrosine kinase structure and















Ick, Fyn (protein tyrosine kinases, of the Sic family, used by T-cell antigen receptor CD3)
Figure 1.4. The two major pathways for the stimulation and formation of Ins(l,4,5)P3 
and DAG.
[G = G-Protein, PI-K = Phosphatidylinositol 3-Kinase, GAP = GTPase activating 
protein, PKC = Protein kinase C, R = 7-membrane spanning domain receptor, EGF = 
Epidermal growth factor, PDGF = Platelet derived growth factor].
On binding their ligands, the G-protein-activated receptors activate PLC-P 1 via Gq/n 
subunits of their associated heterotrimeric G proteins. PLC-p 1 then catalyses the 
hydrolysis of PtdIns(4,5)P2.
The tyrosine kinase-linked receptors relay information through a direct interaction 
between the receptor and PLC-yl. As the ligand binds, the receptors dimerise and 
phosphoiylates one another on tyrosine, creating a docking site for PLC-yl. PLC-yl then 
binds to the receptor and is pulled onto the membrane where it effects the hydrolysis of 
its substrate PtdIns(4,5)P2. [Tyrosine kinase-linked receptors can also activate other 
effectors such as phosphatidyl-3-kinase and GTPase activator protein (GAP)]. The 
hydrophilic head group of PtdIns(4,5)P2 released by both mechanisms is Ins(l,4,5)P3. 
Ins(l,4,5)P3 diffuses into the cytoplasm and causes the release of Ca2+ from intracellular 
stores by interaction with Ins(l,4,5)P3 receptors, causing the conformational change 
which opens the Ca channel. The other product of the hydrolysis is the lipophilic 1,2- 
di-O-acylglycerol (DAG) which remains in the membrane, and can activate a family of 
protein kinase C isoenzymes.
1.7. Ins(l,4,5)Pi receptors.
To date, three types of Ins(l,4,5)P3 receptors, derived from three distinct genes have
been discriminated and are designated IP3R-1, IP3R-2 and EP3R-3.43
These three isoforms are co-expressed in a variety of haematopoietic cells and
lymphocyte cell lines 44 but differential localisation of the different types is far more
common.45
Table 2. Characteristics of Ins( 1,4,5)P3 receptors.
12
Family of receptor % Homology with Amino acids Predominant tissue
Type-1 distribution46
Type-1 2749 Brain and peripheral
tissues
Type-2 69% 2701 Liver, lung, testis,
spleen
Type-3 64% 2670 Intestine, kidney,
pancreatic islets
IP3R-I is predominant in the cerebellum. Mutant mice lacking LP3R-I usually die in
utero, and bom animals suffer severe ataxia and epileptic siezures.47’48
A more recent finding suggests that T-cells deficient in IP3R-I exhibit defective
signalling via the T-cell receptor (TCR), and are resistant to apoptosis induced by
dexamethasone, TCR stimulation and ionising radiation. The conclusion drawn is that
intracellular Ca2+ release via the EP3R-I is a critical mediator of apoptosis, programmed
cell death that is fundamental to the normal development and function of the immune 
49system.
IP3R-3, abundant in adult pancreatic islets, may be responsible for mediating the effects 
of Ins( 1,4,5)P3 on insulin secretion.50
Ins(l,4,5)P3 receptors exist as tetramers,51 comprising four subunits surrounding a 
cationic pore, the Ca channel, and have an overall structure organisation in three basic 
domains; an amino-terminal Ins(l,4,5)P3 binding domain, a carboxy-terminal Ca 
channel domain and a linking domain containing sites for regulatory processes.52
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Figure 1. 5. Cross section of a generalised Ins(l,4,5)P3 receptor.
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This regulatory domain is by far the largest segment of the receptor and represents the 
sites of interaction of the two primary physiological regulators of this ion channel, 
notably Ca2+ 53, 54 and phosphorylation.55 There is a general agreement that channel 
function shows a biphasic dependence of cytosolic [Ca2+] in a wide variety of tissues. 
This provides for both feed-forward and feed-back effects on Ca2+ that are believed to 
be centred to the generation of Ca2+ oscillations.56 ( By contrast, the regulation by Ca2+ 
of ligand binding to the IP3R is complex and tissue dependant.57)
FO
Since IP3R channel activity in systems as diverse as cerebellum and Xenopus 
oocytes59 both show the same basic biphasic dependence of Ca2+, it is concluded that 
the binding sites for Ca2+ that affect ion-conduction are distinct from those that alter the 
ligand binding properties of the receptor. Ca stimulation and inhibition of
14
Ins(l,4,5)P3-mediated Ca2+ release in liver membranes has been shown to involve 
separate binding sites.60’61
Sites for phosphorylation by a variety of protein kinases and two putative ATP binding 
sites are also found on the regulatory domain of the receptor.
The ligand-binding domains of the three isoforms show different binding affinities for 
Ins(l,4,5)P3 in the order; Type-2 > Type-1 > Type-3, and also differentially recognise 
regioisomers of Ins(l,4,5)P3.62, 63 Why one isoform should have a greater affinity for 
Ins(l,4,5)P3 over another has been studied,64 and the proposal so far is that it is the 
overall interaction between the ligand and the receptor leading to the requisite 
conformational change in the receptor that determines the potency of the Ins(l,4,5)P3 
regioisomers in their abilities to mobilise Ca2+ from intracellular stores.63 
Deletion mutagenesis studies suggest that the N-terminal 576 amino acids represent the 
minimal primary sequence required to fold into a competent ligand-binding domain.
The channel domain in all isoforms consists of six transmembrane helices surrounding 
the ion conducting pore of the Ca2+ channel. Negatively charged residues are present on 
either side of this putative pore region and these IP3R ion-channels appear to have a 
relatively poor ability to discriminate between monovalent and divalent cations. In 
addition, studies indicate that the conduction pathway of these channels behaves as a 
single file pore.65
In both these respects, the conduction mechanism of the IP3R ion channel is quite 
distinct from voltage gated monovalent and divalent cation channels.66 
Until recently, Ins(l,4,5)P3 receptors were assumed to be strictly homotetrameric, 
composed of four identical subunits, but evidence is now emerging to suggest that
l»7distinct types of subunits may assemble to form heterotetramers. ’
This heteroligomerisation of isoforms may provide a mechanism for generating a 
greater diversity of Ins( 1,4,5 )P3 receptors.
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1.8. Capacitative Ca2* entry (CCE)
On binding to its receptor, Ins(l,4,5)P3 causes a release of Ca2+ stored in the ER. Sub- 
maximal concentrations of Ins(l,4,5)P3 release only a fraction of the Ins(l,4,5)P3 
sensitive Ca2+ store, while further increases in agonist concentration can mobilise more 
Ca2+. This phenomenon, which is also a property of ryanodine receptors, is described as 
“quantal” calcium release.69
The Ca2+ thus liberated can activate a range of Ca2+-dependant processes by inducing 
conformational changes in various Ca2+-binding proteins. On completing its task, it is 
pumped both out of the cell and back into the ER by ATPases. There is, therefore, a net 
loss of Ca2+ from the cell and a small amount of extracellular Ca2+ is required to restore 
the balance. This influx is known as capacitative calcium entry.
As well as replacing the lost intracellular Ca2+, this process maximises the [Ca2+] near 
the plasma membrane where specialised Ca2+ proteins are found.
The specific depletion-activated Ca2+ current is now designated Icrac (calcium-release- 
activated calcium current, and the channel by which it enters is termed CRAC (calcium- 
release activated channel).
By which mechanism these channels open to allow the flow of Icrac is a subject of 
controversy. As already discussed, two suggestion currently exist, that of a messenger
70termed calcium influx factor, a hypothetical species which has not yet been identified, 
and an alternative model based on protein-protein interaction which now seems to be 
more likely.71 One hypothesis is that information is transmitted directly from 
Ins(l,4,5)P3 receptors to CRAC channels by a conformational coupling mechanism, 
perhaps involving specific Ins(l,4,5)P3 receptor subtypes. It has been shown, for 
example, that an over-expression of Type-3 Ins(l,4,5)P3 receptors in Xenopus oocytes 
has no effect on the Ins(l,4,5)P3-induced Ca2+ release 72 but markedly enhances the
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magnitude and duration of Ca2+ influx.73 A recent report suggests that both IP3Rs and 
RyRs activate CCE but through independent pathways.24 However the mechanisms 
remain unknown.
Figure 1.6. The suggested mechanisms of Capacitative Ca2+ Entry.
Extracellular space












1.9. Structure-activity relationships at the Ins(l,4,5)Pj receptor.
The Ins(l,4,5)P3 receptor demands considerable stereo- and regiospecificity in the 
structural requirements of its natural ligand in order to effect Ca2+ release. This section 
will address the effects of structural modification to Ins(l,4,5)P3 on its interaction with 
the receptor. Only a selection of relative analogues will be illustrated here. The reader is 
directed to a review for a broad variety of structural analogues of Ins( 1,4,5)P3 1
17
Figure 1.7. Structural requirements of Ins( 1,4,5)P3 necessary for receptor binding and 
Ca2+ mobilisation.
Axial C-2 hydroxyl
The least important part of 
Ins (1,4,5 )P3- Of only 
minimal importance in 
receptor binding.
Equatorial C-3 phosphate
Enhances binding, but is less 
important than the C-6 hydroxyl 
May have H-bond interactions 
with binding site via the oxygen 
lone pair electrons.
Equatorial C-l phosphate
Less important than C-4 and C-5 
phosphates.Enhances binding, but 
not essential. May have a long 




Very important for receptor binding. 
May have H-bond interactions with 
the binding site probably via the OH- 
hydrogen than the oxygen lone pair 
electrons.
Equatorial C-S phosphate
This vicinal trans-diequatorial 
bisphosphate is the most important 
part of the molecule for binding, 
and is important for activity.
Equatorial C-l phosphate
Ballou and co-workers,74,75 have shown that the C-l phosphate is insignificant for Ca2+ 
mobilisation, by examining the activities of Ins(2,4,5)P3 and D-chiro-Ins(l,3,4)P3, an 
analogue of Ins(2,4,5)P3 with an axial C-l hydroxyl group instead of an equatorial one. 
They obtained the same EC50 value for both analogues, about 30 fold higher than that 
for Ins(l,4,5)P3.
Large groups can also be introduced at this position without major loss of activity.76 
Phosphorothioate substitution here is also well tolerated.77 
Axial C-2 hydroxyl
This axial hydroxyl is of only minimal importance in receptor binding. A variety of 
analogues have been designed, constructed and shown to exhibit this. The introduction 
of bulky groups is well tolerated and does not affect the ability of the analogue to act as
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a full agonist at the Ins(l,4,5)P3 receptor.78 Deoxygenation79 and inversion of
Of}
configuration at the C-2 stereogemc centre of Ins(l,4,5)P3, [scyllo-\m{ 1,2,4)P3] gives
potent, full agonists. Fluorination at this centre to give DL-2-F-Ins(l,4,5)P3 80 has the 
same potency as Ins(l,4,5)P3 for mobilising sequestered Ca2+. 2-F-scy//o-Ins(l,4,5)P3 
and 2,2 F2-Ins(l,4,5)P3 are also full agonists.81,82 Phosphorylation at this position gives 
Ins(l,2,4,5)P4 which has recently been shown to be a full agonist, 1-2 times less potent 
than Ins(l,4,5)P3 83 It is, therefore, likely that the C-2 hydroxyl may interact with the 
receptor binding site by acting as a hydrogen-bond acceptor rather than a donor, as a 
fluoro- substituent at this position can no longer donate a hydrogen-bond but the 
analogue still retains its activity. DL-Ins(l,2,4,5)P4 is the most potent tetrakisphosphate 
yet described.83,84 The C-2-OH is therefore not intimately associated with the receptor 
binding pocket.
Equatorial C-3 hydroxyl
The C-3 hydroxyl is relatively insignificant in receptor binding and Ca2+ release.85 
D-3-deoxy-Ins(l,4,5)P3,86 D-3-F-Ins(l,4,5)P387 and D-3-<9-(trifluoromethyl)-Ins( 1,4,5)P3 
88 all mobilise Ca2+ as full agonists with a potency similar to that of Ins(l,4,5)P3. 
Analogues with 3-chloro, 3-fluoro and 3-O-methyl substitution show decreasing activity
94-with respect to receptor binding and Ca release, so increasing steric bulk does reduce 
activity.89, 90 Inverting this hydroxyl from equatorial to axial, to give L-chiro- 
Ins(2,3,5)P3, gives a potent agonist with an EC50 only 5-10 times higher than that of 
Ins(l,4,5)P3. 82,91 Phosphorylated analogues L-c/z/ro-Ins(l,2,3,5)P4 and D-Ins(l,3,4,5)P4 
both show reduced activity.82,88 
Vicinal C-4 and C-5-bisphosphate
This bisphosphate motif is crucial for Ca2+ mobilisation. The phosphate at C-4 is 
essential for recognition by the Ins(l,4,5)P3 receptor, and analogues lacking this moiety 
are inactive.92 Ins(l)P-(4,5)PS2 is a potent Ca2+ mobilising agonist, so phosphorothioate
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substitution at this position is well tolerated.93 No selectively modified analogues at C-4 
have appeared in the literature as yet.
Ins(l,4)P2-(5)PS binds to the receptor with high affinity and acts as a full agonist.94,95 
The 5-methylphosphonate analogue of Ins(l,4,5)P3 however is reported to antagonise 
Ins( 1,4,5)P3-stimulated Ca2+ release in a pH dependant manner and to act as a 
competitive inhibitor of [3H]Ins(l,4,5)P3.96,97 The same authors also report that the 5- 
difluoromethylphosphonate analogue is also a weak antagonist.
Even though relatively little synthetic work has gone into the determination that the 4,5- 
bisphosphate is the essential pharmacophore for activity at Ins(l,4,5)P3 receptors, it 
seems so owing to the fact that this moiety appears in all active analogues. It is also 
possible for two vicinal phosphates positioned elsewhere on the inositol ring to mimic 
this vicinal trans-diequatorial bisphosphate system and thus exhibit some intrinsic 
activity. This idea will be a recurring theme throughout this text Mimetic 4,5- 
bisphosphate species will be referred to as “pseudo” 4,5-bisphosphates.
Equatorial C-6 hydroxyl
The C-6 hydroxyl plays a significant role in receptor binding or in fixing the 
conformation of the C-5 phosphate group by hydrogen-bonding.
DL-6-0-methyl-Ins( 1,4,5)P3 is found to mobilise Ca2+ with an EC50 value over 200 
times that of Ins(l,4,5)P3,98 and similar results are obtained for other 6-O-substituted 
analogues.99 Substitution of this hydroxyl group by both charged and uncharged groups 
abolishes activity. D-6-deoxy-Ins(l,4,5)P3, however, is found to be a full agonist for 
Ca2+ release, roughly 70 times less potent than Ins(l,4,5)P3.l0°
1.10. Adenophostins.
The adenophostins A and B were first reported in 1994 by Takahashi et a lm  These 
molecules were isolated from the culture broth of a fungus, PeniciIlium
brevicompactum, and found to be highly potent agonists at the Ins(l,4,5)P3 receptor, 
100 fold more potent than the native ligand Ins(l,4,5)P3 itself To date, no other 
compound had been found to be more potent than Ins(l,4,5)P3, so this was an exciting 
discovery in the field. The elucidation of the structure of these molecules confirmed 
most of the necessary features for Ins(l,4,5)P3 receptor binding and activity, e.g. a trans- 
diequatorial 4,5-bisphosphate moiety together with another phosphate group close to 
position-1 and a 6-hydroxyl group. There were also some markedly different structural 
features (i) It was, therefore, necessary to dissect the structural features of the 
molecule and design analogues which would determine which combinations of the 
structure were enhancing its receptor binding and Ca2+ -release properties as compared 
to Ins(l,4,5)P3.
Some recently constructed analogues, (3), (4) and (5)102 have been synthesised under the 
working hypothesis that the a-D-glucopyranose feature may be a bioisostere of the D- 
myo-inositol moiety in Ins(l,4,5)P3.
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Figure 1.8. Adenophostin Analogues.
R=H Adenophostin A (1)




0 P 0 32-
1 -0-[(3S , 4R)-3-hydroxytetrahydrofiiran-4-yl] 
-a-D-glucopyranoside 3,4,3-trisphosphate. (5)
Indeed, this assumption was proved correct, with analogue (4) being an agonist some 
10-fold lower in potency than Ins(l,4,5)P3 due to the conformational flexibility of the 
side chain moiety bearing one of the phosphates. However, this analogous phosphate of 
both analogues (4) and (5) is conformationally restricted in space by a tetrahydrofuran 
ring, just as in the structures of the adenophostins. The biological effects of both these 
molecules are comparable to Ins(l,4,5)P3 and indicate that the a-glucopyranose 
structure is indeed a good bioisostere of the myoinositol backbone of Ins(l,4,5)P3, and 
that adequate conformational restriction of the phosphate group of the side chain moiety 
attached at the la-position improves receptor binding.102
The kinetics of Ca2+ release induced by the adenophostins at the Ins(l,4,5)P3 Type-1 
receptor have been reported.103 Ins(l,4,5)P3 receptors have been shown to exist in two
2-hydroxyethyl-a-D-glucopyranoside 
3,4,2' trisphosphate. (4)
different states with different affinities for the adenophostins and for Ins( 1,4,5)P3 itself, 
a high and a low affinity state. This could arise from alternative splicing leading to the 
production of variants of the receptor or there may be two different states of a single 
variant due to ligand-dependant inactivation or interconversion.
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1.11. Antagonists at the Ins(l<4,5)P^receptor.
The potent antagonism of Ins(l,4,5)P3-activated Ca2+ release by heparin, a 
polysulphated polysaccharide, has been demonstrated to be both competitive and 
reversible at Ins(l,4,5)P3 receptors.104 The heparin fragment TV4558-S1 is as potent as 
heparin itself in inhibiting [3H]Ins(l,4,5)P3 binding, whereas smaller fragments and less 
sulphated or unsulphated glycosaminoglycans do not affect binding.58 It may seem 
likely that the negatively charged sulphate groups of heparin interact with the 
hydrophilic pockets in the receptor binding site that usually accommodates the 
phosphate groups of Ins(l,4,5)P3. These antagonistic properties however, are not 
exhibited by wyo-inositol 1,4,5-trisulphate105 or the hexadeoxy 1,4,5- 
tris(methylenesulphonic acid) analogue of Ins (1,4,5)P3 ,47 The design of antagonists 
based on heparin is made difficult by the large and flexible nature of the molecule and 
its use in studies of intact cells is complicated by the fact that it is also a potent 
antagonist of Ins(l,4,5)P3 3-kinase.106 Heparin has been found to interact with the 
ryanodine receptor causing Ca2+ release.107
Caffeine also acts as an inhibitor of Ins(l,4,5)P3-induced Ca2+ release, by acting at an
1 A ftATP binding site present on the cytoplasmic regulatory domain of the receptor, and 
like heparin, also interacts with ryanodine receptors.
Physiological concentrations of polyamines can inhibit Ins(l,4,5)P3-induced Ca2+ 
release,109 as can various tetraalkylammonium cations particularly tetrahexylammonium 
ions. The mechanism of action may involve interaction with negatively charged amino 
acids in the channel region of the receptor. To date, it is not clear whether 
triethylammonium ions can have any significant effect on Ca2+ release but, as all the
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compounds described in this thesis were isolated and used as the triethylammonium 
salts, the possibility must be considered until experiments prove otherwise.
Studies of various reagents used as Ca2+ chelators, EGTA, EDTA, BABTA, QUIN-2, 
have been shown to competitively antagonise binding of Ins( 1,4,5)P3 to the receptor.110, 
111 These findings are of importance as these reagents are commonly used to monitor or 
manipulate Ca2+ levels in biological studies of Ca2+ release and may therefore give rise 
to experimental artefacts.
The racemic 5-methylphosphonate analogue of Ins(l,4,5)P3 was reported to antagonise 
Ins(l,4,5)P3-stimulated Ca2+ release in a pH dependant manner, in human platelets.97 
This finding would be of major significance to the understanding of receptor-ligand 
interaction manifesting antagonistic activity, but confirmatory biological data are still 
unavailable. The naturally occurring Ins(l,3,4,5,6)P5 behaves as a weak antagonist in 
vitro, which may have a physiological significance for Ins(l,4,5)P3 receptor regulation 
in v/'va112
A more recent publication claims that certain anti-malarials namely chloroquine, 
quinidine and quinine block [3H]Ins(l,4,5)P3 from binding to its receptors by 90%, 88% 
and 71% respectively.113 These observations suggest a previously undetected 
mechanism by which these agents may, in part, function as anti-malarials.
7*4-Decavanadate is yet another structure found to inhibit Ins(l,4,5)P3-induced Ca 
mobilisation114 in permeabilised rat insulinoma cells and PC 12 cells. Inhibition of 
[3H]Ins (1,4,5)P3 binding to its receptor is also apparent.115 Its specificity is low and this 
prevents it from becoming a useful tool to investigate the second messenger role of
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Ins(l,4,5)P3. However, molecular modelling studies based upon decavanadate and, 
indeed, the afore- mentioned molecules may provide important leads.
1.12. Partial agonists at Ins(l,4,5UN receptors.
A partial agonist, or alternatively a partial antagonist, is one which can fully displace 
[3H] Ins(l,4,5)P3 from the Ins(l,4,5)P3 receptor but induce only partial Ca2+ release 
compared to that which is released by Ins(l,4,5)P3 alone. So far, however, the great 
majority of Ins(l,4,5)P3 analogues found to bind to Ins(l,4,5)P3 receptors can also cause 
Ca2+ release to a level which classifies them as agonists. The first partial agonist 
identified at the Ins(l,4,5)P3 receptor was the naturally occurring myo-inositol 1,3,4,6- 
tetrakisphosphate (9).116,117
Ins(l,3,4,6)P4 (9) releases around 80% of the Ca2+ mobilised by Ins(l,4,5)P3 when 
tested in SH-SY5Y neuroblastoma cells.117 When the maximally effective Ca2+ 
releasing concentration of (9) is administered together with Ins(l,4,5)P3, the EC50 of the
|  f  o
latter is increased. This indicates that (9) and Ins(l,4,5)P3 are competing for the same 
site, and is strong evidence that (9) is behaving as a true partial agonist.
Ins(l,3,4,6)P4 can adopt a binding conformation which efficiently mimics Ins(l,4,5)P3 
with the exception of presenting an axial hydroxyl group at pseudo position-3 (figure
1.9.).
Figure 1.9. Possible binding orientations of Ins( 1,3,4,6)P3
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Ins (1,4,5 )P3
m Binding conformation 1
m Binding conformation 2
>H
Ins (1,3,4,6 )P4( 9)
P =  P—< f  
Cf
Another binding orientation, which again mimics the conformation in space of the three 
phosphates of Ins( 1,4,5)P3, is possible (orientation 2). This orientation presents an axial 
hydroxyl at the pseudo-6 position. So which way up does (9) bind ? Is it a pseudo-3 or - 
6 axial hydroxyl which causes partial agonism? These questions are addressed in 
Chapter Four.
D-3-amino-3-deoxy-myo-Ins( 1,4,5 )P3 (10) is found to behave as a high intrinsic activity 
partial agonist, releasing about 80% of the Ins(l,4,5)P3-sensitive Ca2+ pool at pH 6.8, 
but apparently as a full agonist at pH 7.2 and 7.6.118
Additionally, two low intrinsic activity partial agonists have been identified: L-chiro- 
inositol 2,3,5-trisphosphorothioate [L-c/z/ro-Ins(2,3,5)PS3] (11) and D-6-deoxy-myo- 
inositol 1,4,5-trisphosphorothioate [D-deoxy-Ins(l,4,5)PS3] (12)119 and a high intrinsic 
activity partial agonist: scy//o-inositol 1,2,4,5-tetrakisphosphorothioate (13). 
L-c/nroIns(2,3,5)PS3 (11) has been tested in rabbit platelets and shown to be the first 
partial agonist at the platelet Ins(l,4,5)P3 receptor.120
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Figure 1.10. Partial agonists at the Ins(l,4,5)P3 receptor.
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D-6-deoxy-Ins( 1,4,5 )PS3 (12) scyllo-lm  (1,2,4,5 )P4 (13) L-chiro-lns (2,3,5 )P3 (14)
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The partial agonists described are modified at C-3 or C-6, sometimes together with 
phosphorothioate substitution in the place of phosphates, which appears to assist in 
triggering a substantial loss of agonist efficacy accompanied by a less significant loss of 
affinity. These observations led to the synthesis of L-wyo-inositol 1,3,4-tris- 
phosphorothioate [L-Ins(l,3,4)PS3] (15), DL-6-deoxy-6-hydroxymethyl-scy//o-inositol 
1,2,4-trisphosphorothioate [DL-6-deoxy-6-hydroxyethyl-.vcy//o-Ins(l,2,4)PS3] (16) and 
D-myo-inositol 1,4,6-trisphosphorothioate [D-lns(l,4,6)PS3] (17), within the Potter 
group.121 Compound 15 is found to be a low efficacy partial agonist. Compound 17 has 
a high affinity for the receptor and yet maintains very low efficacy, making it an 
important lead compound in the further design of receptor blockers. 16 is a very weak, 
high efficacy agonist. This is a surprising result, as the parent trisphosphate (18) shows 
one of the highest binding affinities at the Ins(l,4,5)P3 receptor of any analogue yet
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synthesised. It is not known why the presence of a hydroxymethyl group should have 
this effect on the phosphorothioate but this finding may have implications for the design 
of adenophostin-based partial agonists.
The partial agonist activities of (15) and (17) were observed at 4°C but disappeared 
when experiments were repeated at 20°C. Quantal Ca2+ release seems to disappear at 
low temperatures and it has been argued that this phenomenon may obscure partial 
agonist behaviour.119
Figure 1.11. Partial agonists at the Ins(l,4,5)P3 receptor.
L-m yoIns( 1,3,4)PS3 (15) 6-deoxy-6-hydroxym ethyl-5cy//o-Ins(l,2,4)PS3 (16)
s
II .PS= — P—o
<*f
D-/wyo-Ins(l,4,6)PS3 (17) 6-deoxy-6-hydroxym ethyl-scy//o-Ins(l,2,4)P3 (18)
The syntheses of analogues modified at the Ins(l,4,5)P3 C-3 position, with selective 
phosphorothioate substitution of the 1,4,5-trisphosphate motif, have also been 
described, in the search of potent partial agonists with the ambition of moving closer 
to a receptor blocker. D-3-Fluoro-/wyo-inositol l,5-bisphosphate-4-phosphorothioate 
[3F-Ins(l,5)P2-4PS] (19), D-3-fluoro-myo-inositol l,4-bisphosphate-5-phosphorothioate
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[3F-Ins(l,4)P2-5PS] (20) and D-3-fluoro-m^o-inositol-1 -phosphate-4,5-bisphosphoro- 
thioate [3F-Ins(l)P-(4,5)PS2] (21), have been synthesised and studied for biological 
activity. The 4,5-bisphosphorothioate analogue 21, is shown to exhibit partial agonist 
activity, whilst 19 and 20 show full agonist activity in the order shown in Fig. 1.12. The 
difference in the agonist properties of these two analogues confirms the expectation that 
modification of the 5-phosphate of Ins(l,4,5)P3 is more perturbing for Ins(l,4,5)P3 
receptor binding than a similar modification of the 4-phosphate and that 
phosphorothioate substitution at both of these stereogenic centres is necessary for 
partial agonism.








Full agonist (19) Full agonist (20) Partial agonist (21)
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It appears that small-molecule ligand efficacy and affinity at the Ins(l,4,5)P3 receptor 
are difficult to distinguish. A major goal in this area of research is the development of a 
specific competitive antagonist whose structural features can be dissected and further 
analogues designed in an attempt to understand how Ins(l,4,5)P3 receptors function. As 
yet, it has not been possible to identify any structural feature that is related to receptor 
affinity and not efficacy. Molecules that bind to the Ins(l,4,5)P3 receptor with
30
reasonably high affinity and yet appear to behave as partial agonists are therefore 
important lead compounds in the search for specific Ins(l,4,5)P3 receptor antagonists. 
Ins(l,4,5)P3-induced Ca2+ release is a complex phenomenon and care must be taken in 
identifying these lead compounds. Ins (l,4,5)P3-sensitive stores can respond rapidly and 
transiently to a low concentration of agonist and yet maintain the ability to release Ca2+ 
in response to higher concentrations (Quantal Ca2+ release). This complicates the 
investigation of the relationship between receptor occupation and Ca2+ release and 
discrimination between agonists of different efficacies. Even a partial agonist may be 
able to deplete the Ca2+ stores in time, particularly if it is resistant to metabolism. Only 
partial agonists with very low intrinsic efficacy will give a dose response curve which 
will classify them as such.
Figure 1.13. Identification of a partial agonist from Dose-Response data.





1.13. Conformation of Ins(1.4.5)Pj
The information currently available on the three-dimensional structure of the active site 
of an Ins(l,4,5)P3 receptor is very limited, so research is presently limited to the study of
compounds that are active at this site. Inferences are made about the active site and the 
nature of the receptor-ligand interactions by systematically altering the structure of the 
natural ligand and observing the effects on activity made by this change. However, it is 
not always clear whether a change in activity is brought about by a purely local effect or 
whether there are more widespread consequences for the conformation or ionisation 
state of the molecule as a whole. Modifications at C-3 of Ins(l,4,5)P3, for example, can 
have various consequences for affinity and efficacy of analogues at Ins(l,4,5)P3 
receptors. These effects may arise from the altered interaction of the 3-substituent with 
the receptor, or through effects on the orientation and ionisation state of the adjacent 4- 
phosphate group, or both. The idea that change at one of the stereogenic centres could 
alter the conformation of the cyclohexane ring has been suggested to explain the 
unexpectedly high activity found for L-wyo-inositol 2,4,5-trisphosphate.74 
Interactions between the receptor and ligand can be stabilising, allowing considerable 
distortion of the ligand away from an energy minimum. This may be of particular 
relevance in the binding of highly charged molecules such as Ins(l,4,5)P3 with 
positively charged residues at the binding site, so that electrostatic interaction with the 
receptor may compensate the energetic penalty of large conformational changes. 
Molecular modelling studies can be utilised to predict the energy minima in the 
conformational space available to a molecule and, together with information from 
NMR, e.g. NOE and coupling constants, conformational distortions can be rationalised. 
Thus, by comparing a number of agonists with varying structures, it may be possible to 
deduce a three dimensional pharmacophore that is attainable at reasonable energetic 
cost by all active ligands. In the case of Ins(l,4,5)P3, however, we do not have an 
available range of active molecules that differ sufficiently in structure and 
conformational mobility to make such a study feasible. The inositol phosphates that 
show significant affinity for the Ins(l,4,5)P3 receptor all have the 4,5-bisphosphate
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motif. This conformationally mobile system is found to be essential for receptor 
recognition and Ca2+ mobilisation and yet relatively little attention has been focused 
upon the modification of this structure. Little is known about the way that these two 
phosphate groups interact with the receptor in the series of events leading to the 
opening of the ion channel. An attempt to probe this issue will be described in Chapter 
Four.
1.14. Metabolism of Inositol Phosphates.
Once released inside the cell, a second messenger must be efficiently de-activated in 
order to terminate its action and return the cell to a basal state in preparation for a new 
stimulus. Ins(l,4,5)P3 is a substrate for various enzymes whose function is to do just 
this. However, it is now becoming clear that the metabolism of Ins(l,4,5)P3 is complex, 
and the expanding number of metabolites, enzymes and isoenzymes reported in the 
literature have brought this almost simplistic view into question. Of the 63 possible 
monoesterified phosphate derivatives of inositol, almost half have been found to occur 
in eukaryotic cells for instance,123 and it seems that some of these will have cellular 
funtions of their own, particularly the higher inositol phosphates. Indeed the discovery 
of a number of binding proteins for inositol 1,3,4,5-tetrakisphosphate, inositol 1,3,4,5,6-
pentakisphosphate and inositol 1,2,3,4,5,6-hexakisphosphate (IP6), is the subject of a
1 1 1recent review. Cyclic phosphate-containing inositol phosphates ‘ and pyro­
phosphate bearing structures have also been observed.129,130
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This section will provide a highly selective account of some of the enzymes involved in 
phosphoinositide metabolism and will deal with only those with which some of the 
analogues prepared as part of this work have been designed to interact.
1.15. Ins(1.4,5)P^ 3-kinase.
3-kinase
D-Ins(l,4,5 )P3 , D-Ins(l ,3*4,5 )P4
The enzyme, inositol 1,4,5-trisphosphate 3-kinase, catalyses the phosphorylation of 
Ins(l,4,5)P3 to Ins(l,3,4,5)P3. Two isoforms of the enzyme have been identified, 3- 
kinase A and 3-kinase B, which are differentially regulated by calcium, calmodulin and 
via phosphorylation by protein kinase C or the cyclic AMP-dependant protein kinase.131. 
Evidence suggests that the human forms are specifically expressed in different
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tissues and cells.133 Differential expression and regulation of the two isoforms may 
provide multiple mechanisms for regulating the cytosolic level of Ins( 1,4,5 )P3 in cells. 
Focal cerebral ischaemia in rats has been shown to result in a time-dependant 
irreversible decrease in 3-kinase activity, suggesting that 3-kinase is one of the target 
enzymes of cerebral ischaemia and that the resulting perturbation of Ins(l,4,5)P3 
metabolism may be an important factor underlying the changes in intracellular Ca2+ that 
lead to neuronal cell death.134
The structural identification of the Ins(l,4,5)P3 binding domain of rat brain Ins(l,4,5)P3 
3-kinase, has appeared in the literature and is a an important lead in the development of 
inhibitors of Ins( 1,4,5)P3 3-kinase.135
Of particular interest is the product of Ins( 1,4,5)P3 3-kinase which has been postulated 
to regulate Ca2+ influx through the plasma membrane.29 The purification and cloning of 
an Ins(l,3,4,5)P4-binding protein of the GAP1 family,136 now designated GAP1IP4BP, has 
lent weight to this suggestion.137 The subsequent discovery that Ins(l,4,5)P3 3-kinase B 
is membrane associated and localised to specific regions of the ER membrane system 
involved in Ca2+ homeostasis,137 has led to the postulate that the mechanism for Ca2+ 
influx from the plasma membrane, dependant on G-proteins and activated by 
Ins(l,3,4,5)P4, may also exist in intracellular membranes. In this model, Ins(l,4,5)P3 
would release Ca2+ from the ER during cell activation, which in turn would stimulate 
Ins(l,3,4,5)P4 production and subsequent Ins(l,3,4,5)P4 regulated Ca2+ release in a 
GTP-dependant manner. Thus, the production of Ins(l,3,4,5)P4 on ER membranes 
would cause Ca2+ release into the cytosol just as it causes Ca2+ influx from the plasma 
membrane.137
Ins(l,3,4,5)P4 may therefore be an important regulatory molecule, and hence 3-kinases 
important regulatory enzymes.138
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Debate still exists as to whether Ins(l,3,4,5)P4 itself can mobilise intracellular Ca2+ by 
acting at Ins(l,4,5)P3 receptors as conflicting results from various biological assays 
have been reported.139'144
1.15.1. Molecular interaction with Ins( i ,4.5 )Pj 3-kinases .
Ins(l,4,5)P3 3-kinases show a remarkable stereo- and regioselectivity towards the 
recognition of Ins(l,4,5)P3 which appears to be higher than that for either Ins(l,4,5)P3 
receptors or Ins(l,4,5)P3 5-phosphatases.145 Choi et a l146 have examined the inhibitory 
potencies of all possible 38 regioisomers of synthetic racemic myo-inositol phosphates 
with Ins(l,4,5)P3 3-kinase and have proposed a binding model of Ins(l,4,5)P3 3-kinase 
for Ins(l,4,5)P3. The recognition of /wyo-inositol phosphate regioisomers was shown to 
be highly structure selective and DL-Ins(l,4,6)P3 shown to be the most potent inhibitor 
of the structures studied.
Figure 1.15. The proposed binding site environment of Ins(l,4,5)P3 3-kinase.146
Extra space available 
in the axial direction.
_  _  Auxiliary binding
site.
Some space available 
in the equatorial E 
direction.
Major binding site.
Extra space available 
in the axial direction,
possibly for ATP.
The binding site environment, especially the location of vacant spaces, may be 
exploited for the design of useful derivatives and analogues of Ins(l,4,5)P3. 
Understanding the key binding site structure differences between Ins(l,4,5)P3 3-kinase,
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5-phosphatase and Ins(l,4,5)P3 receptors is necessaiy before selective receptor 
antagonists or enzyme inhibitors for pharmacological applications can be developed.
The specificity of 3-kinases poses problems for the design of inhibitors. Heparin 
inhibits the activity of bovine adrenal cortex cytosol 3-kinase in a non-competitive 
fashion 106 but, as already mentioned, has many disadvantages as a pharmacological 
tool. The anthracycline antibiotic adriamycin widely used in antineoplastic therapy, has 
also been found to inhibit Ins(l,4,5)P3 3-kinase but it too has numerous other biological 
effects.147
Unexpectedly, L-2,2-difluoro-2-deoxy-/wyo-inositol 1,4,5-trisphosphate is also a 
competitive inhibitor ( K,=l 1.9pM ),148 and a carbohydrate based 3-kinase inhibitor 
synthesised from mannose has also been reported ( K{=26.8pM ).149 These two 
molecules are important lead compounds in the search for non-Ca2+ releasing, small 
molecule inhibitors of 3-kinases.




PtdIns(3,4,5)P3 — ► PtdIns(3,4)P2
Inositol polyphosphate 5-phosphatases are Mg2+ dependant enzymes which were 
initially identified by their ability to hydrolyse Ins(l,4,5)P3 to Ins(l,4)P2.150 
Because the substrate mobilises intracellular Ca2+ ions through the Ins(l,4,5)P3 receptor 
and the product is inactive in this respect, it was presumed that this enzyme was a 
signal- terminating enzyme analogous to cyclic nucleotide phosphodiesterase in the
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cAMP system. However, multiple genes encoding IP5-Pases have been discovered in 
the last few years, indicating a much broader role in cell signalling for this family of
151-153enzymes.
There are six mammalian IP5-Pases that have been characterised at the enzymatic level. 
They have been grouped according to their substrate specificity. Group 1 includes the 
Type-1 IP5-Pases that that have a molecular mass of 32-43kDa and hydrolyse both 
Ins(l,4,5)P3 and Ins(l,3,4,5)P4 but neither lipid substrate. They most likely represent the 
enzymes that serve a “signal-terminating” function in Ca2+ mobilisation.
Group 2 includes enzymes that hydrolyse the soluble phosphates mentioned above, and 
the lipids PtdIns(3,4,5)P3 and PtdIns(4,5)P2. The original member of this group, IP5- 
Pase Type-2, was isolated from platelets as a 75kDa protein. A second enzyme in this 
group is the IP5-Pase mutated in Lowe’s occulocerebrorenal syndrome gene (OCRL). 
This is an X-linked disorder characterised by mental retardation, eye abnormalities and 
renal tubular absorption defects.154 This discovery highlights the potential significance 
of the 5-phosphatases, and OCRL became the first known example of an inborn defect 
in polyphosphate metabolism.
OCRL shows a clear preference for the lipid substrates even though it does hydrolyse all 
four of the known substrates, and is closely related to IP5-Pase Type-2 with 51% amino 
acid identity over the entire 741 amino acids of the mature enzyme.155 A third member 
in this family, synaptojanin, has been isolated and proposed to function in synaptic 
vesicle trafficking.156
Group 3 includes IP5-Pases that form complexes with haematopoietic cytokine 
receptors and activate the Ras pathway. These enzymes hydrolyse only the 3-phosphate- 
containing substrates, Ptd(3,4,5)P3 and Ins(l,3,4,5)P4.
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Additionally, there are several putative IP5-Pases that have not been characterised as 
yet. these include a protein which was isolated by its ability to complement the defect in 
DNA repair in cells from patient with Fanconi’s anaemia.157
It has been reported that inositol polyphosphate metabolism is deranged in lymphocytes 
infected with the HIV virus and that these effects can be reversed with AZT therapy.158 
It seems that 5-phosphatase activity is reduced in these patients, and as the disease 
progresses, another enzyme Ins(l,3,4,5)P4 3-phosphatase (MIPP) is also decreased. In 
the later stages of the disease, both activities are completely lost.
A study of 5-phosphatase in normal and malignant haemopoietic cells also found that 5- 
phosphatase activity was significantly reduced or completely absent in sub-populations 
of cells taken from patients with various leukaemias.159 The authors speculate that the 
half- lives of Ins( 1,4,5)P3 and Ins(l,3,4,5)P4 may be increased in these cells, resulting in 
prolongation of Ca2+ signals and aberrations in cellular regulatory processes including 
those involved in cell proliferation and differentiation.
A 5-phosphatase isolated from haemopoietic cell lines and found to contain an SH2 
(Src homology) domain has been shown to induce apoptosis. This 5-phosphatase is now 
designated SHIP (Src homology 2 domain inositol phosphatase). It is the SH2 domain 
that has been identified as been the inducer of programmed cell death.160
1.16.1. Structure-recognition relationships between Ins(1.4,5)P? 5-phosphatase and 
ligands.
In contrast to the Ins(l,4,5)P3 receptor and the Ins(l,4,5)P3 3-kinase, Ins(l,4,5)P3 5- 
phosphatase seems to be relatively non specific. A range of phenothiazines, used in 
medicine as antipsychotics, including chlorpromazine and trifluoroperazine inhibit 5- 
phosphatases, as does disulfiram (used in alcoholism) and several of its analogues.161
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An extensive survey of the structure-activity relationships for Ins(l,4,5)P3 5- 
phosphatase has been reviewed by Potter and Lampe,78 and only selected examples will 
be illustrated here.
Figure 1.16. Structure-activity relationships for Ins(l,4,5)P3 5-phosphatase.
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The most potent 5-phosphatase inhibitor described to date is L-c/?/ro-Ins(2,3,5)P3 (14), 
which can be visualised as Ins(l,4,5)P3 with an inverted configuration at the 
Ins(l,4,5)P3 C-3.170
Potter and Lampe suggest two possible mechanisms for this phenomenon; that the 
conformation of (14) in solution and/or bound to the enzyme may be sufficiently 
different from that of Ins(l,4,5)P3, that, although the analogue binds to the enzyme in a 
similar mode to Ins(l,4,5)P3, the catalytic mechanism of the enzyme is interrupted.
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Alternatively, the inhibition may be the result of a non-productive binding of the 
inverted substrate in a rotated fashion (Fig. 1.17). In this arrangement the analogue 
would mimic three elements of Ins(l,4,5)P3 correctly, namely the ring pucker, the 
crucial 4,5-bisphosphate moiety (as the 2,3-bisphosphate pair) and the 3-hydroxyl group 
(as the 4-hydroxyl group).
Figure 1.17. Suggested binding orientation of 14.78
Ins(l,4,5)P3 L-c/wro-Ins(2,3,5)P3 (14)
HO
Inverted and rotated 
(14)
This compound, however, is also a 3-kinase inhibitor and a partial agonist at the 
Ins(l ,4,5)P3 receptor.
More selective inhibitors of 5-phosphatase include L-Ins(l,4,5)PS3 (24), the achiral 
meso compound Ins(l,3,5)PS3(25), and (1R,2R,4R)-cyclohexane-1,2,4-
trismethylsulphonate (26).l68,171
The most potent inhibitor described to date is L-c/2/ro-Ins(l,4,6)PS3,(27), with a 
K,=0.3pM. Together with (24) and (25), this compound does not interact with 3-kinase 
nor does it mobilise Ca2+. All three are therefore ideal tools for the selective inhibition 
of 5-phosphatase. Proposed conformations by which (27) may bind with Ins(l,4,5)P3 5- 
phosphatase are given by Riley.121
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Figure 1.18. Inhibitors of Ins( 1,4,5)P3 5-Phosphatase.
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D-Ins(l,3,4P3,(28), is phosphorylated by a 5/6-kinase to produce Ins(l,3,4,6)P4 (9), and 
Ins(l,3,4,5)P4 (29). It now seems likely that Ins(l,3,4,5)P4 has a signalling function of 
its own but it is still unclear as to whether Ins(l,3,4,6)P4 is responsible for any other 
activity apart from being a precursor of Ins(l,3,4,5,6)P5 and IP6.
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The entity responsible for the phosphorylation of D-Ins( 1,3,4)P3 has been purified and 
appears to be a single enzyme which combines 6-kinase and 5-kinase activities in a 
ratio of about 5:1 respectively.172 This enzyme is widely distributed,173 and its affinity 
for D-Ins(l,3,4)P3 is the highest yet determined for an inositol phosphate.
Several inositol phosphate structures have been reported to inhibit D-Ins(l,3,4)P3 5/6 
kinase activity.174 These inhibitors can be separated into two groups; Ins(l,4,5)P3 
isomers having vicinal phosphate groups at positions 5- and 6-, which are moderately 
potent inhibitors, e.g. D-Ins(l,5,6)P3 and D-Ins(3,5,6)P3, and those Ins(l,4,5)P3 isomers 
containing a vicinal 4,5-bisphosphate which are weak inhibitors. It thus follows that it 
may be the 3,4-bisphosphate system of D-Ins(l,3,4)P3 which is the essential 
pharmacophore. A 5,6-bisphosphate seems to mimic this system to some extent. The 
finding that L-Ins(l,3,4)P3 is recognised by the Ins(l,4,5)P3 receptor but not the 
Ins(l,3,4)P3 5/6-kinase, and the antipode has a very high affinity for the kinase but not 
the receptor suggests that the two pharmacophores for recognition by the enzyme and 
by the receptor may be enantiomorphic.121 Care must therefore be exercised when 
designing selective inhibitors for this enzyme from preliminary biological data on 
racemic mixtures.
The most potent competitive inhibitors of D-Ins(l,3,4)P3 5/6-kinase are reported to be 
three inositol tetrakisphosphates; D-Ins(l,3,4,5)P4,(29), Ins(l,3,4,6)P4 (9) and D- 
Ins(3,4,5,6)P4 (30).174 As (29) and (30) are products of the kinase, is likely that the 
physiologically regulate its action through feedback inhibition.
All three compounds can be visualised in binding modes which exhibit the 3,4- 
bisphosphate binding structure and their resistance to phosphorylation rationalised by 
the difference in structure at the site of action of 5/6-kinase. (Fig. 1.19)
Figure 1.19. Inhibitors of Ins(l,3,4)P3 5/6-kinase.
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Preliminary testing of a variety of inositol phosphates synthesised within our research 
group, for Ins(l,3,4)P3 5/6-kinase inhibition are now available.*
DL-5cy//o-Ins(l,2,4)P3 (31) is found to be an inhibitor, with lOOpM of this analogue 
inhibiting the formation of tetrakisphosphate by 98%. Further experiments are still in 
progress.
From the structure-activity relationship already seen, a binding mode for (31) can be 
rationalised, (Fig. 1.20).
Dr Philip Hughes, University o f Birmingham, Centre for Clinical Research in Immunology and 
Signalling. 1996.
Figure 1.20. Proposed binding mode of 31 to Ins(l,3,4)P3 5/6-Kinase.
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Another analogue, DL-«eo-Ins(l,3,4)P3,(65), which was synthesised as part of this work 
and will be further discussed in Chapter Four, also inhibits Ins(l,3,4)P3 5/6-kinase in 
preliminary studies. lOOmM of this compound is found to inhibit [3H]-labelled 
tetrakisphosphate formation by 97%.*
By analogy of one possible binding mode of D-Ins(3,4,5,6)P4 (Fig. 1.21), the activity of 
(65) can be explained by assuming that it adopts a similar binding orientation.
* Dr Philip Hughes, University of Birmingham, Centre for Clinical Research in Immunology and Signalling. 
1996.
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Figure 1.21. Probable binding mode of 65 to Ins(l,3,4)P3 5/6-kinase.
DL-/7eo-Ins(l,3,4)P3 (65)
(presented as theD-isomer)
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One proposed binding mode 
of D-Ins(3,4,5,6)P4 - a known 
competitive inhibitor of the 
5/6-kinase.
1.18. Inositol phosphate binding proteins and PH Domains.
Many of the proteins involved in signal transduction contain recapitulations of 
polypeptide segments called Domains. The first to be identified was found as a 
conserved region of about 100 residues in protein kinases, homologous to Src. This 
domain is different from the enzymatic (SHI) portion of the molecule, and so was given 
the name Src homology 2 domain (SH2).175
Such a domain has recently been identified in the structure of a 145kDa 5-phosphatase 
(SHIP), isolated from haemopoietic cell lines. A study on the role of this SH2 domain in 
the inhibition of haemopoietic cell growth, has shown that the SH2 domain of SHIP was 
necessary for the induction of apoptosis.160
More recently, a sequence block of about 110 amino acids has been identified as a 
conserved region homologous to the repeat within the protein pleckstrin and hence is 
designated the pleckstrin homology (PH) domain.176,177
PH domains have been discovered in many signal transduction proteins, including 
protein kinases, phospholipases, Ptd(4,5)P2 3-Kinase and GAP I1134815.178
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Many proteins implicated in human cancers and in developmental disorders contain PH 
domains, although the significance of this finding is unclear.
Bruton’s tyrosine kinase (Btk), which is reported to bind Ins(l,3,4,5)P4, contains a PH 
domain in which a mis-sense mutation causes either human X-linked 
agammaglobulinaemia (XLA) or murine X-linked immunodeficiency, and also reduces 
the Ins(l,3,4,5)P4 binding affinity, thus suggesting a causal link to the illnesses.179 The 
authors describe the binding specificity of the Btk PH domain and different binding 
properties among the PH domains of other Tec family kinases, and suggest that certain 
inositol phosphates and/or phosphoinositides differentially regulate some Tec family 
kinases.179
Rebecchi and co-workers 180-182 demonstrated that phospholipase C-81 (PLC-81) had a 
high affinity and specificity for PtdIns(4,5)P2 and Ins(l,4,5)P3 before the term “PH 
domains” had emerged. We now know that these molecules bind to the PH domain of 
the enzyme. D-Ins(l,4,5)P3 binds stereospecifically with the highest affinity, and various 
tetrakisphosphates including Ins(l,3,4,6)P4, [ but not Ins(l,3,4,5)P4 ] also bind, as does 
D-Ins(2,4,5)P3.183
The X-ray crystal structure of PLC-81 PH domain in a complex with Ins(l,4,5)P3 
reveals that the recognition of Ins(l,4,5)P3 and the PtdIns(4,5)P2 head-group involves 
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Figure 1.22. The Ins(l,4,5)P3 binding site of the PLC-51 PH domain.184
These interactions are electrostatic in nature, between negative charges of phosphates 
and positive charges of protonated basic amino acids.
A likely function of the PLC-81 PH domain binding to PtdIns(4,5)P2 is to provide an 
attachment to cellular membranes containing this phospholipid. Changes in cellular 
concentrations of PtdIns(4,5)P2 and Ins(l,4,5)P3 could regulate membrane binding of 
PLC-81, and consequently its activity.
The binding of inositol phosphates and phospholipids to various other PH domain 
containing proteins, including p-speckstrin, dynamin, Bruton’s tyrosine kinase and
I  O f
pleckstrin itself have also been investigated.
For all the PH domains characterised to date, the 4,5-bisphosphate motif of Ins( 1,4,5)P3 
appears to be an essential determinant of ligand specificity, while the 1-phosphate 
increases affinity.185 This conclusion is supported by the finding that Ins(4,5)P2 is 
recognised, and is less potent than Ins(l,4,5)P3.
For the first time, the interaction of Ins(l,4,5)P3 with binding sites has been observed in 
detail, and the results are in agreement with the conclusions reached about Ins(l,4,5)P3 
receptor binding through structure-activity studies conducted over a period of years. No 
assumption can be made that the Ins(l,4,5)P3 binding site of these PH domains 
resembles that of Ins(l,4,5)P3 receptors, however. Notice, for instance, that no 
interaction between the PH domain and the 6-hydroxyl group of Ins(l,4,5)P3 is 
observed, and yet this feature is known to be important for binding to Ins(l,4,5)P3 
receptors.
However, many of the structure-activity principles deduced for Ins(l,4,5)P3 receptors 
can be accommodated by the binding site structures of PH domains and this may 
suggest that similar interactions and spatial relationships are involved.
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CHAPTER 2
2.1. The Phosphoinositide System -  Potential For Therapeutic Intervention.
Why is there so much interest in the phosphoinositide signalling pathway?
Why do we try, not only to understand the biochemistry and biomechanics of this 
system, but also to find ways of disrupting it by interfering with various stages of its 
course?
The answers to these questions lie in the fact that, over the past decade, aberrations at
9 +various stages of this signalling pathway, resulting in alterations in Ca signalling, have 
been increasingly observed in a number of disease states, including various cancers.186 
Understanding the molecular basis of a disease state enables correlation of the 
pathological features with the events occurring at the molecular level to be made and 
the subsequent rational attempts for therapeutic intervention, either through the use of 
drugs or the more radical approach of gene therapy. Speculation of such correlation 
have been made for the phosphoinositide system (PI) system and, although it is 
premature to be considering potential drug action on the system, intervention at the 
level of the Ins(l,4,5)P3 receptor and the metabolic enzymes with subsequent 
modification of Ins(l,4,5)P3 signalling is being attempted. The majority of Ins(l,4,5)P3 
analogues so far designed to have such effects, however, have been hydrophilic in 
nature and would thus have no potential therapeutic value due to their cell- 
impermeability. Syntheses of cell-permeable Ins(l,4,5)P3 receptor antagonists and 
metabolic enzyme inhibitors are required before their use as therapeutic interveners can 
be considered.
9+A great technological success has been reported recently of a newly developed Ca 
mobilising Ins(l,4,5)P3 analogue which is not only membrane permeable but also caged,
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requiring photolysis by ultraviolet light for activation.14 It can therefore be loaded into 
intact cells without inducing any effects until the Ins(l,4,5)P3 is released. This molecule 
was designed to study Ca2+ release from intracellular stores modulated at will in 
amplitude and frequency, by varying the duration and frequency of ultraviolet flashes, 
but will undoubtedly set a trend for the design of further signalling probes possessing 
similar characteristics. Further to this consideration, the fact that diseased cells use the 
same signalling pathways as normal cells raises the problem of the degree of selectivity 
that can be obtained by potential drug species.
Can signal-transduction therapy be selective enough against cancer cells, for example, 
without affecting normal cells, and are these agents going to be more toxic or less than 
current anti-cancer agents ?
Clearly, interception of signal-transduction pathways will affect normal cells. However, 
it is likely that cancer cells or abnormally rapidly proliferating cells will be affected 
more severely than normal cells. This should be so since the signalling pathways 
identified to be the amplified pathways in a certain disease situation make the cancer 
cell highly dependent on these on these pathways and therefore more vulnerable. 
Normal cells, in which the signalling network is balanced, can cope and compensate for 
a sudden inhibition of some of its elements with a built in redundancy capable of 
sustaining sudden shocks to the system. This is probably an evolutionary tool of survival 
developed by the normal cell. An encouraging finding is that this principle seems to 
hold true and that signal interceptors tried in vivo seem to be much less toxic than 
classical chemotherapeutic agents.186
2.2. Medical aspects of Ca2+ signalling.
Calcium is a second messenger responsible for regulating a wide range of cellular 
processes and it is normally presented as brief spikes even in non-excitable cells.9'13
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The necessity of limiting the period of calcium stimulation to brief bursts may depend 
on the fact that prolonged elevation of calcium can be toxic. It can act on endonucleases 
to trigger programmed cell death.7,49 Non-lethal effects of elevated calcium release, 
however, have been related to a variety of pathological conditions including 
hypertension, atherosclerosis, transformations, malignant hyperthermia and possible 
neural disorders such as spreading depression and manic-depressive illness. Some of the 
pathological conditions that may arise from a derangement of calcium signalling are 
outlined in Table 3.
Table 3. Medical aspects of Ca2+ signalling.38
Pathological condition Tissues / regions affected




Hypertension Smooth muscle contraction
Atherosclerosis Smooth muscle proliferation
Immunosuppression Lymphocytes
Transformation and cancer Fibroblasts, lymphocytes, etc.
Malignant hyperthermia Skeletal muscle ryanodine receptors
Occulocerebrorenal syndrome Ins(l,4,5)P3 5-phosphatase
Sepsis Smooth muscle etc.
In all these cases, the defect seems to arise from hyperactivity of the signalling pathway. 
The best example of the deleterious effects of prolonged calcium elevation is the 
ischaemia that results in the brain, heart and kidney. Related to ischaemia is sepsis, 
which results from the shock of severe systemic infection.38
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Evidence seems to suggest that there is a large elevation of calcium in the smooth
1 0 7
muscle surrounding the blood vessels. Hyperactivity of smooth muscle may be 
responsible for a number of other pathological conditions, including hypertension and 
atherosclerosis, where the development of plaques in blood vessels result from 
uncontrolled proliferation of smooth muscle cells, which spread into the lumen. A 
contribution of calcium to cell growth may help to explain certain forms of cancer.
Since the brain is an area of intensive signalling, it is not too surprising that alterations 
in calcium levels have been implicated in certain neural disorders. There is some 
evidence to link the PI system with manic-depressive illness and intracellular calcium 
waves may be responsible for spreading depression. On of the clinical disorders 
associated with Lowe’s occulocerebrorenal syndrome is cognitive impairment, so it is 
significant that a recent genetic analysis has suggested that the gene responsible for this 
defect encodes an enzyme which metabolised Ins(l,4,5)P3.154 Malignant hyperthermia is 
another disorder which has been linked to a different calcium signalling component, the 
ryanodine receptor of skeletal muscle.188,189
Psoriasis, a disease of yet unknown aetiology is typified by the persistent activation of 
epidermal growth factor (EGF) receptors on the keratinocytes, by amphiregulin and
1 ontransforming growth factor-a, and therefore a persistence in signal transduction. 
Restenosis, a process of wound healing subsequent to by-pass operations or balloon 
angioplasty, which involves the hyper-proliferation of smooth muscle cells that leads to 
atherosclerosis of the lesion area, has been found to result from Ca“ signalling 
hyperactivity.191 Similar events occur in rheumatoid arthritis,192 pulmonary fibrosis 193 
and glomerular nephritis.194 The inflammatory components of rheumatoid arthritis and 
other diseases also involve signal-transduction pathways which can be targeted for drug 
therapy.
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2.2.1. Hypertension and Athereosclerosis.
Using the spontaneous hypertensive rat (SHR) as a model system, there have been 
numerous reports to indicate that one of the causes of hypertension may be an elevation 
of phosphoinositide metabolism and calcium in smooth muscle cells. 195’ 196 It is not 
known what element of the signalling pathway is altered but there is an indication that 
the delta, isoform of PLC is specifically increased in the aortas of SHRs.197 In the case 
of the mesangial cells in the kidney, the hyper-responsiveness is agonist specific, being 
observed for angiotensin II but not for endothelin or vasopressin.195 Hyperstimulation by 
angiotensin II may contribute to the development of hypertension in two ways; firstly, it 
may alter the peripheral resistance by increasing the contraction of the arterioles. 
Secondly, angiotensin II may decrease lumen diameter by stimulating the proliferation 
of the medial smooth muscle cells. There is some evidence to indicate that angiotensin 
II can induce DNA synthesis in vascular smooth muscle which would account for the
I no
apparent association between hypertension and athereosclerosis.
2.2.2. Transformations and Cancer.
There is now overwhelming evidence to indicate that tumourigenesis often results from 
an alteration in one of the signalling pathways normally responsible for regulating cell 
growth. Some evidence suggests that alterations in the Ca2+ signalling pathway may 
contribute to certain forms of transformation and cancer.186 For example, a single point 
mutation of the a iB-adrenergic receptor can lead to its constitutive activation resulting 
in both increased mitogenesis and tumourigenicity.199 The importance of the 
phosphoinositide pathway has been emphasised by studies showing that antibodies to 
Gq, the G-protein that specifically couples to PLC-pl, will inhibit the mitogenic action 
of thrombin and bradykinin.200 Since the activation of such receptors which are coupled 
to the phosphoinositide pathway generate two second messengers, Ins(l,4,5)P3 and
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DAG, it is difficult to determine the relative contributions of each pathway especially 
since these messengers interact with each other.201 However, it is clear that Ca2+ is 
important especially in lymphocytes where it activates interleukin-2 production. The 
immuno- suppressant cyclosporin A exerts its action by inhibiting this Ca -dependant 
mitogenic action. This indicates that the manipulation of intracellular Ca levels by 
channel antagonists or interferon 202 may help to reduce cell growth in certain types of 
cancers.
The association of phosphatidylinositol 3-kinase with almost every growth factor 
receptor or oncogene protein-tyrosine kinase so far studied, and evidence for its role in 
mitogenesis and cell transformation, 203,204 prompted Kozikowski et al. 205 to focus on 
the ability of novel 3-substituted analogues of myoinositol 1,4,5-trisphosphate to inhibit 
GPI anchor formation, inositol phosphate signalling and phosphatidylinositol 3-kinase 
signalling. The mechanism by which phosphatidylinositol 3-kinase stimulates cell 
proliferation is not yet known but it may be involved in cytoskeletal reorganisation, 
or intracellular protein sorting.207
A pre-cancerous state which brings about the formation of a benign tumour is actually a 
loss of the ability of cells to die, or to undergo apoptosis. Recent findings suggest that
9 +intracellular Ca release via Ins(l,4,5)P3 Type-1 receptors is a critical mediator of 
apoptosis, and mutant cell line deficient in this receptor are resistant to programmed 
cell death.49 This is an important target since most anticancer drugs are aimed at 
proliferating cells whereas the mass of the tumour always possesses a number of 
quiescent undividing cells that escape chemotherapy. Once there is an intermission in 
therapy these cells begin to proliferate. Apoptosis-inducing drugs, however, would 
actually kill non-dividing cells by inducing them to die.
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2.2.3. Manic depressive illness.
Many neurotransmitters in the brain act to stimulate the phosphoinositide pathway. 
There is indirect evidence based on the action of Li+ to suggest that this pathway may 
have some role to play in manic-depression. Based on the fact that Li+ interferes with 
the formation of free inositol by inhibiting inositol monophosphatase, an inositol 
depletion hypothesis was developed to explain the therapeutic action of this ion.
The idea is that the reduction of inositol reduces the re-synthesis of the lipid required to 
generate Ins(l,4,5)P3 and will thus lead to the desensitisation of these signalling 
pathways which employ this second messenger. The corollary of this is that manic 
depressive illness results from the hyperactivity of this second messenger system. 
Valproate, a drug that has been prescribed for years in the treatment of epilepsy, has 
recently found success in controlling bipolar disorder but does not use an “inositol 
depletion” mechanism.209 This raises the question now of whether Li+ really does exert 
antibipolar activity solely via an “inositol depletion” mechanism, or through some other 
previously undetected way.
A recent review on the continuing search for inositol monophosphatase inhibitors as 
lithium mimetics has been provided by Atack (1997).210
2.2.4. Inflammation.
Modulation of the immune system is beneficial for a whole host of pathophysiological 
conditions. Autoimmune disease, tissue rejection, and other inflammatory responses 
such as sepsis, are mediated by signalling of immune cells. Modulation of such signals 
may of therapeutic value in this field and has become an active area of investigation. 
The drugs cyclosporin A, FK506 and rapamycin have revolutionarized organ 
transplantation. These drugs are used as immunosuppressants, since they intercept the
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T-cell immune response. Cyclosporin A, a lipid soluble undecapeptide of fungal origin,
is an extremely potent immunosuppressive drug which blocks the G0 to Gt transition of
2 ^ .
the T-cell by blocking Ca signalling, thus leading to the production of interleukin-2
and the activation of interleukin-2/interleukin-2 receptor autocrine loop.186
Rheumatoid arthritis and other inflammatory reactions, seem to be mediated by PTK
and it is expected that PTK blockers will find broad use in modulating immune 
186responses.
Cecconi et al,21! have shown that inositol polyanions, inositol hexakisphospate (IP6), 
inositol pentakisphosphate (IP5) and inositol hexakisulphate inhibit L- and P-selectins 
and block inflammation. Selectins are cell adhesion molecules known to support the 
initial attachment of leukocytes to inflamed vascular endothelium through their 
recognition of carbohydrate ligands. The possibility that the naturally occurring 
molecules IP6 and IP5 act to suppress inflammatory or immunological responses 
deserves attention. In addition to blocking selectins, inositol polyanions have been 
shown to possess anti-oxidant activity,212 that could enhance their ability to protect 
against the tissue damage associated with inflammation. It is thus anticipated that 
inositol polyanions or their derivatives may prove useful as therapeutic agents in the 
treatment of a variety of human inflammatory diseases.
2.2.5. HIV and Ins(l A5IP,.
Swapan et al.,2U showed that HIV-1 nef expressing N1H-3T3 cells did not release 
intracellular calcium upon stimulation with bombesin or platelet derived growth factor 
(PDGF). HIV-1 nef is a 27-kDA cytoplasmic protein, non-species restricted, encoded by 
HIV-1 (the human immunodeficiency virus type 1), whose function is speculative.
In addition, the authors demonstrated that this change in induced proliferation is due to 
the blockage of intracellular calcium release as normally mediated by Ins(l,4,5,)P3.
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These findings suggest that HIV-1 nef has a distinct biochemical activity, one that 
might have some potential role in HIV infection, and related to the phosphoinositide 
pathway. Further, it has emerged that inositol polyphosphate metabolism appears to be 
deranged in lymphocytes infected with the HIV virus, and that the effect can be 
reversed by AZT therapy.158 It seems that it is the activity of a 5-phosphatase that is 
reduced in patients infected with HTV, and that, as the disease progresses, the activity of 
3-kinase and Ins(l,3,4,5) 3-phosphatase is also decreased. A lysate from HIV infected 
cells has been shown to inhibit 5-phosphatase activity in lysates from healthy cells, 
suggesting that HIV infection may result in the production of an inhibitory factor.
2.2.6. Alzheimer’s disease.
Calcium regulated processing of the Alzheimer amyloid protein precursor (APP) in a 
protein kinase C-independent manner was reported by Buxbaum et al.215 
Alzheimer’s disease is characterised by distinct neuropathological lesions including 
intracellular neurofibrillary tangles, extracellular parenchymal and cerebrovascular 
amyloid deposits and selective cell death that particularly affect cholinergic neurones in 
the basal forebrain.216 The principal component of parenchymal amyloid plaque cores 
and cerebrovascular amyloid is the amyloid-(3-protein (ap).217'219 It has been shown that 
this 4kDA protein is produced by various cultured cells, 220-222 including transfected 
cells expressing the APP from which Ap is derived.223
During the past few years, a variety of evidence has emerged indicating that the 
processing of APP is regulated by signal transduction pathways..
More recently, it has been shown that first messengers which activate the phospolipase 
C/protein kinase C cascade, increase the secretion of APP.31, 224 It was also shown that 
the formation of a peptide with properties similar to those of Ap was decreased by
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phorbol esters, okadaic acid, and by direct activators of phospolipase C and first 
messengers that activate phospholipase C.225 However, activation of phosphlipase C not 
only activates protein kinase C (through the formation of DAG) but also increases 
cytoplasmic calcium through the action of Ins( 1,4,5 )P3 and this calcium increase was 
shown to inhibit Ap production whilst stimulating APP secretion.215 
The regulation of the formation of Ap is clearly of potential clinical relevance, and the 
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2.2.7. Diabetes and Ca2+ signalling.
Glucose is the primary stimulus of insulin secretion and synthesis in pancreatic P-cells 
of the islets of Langerhans. Increases in the intracellular Ca2+ concentration mediate the 
biochemical events that couple glucose stimulation to insulin secretion. Ca2+ 
mobilization is predominantly via the cADPR signal system in healthy cells. A recent 
report however, suggests that in diabetic P-cells, the cADPR pathway “switches off’ 
and the Ins(l,4,5)P3 Ca2+-mobilizing pathway takes over.226 The two systems for 
intracellular Ca2+ mobilization thus appear to be used differentially, depending on 
whether the condition is physiological or pathological. The significance of this finding 
is unclear and whether blocking one Ca2+ release pathway over the other will have any 
effect on the symptoms of the disease remains to be seen.
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It is thus seen that a vast array of pathological conditions have been linked with 
augmentation of calcium signalling due to possible malfunction upstream of the second 
messenger system. The phosphoinositide pathway has been often implicated with the 
suggestion that intervention primarily at the level of the Ins(l,4,5)P3 receptor and the 
metabolic enzymes may enable us to control the pathway and bring us closer to the 
design of analogues as potential drugs to act on this complicated network. However, it 
is too early for anything but the most general speculation as to the possible role of drugs 
acting on the phosphoinositide system.
CHAPTER 3
3.1. General synthetic considerations for Inositol Phosphate derivatives.
The following chapter will outline the principals for the synthesis of inositol phosphates. 
Points of discussion will be selective and limited to areas relative to the work which will 
be reported in the following chapters. Alcohol group protection chemistry, various 
phosphorylation methods and resolution procedures have been thoroughly reviewed in the 
literature and there is no need to reiterate them here.227,228
For most syntheses these days, myo-inositol is the starting material of choice owing to its 
commercial availability and inherent symmetry. Early syntheses of Ins(l,4,5)P3 have used 
D-(-)quinic acid 229 and D-pinitol 230 as well as myoinositol,231 as starting materials.
Figure 3.1. Starting materials used synthesise inositol phosphates.
OH
OH
D-Pinitol D-(-)Quinic acid L-Quebrachitol
232 233A conceptually different approach has been provided by Ley et al. ’ who have used 
benzene as a starting material in the synthesis of Ins(l,4,5)P3, taking advantage of the 
observation that microbiological oxidation of benzene affords c/s-3,5-cyclohexadiene-l,2-
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Scheme 3.1. Ley’s Synthesis of D-Ins(l,4,5)P3 from Benzene.
Since then, several of the configurational isomers of /wyo-inositol have been synthesised 
from conduritol epoxides obtained biocatalytically from halobenzenes.234 These ideas stem 
from the discovery of Gibson et al,,235 who reported the oxidation of aromatic 
hydrocarbons with mutant bacterial strains.235
A second approach, involving the use of benzene to synthesise conduritol derivatives and 
hence substituted cyclohexanes as precursors to inositol phosphates, has also been reported 
for an early synthesis of Ins(l,4,5)P3. This is a totally synthetic approach and does not 
involve any biotransformation steps.
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Scheme 3.2. Carless’s Synthesis of Racemic Ins(l,4,5)P3 from Benzene.
MEM = 2-methoxyethoxymethyl
The naturally occurring L-quebrachitol is usually the choice of starting material for L-
c/2/ro-inositol phosphate analogues, and D-pinitol that for D-chiro analogues.
The synthesis of an inositol phosphate derivative presents four main synthetic tasks;
(a) The preparation of a suitably protected inositol derivative, having free hydroxyl groups 
at the desired positions ready for phosphorylation. More often than not, this requires a 
series of selective protections, deprotections and selective protections again, before the 
desired precursor is reached.
(b) An efficient phosphorylation methodology for secondary hydroxyl groups must be 
employed, with a reagent possessing suitable phosphate protecting groups which can be 
removed prior to those on the inositol ring thus avoiding the formation of 5-membered
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cyclic phosphates and mixtures of regioisomers due to phosphate migrations. The use of 
benzyl groups to protect both the inositol hydroxyls and the phosphate esters overcomes 
either of these possibilities, as hydrogenolysis cleaves the phosphate benzyl esters faster 
than the benzyl ethers blocking the ring hydroxyls. The analogue is thus never in the
237 238position to have free hydroyl groups adjacent to its phosphate esters. ’
(c) The final deblocking of the fully protected phosphate precursor, preferably as described 
above.
(d) For the synthesis of an optically active inositol phosphate, a suitable intermediate in the 
synthetic pathway must be available for resolution, which usually involves the conversion 
of a partially protected racemic inositol derivative into a pair of diastereomeric esters via 
esterification with a chiral acid or acid derivative.
Separate hydrolyses of these esters then gives the antipodes of the starting racemic 
material, and the chiral acid/derivative is recovered. This can be a trial and error step 
however, as there is no guarantee that the diastereoisomers will be easily separable by 
conventional methods such as column chromatography or crystallization. The 
diastereomeric purity can be evaluated by HPLC and X-ray crystallography of the ester 
derivatives used to determine unambiguously the absolute configuration of the individual 
enantiomeric alcohols.239
3.2. Synthesis of DL-Insn.3«4)Pj by Riley.239
This section will serve to illustrate some common features of the chemical syntheses of 
inositol phosphates from myo-inositol. The syntheses used as examples here are those of 
the enantiomers of myo-mos\Xo\ 1,3,4-trisphosphate,239 racemic mjw-inositol-1,3,4- 
trisphosphate 239 and DL-zwyo-inositol 1,3,4-trisphosphorothioate.240 
The relevance of this regioisomer to some of the work covered in this thesis will be 
discussed in Chapter Four.
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Scheme 3.3. Synthesis of DL-Ins(l,3,4)P3 by Riley 239
myoinositol 9H Qh 
(35)


























(i)(a) 2,2-dimethoxypropane, PTSA, DMF,reflux, (b) BzCl, Pyridine; (ii) NaOH, 
MeOH, reflux; (iii) AllBr, NaH, DMF; (iv) AcOH/H20 , 4:1, reflux, (v)(a) Bu2SnO, 
toluene, reflux, (b) PMBC1, CsF, KI, DMF; (vi) BnBr, NaH, DMF; (vii) KOBu1, DMSO, 
50°C; (viii) 1M HCl/EtOH, 1:2, reflux; (ix) (aXBnO)2PNPP2, ///-tetrazole, CH2C12,
(b)BulOOH; (x) Na/liquid NH3.
Bn = benzyl, Bz = benzoyl, PMB =/>methoxybenzyl. All compounds are racemic.
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/wyo-Inositol (35) is treated with 2,2-dimethoxypropane in DMF with a catalytic 
quantity of PTSA to give a mixture of three bis-isopropylidene ketals.






These three regioisomers are then converted to their dibenzoates. The dibenzoate of 37, 
in contrast to the other two, is relatively insoluble in pyridine, water, acetone and ether, 
and can therefore be isolated by filtration and washing with these solvents. The benzoyl 
groups are then removed by boiling with methanolic sodium hydroxide to give (37). 
Compound 37 is allylated to afford 38. The isopropylidene groups are then hydrolysed 
to give the tetrol (39). Some (39) is converted to the tetra-acetate for the unambiguous 
analysis of NMR data (40).
The next step is the selective /?-methoxybenzylation of the tetrol at position C-3, (41). 
This involves regioselective protection of one hydroxyl group in the presence of three 
other hydroxyl groups; one axial and two equatorials. The reactivity difference between 
the equatorial OH groups in inositol is slight, and an organotin derivative is employed 
for the selective activation of the equatorial OH of a vicinal equatorial-axial pair.241 It 
has been shown that maximum yields in tin-mediated monoalkylations can be obtained 
by the use of caesium fluoride.242 The authors of this study suggest that the polarisable 
caesium cation interacts with the halogen atom of the alkyl halide, causing its activation 
and, furthermore, that Sn-O bonds are also activated by the formation of a pentaco- 
ordinate complex.
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The tetrol (39) then reacts with dibutyltin oxide in boiling toluene with azeotropic 
removal of water to give a dibutylstannylene derivative, which is not isolated, but 
treated with /?-methoxybenzyl chloride in DMF in the presence of caesium fluoride, to 
give the 3-0-/?-methoxybenzyl ether (41) in 65% yield. Finally, (41) is benzylated to 
give the fully protected intermediate (42). Triol (44) is generated by the removal of both 
the allyl and p-methoxybenzyl protecting groups from (42). Allyl groups are similar to 
benzyl groups in their high stability to acidic and basic conditions but, in the presence 
of very strong base, isomerisation of allyl ethers to c/s-prop-l-enyl ethers occurs. These 
enol ethers can then be cleaved by mild acid hydrolysis.243 The cw-prop-l-enyl ether 
(43) is obtained in high yield. In contrast to the unsubstituted benzyl ethers, p- 
methoxybenzyl ethers are acid labile, although less so than c/s-prop-l-enyl ethers. Thus
(43) can be converted into a diol by subjecting it to mild acid hydrolysis, or to the triol
(44) by the use of harsher conditions. For triol (44), (43) is boiled in 1M HCl-ethanol 
(1:2) for two hours, resulting in the complete conversion of (43) to (44). Flash 
chromatography is employed to remove the /7-methoxybenzyl alcohol produced in the 
hydrolysis, to give the pure triol (44).
3.2.1. Phosphorylation of the alcohol precursor (44).
Because the triol (44) possesses a vicinal diol, a P(III) phosphorylation method is 
appropriate. Direct phosphorylation of a vicinal diol using P(V) reagents, in which the 
phosphorus atom is already in the +5 oxidation state, can cause difficulties, such as the 
formation of unwanted five-membered cyclic phosphates. Using P(III) methods, the 
hydroxyl groups are first phosphitylated and are subsequently oxidised to give the 
protected phosphate ester. P(III) methodology can also be adapted to give 
phosphorothioates by using sulphur as the oxidising agent in the second stage.
The phosphitylation of (44) is carried out using the P(II1) reagent bis(benzyloxy)-A/^7V-
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diisopropylaminophosphine which has to be catalytically activated by a weak acid, such 
as ///-tetrazole, giving a reactive tetrazolide. When the substrate is added, any vicinal 
phosphite triesters formed will show 5JpP spin couplings which can confirm the 
substitution pattern of the product. Finally, after oxidation (or sulphoxidation), the 
disappearance of all phosphite signals confirms that the reaction has gone to 
completion.
After ///-tetrazole is added to a solution of phosphitylating agent in dry 
dichloromethane, and stirring continued for ten minutes, a proton-decoupled 31P NMR 
spectrum shows a singlet at 5p127 representing the phosphitylating agent-tetrazolide. 
The triol (44) can now be added. After stirring for one hour, 31P NMR shows the 
appearance of signals 8p 140.39(2P) and 8P 142.21 (IP) corresponding to the 
trisphosphate triester. A high resolution, low sweep-width 31P NMR spectrum of the 
signals close to 5P 140 resolves three signals, two of which are doublets with a coupling 
constant of 3.7Hz. This arises from the 5Jpp spin coupling between the P atoms at C-3 
and C-4, and is clear evidence that the compound contains a vicinal bisphosphite. Thin 
layer chromatography was used to judge the purity of the phosphitylating agent and the 
course of the reaction thereafter. A small amount of water added before oxidation reacts 
with any excess phosphitylating agent-tetrazolide and thus simplifies the later 
purification stage. The oxidation is carried out by adding excess tert-butyl 
hydroperoxide, (w-chloroperbenzoic acid is found to give higher yields of oxidised 
compound and was thus the choice of oxidising agent used in the work described in this 
thesis), to give the protected trisphosphate triester (45). 3lP NMR now shows 
disappearance of the signals at around 8P 140, to be replaced by three clear singlets at 
8p-1.42, -1.57 and -1.81. //-phosphonate at 8p7.5 is also commonly seen at this stage 
and can be easily removed by flash chromatography to give the pure benzyl protected
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trisphosphate triester (45).
3.2.2. Deprotection and purification of the deprotected target phosphate 33.
The final deblocking of (45) involves the removal of nine protecting benzyl groups 
using sodium in liquid ammonia to give compound (33).
An alternative deprotection strategy for this synthesis would be to use hydrogenolysis, 
which is more reliable and usually gives near quantitative yields. This was the preferred 
method used for the deblocking of phosphate esters in this work. Hydrogenolysis cannot 
be used to deprotect phosphorothioates, compounds with ester protecting groups or 
unsaturated compounds. Deprotected inositol phosphates sire purified by ion exchange 
chromatography. The ion exchange column is eluted using a gradient of 
triethylammonium hydrogencarbonate (TEAB) buffer from 0 to 1M over a volume of 
900 mL. It is not immediately apparent which fractions contain the target compound as, 
with no chromophore present, the usual post-column detection by UV absorption is not 
possible. The fractions containing phosphate are detected using a method which relies 
on the complexation of free phosphate with molybdate ions 244 and are then subjected to 
31P NMR to determine which phosphate-containing fractions contain the desired 
product.
As the inositol phosphates obtained by ion-exchange purification are isolated as their 
triethylammonium salts, whose stoichiometries may be different in each case, the 
formula mass is not known accurately and they cannot therefore be quantified on the 
basis of mass. Instead, a quantitative assay must be carried out for phosphate. The result 
of this assay is a quantity of inorganic phosphate (prnoles) cleaved from the molecule 
which is then divided by three for a trisphosphate, four for a tetrakisphosphate, etc. The 
Briggs phosphate assay,244 has been used in the work carried out in this thesis.
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The proton coupled 31P NMR spectrum of (33) confirms the presence of three 
phosphate groups with heteronuclear 3JHcop coupling.
3.2.3, Optical resolution.
The optical resolution of derivative DL-(46) in order to synthesise the optically pure 
antipodes of the racemate, is carried out via the formation of the camphanate esters of 
DL-(46) to give the diastereoisomers (47) and (48). Both S-(-)- and R-(+)-camphanic 
acid chlorides are available in high optical purities and their use as reagents in the 
resolution of optical derivatives is common.245-247 The diastereoisomeric camphanate 
esters can sometimes be separated by crystallisation or their polarities may be 
sufficiently different to allow separation by column chromatography.
Figure 3.3. Reagents used to resolve inositol derivatives.
C10CCH2Cr"
L-menthoxyacetyl chloride248 r _(+)_ i -phenyl ethyl
isocyanate
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Il'^ 'Cl (lS)-(-)-Camphanic acid chloride O
( i ) M HCl/acctonc. 1:10, 50°C. ( i i ) (S)-ru-camphanic acid chloride. DMAP. pyridine; 
( iii) NaOH. MeOH. reflux. ( iv ) BnBr. NaH, DMF. ( v ) MHCl/EtOH. 1:2, reflax.
( v i) (a) (BnO)2PNPri2, 1H-tcirazole. (b) BuUDOH; ( v ii) Na/liquid NH3.
Bn = benzy l, PMB = />-methoxybenzyl, (-) Camph =  (S)- (-) - <y-camphanate
43 is treated with 1M HCl-acetone to form the racemic diol 46. The acid is quickly 
neutralised before any cleavage of the /?-methoxybenzyl ether can occur. Racemic (46) 
is then converted to its bis(-)-*y-camphanate esters to give the diastereoisomers (47) and 
(48). These are then separated by column chromatography. Saponification of the 
individual diastereoisomers gives the enantiomeric diols D-(46) and L-(46). These are
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then converted to the phosphorylation precursor triols by removal of their p- 
methoxybenzyl groups as described for (12). These are then converted to their 
corresponding chiral inositol phosphates, as described for the racemate.
3.2.4, Phosphorothioate substitution.
As described in Chapter 1, substitution of phosphates with phosphorothioates causes a 
substantial loss of agonist activity at the Ins(l,4,5)P3 receptor accompanied by a less 
significant loss of affinity and is therefore an important lead in the designing of partial 
agonists, with the view of identifying the structural requirements necessary to produce 
an antagonist at the Ins(l,4,5)P3 receptor.












DL-Ins(l,3,4)PS3 - a partial agonist.
The phosphitylation of (44) has been described above. Oxidation of the trisphosphite 
triester with elemental sulphur in pyridine affords the benzyl protected
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trisphosphorothioate ester (49). Column chromatography is required at this stage to 
purify 49. Removal of the nine benzyl groups is affected by ammonolysis as described 
above, and purification of the desired trisphosphorothioate compound (34) by ion 
exchange chromatography. Qualitative and quantitative analyses are as described for the 
trisphosphate 33.
The routes discussed above serve to illustrate some common features of most published 
syntheses of inositol phosphates and phosphorothioates from myo-inositol.
These can be summarized as follows:
Step 1) Selective protection of hydroxyl groups
Step 2) Resolution of a protected intermediate if a chiral entity is required,
often followed by more protection and deprotection steps to achieve 
the desired precursor for Step (3)
Step 3) Phosphorylation of exposed hydroxyl groups by P(III) methodology
which involves phosphitylation followed by oxidation to produce 
phosphates or sulphoxidation for phosphorothioates 
Step 4) Deprotection of hydroxyl groups and phosphate/phosphorothiote
groups, preferably simultaneously.
Step 5) Purification, usually by ion-exchange chromatography or HPLC. This
final purification step is very important to ensure that samples used for 
biological investigations are free of contaminants which, if present, 
may result in misleading biological results
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3.3. Aims and Objectives of this Project.
The theme of this research project is the study of the effects of single and multiple 
stereocentre inversions of the Ins(l,4,5)P3 molecule on binding with its metabolic 
enzymes and its ability to release Ca2+ via the Ins(l,4,5)P3 receptor, the focus being on 
the position-3 and -6 hydroxyl groups and the 4,5-bisphosphate system. The effects of 
configurational change at positions-1, -2 and -3 of Ins(l,4,5)P3 are well documented in 
the literature but the importance of the 4,5-bisphosphate moiety and the 6-OH for 
productive enzyme binding and Ca2+ release, have been judged only by deletion or 
substitution.92-99 Inverting the stereochemistry at any one of the six substituents has 
often been predicted to have the same effects as deletion of the substituent at that 
particular centre,92’100 and the understanding that the 4,5-bisphosphate system and the 6- 
position hydroxyl are the crucial motifs for receptor binding and Ca2+ mobilisation, has 
inhibited scientists in the field from probing the effects of stereochemical change at 
these positions. The current aim in the field, however, is the identification of the 
structural features of Ins(l,4,5)P3 which are responsible for receptor affinity but not
2"bCa release efficacy and thus the design of a receptor antagonist. Compounds that bind 
with reasonably high affinity and yet appear to behave as partial agonists are therefore 
important lead compounds. Could it be possible that such a feature may exist within the
4,5-bisphosphate and flanking 6-hydroxyl system, such that deletion of one of these 
substituents is too disruptive a modification and yet inversion of stereochemistry is not 
? Could it be that stereochemical change can alter the conformation of the inositol ring 
to cause non-productive receptor binding and thus the discovery of a partial agonist ? 
These are the working hypotheses of this piece of research for which it is hoped that 
many questions will be answered. All the target compounds synthesised in this work are 
currently under biological evaluation.
/  4
The following diagram aims to relate the structures of the diastereomeric compounds 
synthesised as part of this project, with some of the relevant regioisomers of 
Ins(l,4,5)P3 already reported.
Figure 3.4. scy/Zo-Inositol 1,2,4-trisphosphate and trisphosphate mimics with different 
configurations synthesised to date.
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Two chiral regioisomers of Ins(l,4,5)P3 have been synthesised, namely D-Ins(2,3,5)P3 
(96) [also the racemic analogue DL-Ins(l,2,5)P3 (89)] and D-Ins(2,3,6)P3 (100), which 
can be visualised as Ins(l,4,5)P3 with the 4- and 5-position phosphates inverted, 
respectively. The axial 2-hydroxyl of Ins( 1,4,5)P3 is equatorial in these structures but it
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is well established that this centre plays little part in the receptor affinity and Ca2+ 
release efficacy of Ins (1,4,5) P3 . 78-84 Also synthesised were the racemic epimers of 
Ins(l,4,5)P3, DL-weo-Ins(l,2,4)P3 (111) and DL-<?/?/-Ins(l,3,6)P3 (112) which can be 
seen as Ins(l,4,5)P3 with the 5-phosphate inverted and the 6-hydroxyl inverted 
respectively. Note that the only difference between the structures of 100 and 111 is the 
orientation of the 2-hydroxyl. It is expected that these two analogues will exhibit similar 
biological properties. Two racemic diastereoisomers of Ins(l,4,5)P3 were also 
synthesised as part of this work: DL-neo-Ins(l,3,4)P3 (65), which has the 1,4,5- 
trisphosphate arrangement of Ins(l,4,5)P3, but with the configurations of the three 
hydroxyl groups inverted, and DL-a//o-Ins(l,3,6)P3 (121) which has the 3- and 6- 
position hydroxyls inverted. The corresponding racemic phosphorothioate of 65 was 
also constructed to probe the effects of 3- and 6-hydroxyl inversion together with 
phosphorothioate substitution, as trisphosphorothioate analogues of Ins( 1,4,5)P3 with 3- 
position or 6-position hydroxyl inversions are known to be partial agonists at the 
Ins(l,4,5)P3 receptor.119
A meso tetrakisphosphate, «eo-Ins(l,3,4,6)P4 (60) was also made in order to propose a 
binding orientation for the previously established naturally occurring partial agonist 
Ins(l,3,4,6)P4 (9).116,117 This latter tetrakisphosphate (9) can present three of its 
phosphates in the arrangement of those of Ins( 1,4,5 )P3 in two different orientations, one 
possessing a pseudo-axial 3-hydroxyl and the other possessing an axial 6-hydroxyl 
group (Figures 4.1. and 4.2.). The tetrakisphosphate constructed (60) presents both 3- 
and 6- hydroxyls in an axial orientation and is thus expected to prove that 60 adopts 
only one of the two possible binding conformations. (An assumption is made here that 
the “new” axial hydroxyl does not interfere with receptor binding or efficacy.)
More detail about the design of each of these molecules together with a discussion of 
their respective syntheses will be given in the following chapters of this thesis.
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CHAPTER 4
4.1. Dissection of the structural features of Ins(l,3»4,6)P4 to determine 
its behaviour as a partial agonist at the Ins(l,4,5)P3 receptor.
4.1.1. Design of wgg-inositol-1.3.4.6-tetrakisphosphate (60)
The naturally occurring tetrakisphosphate Ins(l,3,4,6)P4 (9) behaves as a partial agonist 
at the Ins(l,4,5)P3 receptor, releasing around 80% of the Ca2+ mobilised by Ins(l,4,5)P3 
in SH-SY5Y neuroblastoma cells.116,117 When the maximally effective Ca2+ releasing 
concentration of Ins( 1,3,4,6)P4 is administered together with Ins(l,4,5)P3, the EC50 of
I |  o
the latter is increased, indicating that both species are competing for the same site. 
This is strong evidence that Ins(l,3,4,6)P4 is behaving as a true partial agonist, making 
it an important lead compound in the search for a specific receptor antagonist. It was 
decided that dissection of the structural similarities and differences between 
Ins(l,3,4,6)P4 and Ins(l,4,5)P3 should present some idea for their behavioural 
differences.
Figure 4.1.. Possible binding orientations of Ins( 1,3,4,6)P4 mimicking the trisphosphate 







At a glance, Ins(l,3,4,6)P4 appears to lack the 1,4,5-trisphosphate arrangement of 
Ins(l,4,5)P3 known to be necessary for Ca2+ mobilisation.
Turning the molecule 180° about the x-axis (orientation 1) and about the y-axis 
(orientation 2) presents two alternative binding modes, each of which exhibits three 
phosphate groups in the same spatial distribution and orientation as the phosphates of 
Ins(l,4,5)P3 (Fig. 4.1). However, this can only occur at the expense of placing an extra 
phosphate group at the position analogous to position-2 of Ins(l,4,5)P3 (pseudo-2 
position). This difference in the two structures may be disregarded as the cause of 
partial agonism of Ins(l,3,4,6)P4, as sole modification of the axial C-2-OH of 
Ins(l,4,5)P3 has been shown to produce potent full agonists.78*80 Notice, however, that 
binding orientation 1 presents an axial hydroxyl group at the pseudo-3 position and 
orientation 2 presents the same inverted configuration at the pseudo-6 position. One or 
both of deviations from the structure of Ins( 1,4,5)P3 can thus be taken to be responsible 
for the partial agonist property of Ins( 1,3,4,6)P4. This deduction was the stimulus for the 
design and synthesis of the stereochemically meso compound weo-inositol-1,3,4,6- 
tetrakisphosphate (60).
Figure 4.2. The only possible binding orientation of (60) presents axial hydroxyl groups 




There is only one binding conformation of (60). Whichever way up about the x-axis the 
molecule binds, its exhibits the hydroxyls flanking the 4,5-bisphosphate in an axial 
orientation (fig.4.2). It is expected that biological evaluation will prove whether 
Ins(l,3,4,6)P4 can bind to the Ins(l,4,5)P3 receptor with both proposed binding
comparable affinity and intrinsic efficacy as Ins(l,3,4,6)P4, it may be assumed that the 
latter interacts with the Ins(l,4,5)P3 receptor with both of the proposed binding 
orientations, that is to say that both an axial position-3 and -6 are tolerated. It will be 
interesting to compare the biological activities of 9 and 60 with those of •sqy/Zoinositol-
1.2.4.5-tetrakisphosphate (13) which presents the two hydroxyls flanking the pseudo-
4.5-bisphosphate system in the equatorial orientation.(Fig. 4.3).
Figure 43. Ins(l,3,4,6)P3 (9), 60 and 13.
orientations 1 and 2 or not. If receptor binding and Ca2+ release studies show 60 to have
Ins(l,3,4,6)P4 (60) (13)
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Scheme 4.1. Synthesis of «eo-inositol-l,3,4,6-tetrakisphosphate (60).
(i) 2,2-dimethoxypropane, PTSA, DMSO, reflux; (ii) Bu2SnO, Bu4NBr, AllBr, CH3CN; 
(iii) a) (CF3S02)20, CH2C12; b) CsOAc, DMF; (iv) MeOH, NaOH; (v) MeOH-HCl;
(vi) a) Bu2SnO, toluene; b) AllBr, CsF, DMF; (vii) NaH, BnBr, DMF; (viii) Pd/C, 
PTSA, EtOH-H20, reflux; (ix) a). (BnO^PNP^, tetrazole, CH2Cl2b). CIC^CO^H; (x) 
H2, Pd/C, 50psi.
Figure 4.4. Energy minimised models of myo- 
inositol-l,3,4,6-tetrakisphosphate (9) (left) and 
«eo-inositol-l,3,4,6-tetrakisphosphate (60) (right).
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The meso compound «eo-Ins(l,3,4,6)P4 (60) was synthesised by a route starting with 
myo-inositol. The key fully protected intermediate DL-2-O-acetyl-1,3,4-tri-0-allyl-5,6- 
O-isopropylidene-rteoinositol (53) was also used to synthesise DL-«eoinositol-1,3,4- 
trisphosphate (65) and the corresponding trisphosphorothioate (67). A side product of 
this route, DL-l,4,5-Tri-0-allyl-2,3-Oisopropylidene-myo-inositol (52) was employed 
in the synthesis of DL-e/?Mnositol-l,3,6-trisphosphate (83).
4.1.3. Synthesis of the key intermediate DL-2-Q-acetvl-l,3,4-tri-0-allyl-5,6-0- 
isopropvlidene-/igoinositol (53).
DL-2-0-acetyl-l,3,4-tri-0-allyl-5,6-0-isopropylidene-«eoinositol (53) was synthesised 
via the known compound DL-l,2-0-isopropylidene-myoinositol (50).
The next step was the regioselective allylation of 50 to give the tri-0-allyl analogue 51 
using a procedure described by Gigg et al.2Sl The procedure used required the 
regioselective protection of three of the four equatorial hydroxyl groups.
The tetrol 50 was treated with excess dibutyltin oxide, tetrabutylammonium bromide, 
and allyl bromide in acetonitrile, with a Soxhlet apparatus containing 3A molecular 
sieves to remove water, thereby forcing the equilibrium in the direction of products. 
The two major products isolated from the reaction were the two tri-O-allyl ethers 51 
and 52, 51 being the slightly more polar product as judged by TLC. Purification of the 
products was by flash chromatography to afford the two syrups each in approximately 
30% yield.
The next step was to invert the stereochemistry at position-5 of 51 via its corresponding 
triflate. Triflation of the dried alcohol was effected by treatment with 
trifluoromethanesulphonic anhydride in dry dichloromethane. A small quantity of 
pyridine was used as a nucleophilic catalyst.
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The potentially labile trifluoromethanesulphonate was not purified. Completion of the 
reaction was judged by TLC before the reaction was worked up. Treatment of the crude 
triflate with caesium acetate in dimethylformamide displaced the triflate with inversion 
of configuration, to give the fully protected weo-analogue 53. Purification of 53 was by 
flash chromatography.
Scheme 4.2. Displacement of the triflate group with inversion of configuration.
This method of stereocentre inversion provided clear evidence that the reaction had 
proceeded as expected. Deshielding by the acetate of the proton C-2-H attached to the 
stereocentre, allowed the unambiguous assignment of structure 53 by ]H NMR (Figure 
4.5a) and ^ - ’H-COSY (Figure 4.5b). A 13C NMR signal at 5 170.1 showed the 
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Figure 4.5.b. ]H-lH  COSY of 53.
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Figure 4.5.c. 13C NMR spectrum of 53.
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4.1.4. Generation of the phosphorylation precursor 2,5-Di-O-benzvl-ngo-inositol
i m
The acetate ester 53 was saponified to yield the alcohol 54 in excellent yield and the 
product was treated with acid to hydrolyse the isopropylidene ketal, affording the triol 
55. The next stage of the synthesis was the selective protection of the triol 55 at 
position-6 (Scheme 4.1.).
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This involved the protection of an equatorial hydroxyl group in the presence of two 
axially oriented ones. The difference in reactivity of the hydroxyl groups of inositols is 
slight and the use of organotin derivatives has found place in the selective activation of 
the equatorial hydroxyl of a vicinal axial-equatorial pair.241 The triol 55 was treated 
with dibutyltin oxide by boiling in toluene with the azeotropic removal of water to give 
a dibutylstannylene derivative. 119Sn NMR and mass spectroscopic studies of 
carbohydrate derived stannylenes suggest that they are dimeric in all physical states 
except perhaps in polar solvents.252
Figure 4.6. Formation of a dibutylstannylene dimer in a non-polar solvent like toluene. 
O-Sn-O bond angles are approx. 80°, forming a trigonal bipyramid.252
The stannylene derivative can undergo regioselective acylation, alkylation and 
oxidation but the precise mechanism of the regioselectivity is unknown. However, the 
hypothesis can be advanced that one of the two oxygens can be involved in the 
stannylene ring is more nucleophilic than the other. Invoking the dimeric structure may 
provide a plausible explanation. Within one monomeric unit of the dimer, the apically 
bound O-atoms (Oe) are regioselectively alkylated. These are the O-atoms not involved 
in the Sn20 2 parallelogram. Such nucleophilic enhancement may be the result of 
electron channelling from the Sn-atom toward the apically oriented and electronically 
less enriched O-atoms (Oa). Furthermore, these O-atoms are relatively protected by 
three-fold co-ordination. Hence, whichever of the O-atoms will bind apically in the
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stannylene will undergo alkylation. This is likely to be the most electronegative one, as 
it is known that in trigonal bipyramid complexes, electronegative ligands are more 
stable when occupying apical positions. Conversion to a stannylene may thus accentuate 
small electronegativity differences between the two oxygen atoms of a diol252 
The dibutylstannylene derivative of 55 was not isolated but reacted with allyl bromide 
in anhydrous dimethylformamide in the presence of caesium fluoride to give the 
crystalline tetra-O-allyl ether 56 in high yield. Figure 4.7 shows the NMR spectrum 
of 56, demonstrating the symmetry of the molecule.
Figure 4.7. *H NMR spectrum of 56.






It has been shown that maximum yields in tin-mediated mono-alkylations can be 
obtained by the use of caesium fluoride.242 The authors of this study suggest that the 
polarisable caesium cation interacts with the halogen atom of the alkyl halide causing 
its activation. This suggestion, together with that of Sn-0 bond activation by the 
formation of a penta-coordinate complex, may be the explanation for the high yielding 
regiospecific nature of this mechanism. The symmetrical diol 56 was then benzylated 
using sodium hydride and benzyl bromide in dry DMF to give the fully protected di-O- 
benzyl ether 57 in high yield and the minor mono-benzylated product 57a. The next 
step was to generate the phosphorylation precursor tetrol 58 by removing the four allyl 
protecting groups from 57. This involved initial isomerisation of the allyl ethers with 
palladium and acid hydrolysis of the intermediate enol ethers in a one pot procedure
4.1.5 Phosphorylation of 2,5-Di-Q-benzvl-/fgo-inositol (58).













Because the tetrol 58 possesses two pairs of vicinal diols, a P(III) approach to 
phosphorylation was necessary. Using P(III) methods, the hydroxyl groups are first 
phosphitylated and subsequently oxidised to give the protected phosphate ester.
The phosphitylation of 58 was carried out using the P(III) reagent bis(benzyloxy)-N, A/- 
diisopropylaminophosphine which was first catalytically activated by the weak acid 
tetrazole, giving a reactive tetrazolide.
Scheme 4.4. Formation of the phosphitylating agent-tetrazolide. 
bis(benzyloxy)- N, iV-diisopropylaminophosphine
After tetrazole was added to a solution of the phosphitylating agent in dry 
dichloromethane, a proton-decoupled 3,P NMR spectrum showed a singlet at 5p 127, 
confirming the presence of the tetrazolide. The tetrol 58 was then added and the 
formation of the trisphosphite triester was judged by TLC. A small quantity of water 
was added before the trisphosphite was oxidised to the trisphosphate 56. The oxidation 
was carried out with excess m-chloroperoxybenzoic acid.
1H- tetrazole
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The 31P NMR showed a clear singlet at 5p -1.98 corresponding to the four chemically 
and magnetically equivalent phosphate groups of 59 (Figure 4.8), and a small amount of 
a //-phosphonate by-product at 5p 7.5. The latter was easily removed by flash 
chromatography. Determination of the purity of the trisphosphate by TLC, NMR and 
31P NMR is crucial at this stage.
4.1.6. Deprotection and Purification of the target tetrakisphosphate 60.
The final deblocking of 59 involved the removal of the twelve protecting benzyl groups 
by hydrogenolysis at a pressure of 50psi over palladium on carbon. This method is 
reliable and high yielding.
The tetrakisphosphate 60 was purified by ion exchange chromatography. Any 
uncharged by-products from the deprotection step can be easily separated from the 
highly charged tetrakisphosphate by this purification procedure. Problems can occur 
however if other similarly charged inositol phosphates, which may have arisen from 
phosphate migrations during deprotection, are present. Such unwanted products are 
obvious on 31P NMR spectra and HPLC techniques can sometimes be used to separate 
mixtures.
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Figure 4.8. 31P NMR spectrum (proton-decoupled) of 59 showing the magnetic 
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The ion exchange column was eluted using a gradient of triethylammonium 
hydrogencarbonate (TEAB) buffer from 0-1M. Detection of the tetrakisphosphate by 
the usual UV methods after ion-exchange purification is not possible due to the lack of 
a chromophore. The fractions containing the tetrakisphosphate 60 were thus detected 
using a method that relies on the complexation of free phosphate with molybdate ions, 
and then subjected to 31P NMR spectroscopy to determine which phosphate-containing 
fractions contained the desired product.
4.1.7. Post-ion exchange detection of the tareet phosphate compound 60 - A 
modification of the Briggs phosphate assay.244
Post-column detection of the desired phosphate compound was carried out using a 
modified Briggs phosphate assay.244 This assay is very sensitive to inorganic phosphate 
ions. It is therefore crucial that the sample is pure and any phosphate present is only that 
which is related to the compound which is being assayed.
250]uL of each of the fractions collected from the ion exchange column were pipetted 
into clean dry test tubes and heated to dryness, 175°C for 30min. The tubes were 
allowed to cool and three drops of concentrated sulphuric acid were added to each. The 
tubes were placed in an oven at 175°C for 1.5h. After cooling, water (250juL) was added 
to each sample in order to dissolve the residue. A solution of ammonium molybdate 
(500pL, 12.5%"/v) in water and concentrated sulphuric acid (8mL) was added, 
followed by 250pL of hydroxyquinone solution (0.5%w/v in water and one drop of 
concentrated sulphuric acid). Each tube was shaken and finally 250pL of sodium 
sulphite solution (20%w/v in water) was added. Each test tube was heated in turn (for 
approx. 10s with a heatgun) just until the contents started to boil. The formation of a
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blue colour, after heating, was indicative of the presence of inorganic phosphate. The 
column fractions corresponding to the blue solutions were concentrated and P NMR 
and !H NMR spectra were taken to ensure that the required target compound had been 
isolated and satisfactorily purified.
4.1.8. Quantification of the purified target phosphate ester 60.
Because the tetrakisphosphate 60 obtained by ion exchange purification was isolated as 
its triethylammonium salt, the stoichiometry and hence the formula mass was not 
known accurately, therefore it could not be quantified on the basis of mass. Instead, a 
quantitative assay for phosphate was required. (This is only feasible if the compound in 
question is pure, with no other regioisomers or phosphate cleavage products present). 
The isolated phosphate 60 was made up to a known volume with de-ionised water. 
Ascending volumes of this stock solution were pipetted into clean test tubes and treated 
as for the qualitative assay described above. The blue solutions finally obtained were 
transferred to volumetric flasks and made up to lOmL with de-ionised water. The UV 
absorbence of each lOmL fraction was recorded at 340nm using 3mL matched quartz 
cells. The concentration of phosphate was calculated from two standard curves drawn 
from UV absorbance values of known concentrations of KH2P04 which were treated as 
above and their UV absorbance measured at 340nm.
The result of this assay was a quantity of inorganic phosphate (in pmoles) which was 
divided by four to give the quantity of the tetrakisphosphate 60 as 32pmoles. Only one 
signal was observed by 3IP NMR (Figure 4.9) owing to the chemical and magnetic 
equivalence of the four phosphate groups of the symmetrical molecule. The identity of 
60 was further confirmed by *H NMR and mass spectroscopy.
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4.2. Inversion of configuration of the two hydroxyls flanking the 4,5- 
bisphosphate system of Ins(l,4,5)P3, and phosphorothioate 
substitution.
4.2.1. Design of DL-/tgfl-inositol-l,,3,4-trisphosphate (65).
Another analogue designed to probe the effects of inverting the configuration of the two 
hydroxyls flanking the crucial 4,5-bisphosphate system of Ins(l,4,5)P3 was DL-neo- 
inositol-l,3,4-trisphosphate (65).






The L-enantiomer is seen to possess the same structural features as the
tetrakisphosphate 60, with the exception of the equatorial phosphate at position-4 
(position-6 of 65) (Fig. 4.16). If the prediction is true that the extra phosphate group of 
Ins(l,3,4,6)P4 (60) has no contribution to its partial agonist nature, then it is expected 
that 60 and 65 will have very similar binding affinities and intrinsic efficacies.
4.2.2 Potential interaction of 60 and 65 with the Ins(l,4.5)Pj metabolic enzymes.
Both compounds «eo-inositol-1,3,4,6-tetrakisphosphate (60) and DL-rceo-inositol-1,3,4- 
trisphosphate (65) could be Ins(l,4,5)P3 5-phosphatase inhibitors from the structure- 
activity relationships outlined in fig. 1.16. The 6-position equatorial hydroxyl group of 
Ins(l,4,5)P3 is important for Ins(l,4,5)P3 5-phosphate activity.
Figure 4.11. Binding of L-c/7/ro-Ins(2,3,5)P3 to Ins(l,4,5)P3 5-phosphatase.
i
H<
Ins (1,4,5) P3 L-chiro-lns (2,3,5) P3
Inverted and rotated
Recall from Chapter 1 that L-c/z/roIns(2,3,5)P3, which can be visualised as Ins(l,4,5)P3 
with an inverted hydroxyl at position-3, is a potent inhibitor of Ins(l,4,5)P3 5-
enzyme in a non-productive inverted and rotated fashion, presenting an axial hydroxyl 
at the equivalent of position-6 of Ins(l,4,5)P3, as other 3-position-modified analogues of 
Ins(l,4,5)P3 are found to be good substrates for the enzyme. Furthermore, deletion or 
substitution of the equatorial hydroxyl group at position-6 of Ins( 1,4,5)P3 also creates 
potent 5-phosphatase inhibitors.98,100 Both compounds 60 and 65, however, have 
inverted hydroxyl groups at both pseudo positions 3 and 6. Since the effects of inversion 
of stereochemistry at each of these centres is known, it will be interesting to examine 
the effects of the two modifications together.
Figure 4.12. Binding orientations of 60 and 65 to Ins(l,4,5)P3 5-phosphatase.
phosphatase. 163-166 This phenomenon may be attributed to the molecule binding to the
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The site of Ins(l,4,5)P3 3-kinase action is the equatorial 3-OH of Ins(l,4,5)P3. It is 
known that 6-OH deletion of Ins( 1,4,5)P3 is well tolerated by the enzyme," and the 2- 
OH is not important for recognition by the enzyme.148 Inversion of the 3-position 
hydroxyl, however, to give L-c/riro-Ins(2,3,5)P3, produces a potent Ins(l,4,5)P3 3-kinase 
inhibitor. Both compounds 60 and 65 are thus expected to be 3-kinase inhibitors on 
these grounds, assuming that no other features affect binding.
Preliminary tests* have already shown 65 to be a Ins(l,4,5)P3 5/6-kinase inhibitor, and 
60 is expected to exhibit the same characteristics, due to the alteration of the 5,6-di- 
equatorial hydroxyl site of enzyme action.
Figure 4.13. Potential inhibitors of Ins( 1,3,4)P3 5/6-kinase.
D-myo-Ins( 1,3,4)P3-natural substrate for Ins(l,3,4)P3 5/6-kinase.





Altered site of action. 





Altered site of action.
Expected to be a potent inhibitor.
(60)
* Dr Philip Hughes, University o f  Birmingham, Centre for Clinical Research in Immunology and Signalling
1996.
Figure 4.14. Energy minimised 



























Scheme 4.6. Synthesis of DL-«eo-inositol-l,3,4-trisphosphate (65).
i) BnBr, NaH, DMF; ii) KOBu\ DMSO, 50°C; iii) 1M HCl-EtOH;
iv) a). (NCCH2CH20)2PNPri2, tetrazole, CH2C12; b). ClQJ^COsH; v) Na/liquid NH3.
The triol 55 was prepared in the synthesis of 60. Benzylation of 55 gave the fully 
protected crystalline intermediate DL-1,3,4-tri-<9-allyl-2,5,6-tri-0-benzyl-«eo-inositol 
61 in 83% yield. A mono-benzylated minor product 61a was also isolated.
The next step was to generate the phosphorylation precursor triol 63 by removal of 
three allyl groups from 61. Allyl groups are similar to benzyl groups in their high 
stability to acidic and basic conditions but, in the presence of a very strong base, 
isomerisation of allyl ethers to c/s-prop-l-enyl ethers occurs. A 3-carbon prototropic
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shift mechanism has been suggested to explain the high degree of cri-specificity of this 
rearrangement.253 The enol ether thus formed can be cleaved by mild acid hydrolysis.
Figure 4.15. Proposed structure of two intermediate states of the allyl ether to cw-prop- 
1-enyl ether rearrangement.253
-  R
 Partial covalent character in the
transition complex.
 Electrostatic bonds.
The a-hydrogen (Ha) is labilised by the attraction to the alkoxide oxygen atom. By 
movement of only a proton, the complex with the hydrogen at position Hb results.
Scheme 4.7. Mechanism of allyl isomerisation with potassium /-butoxide.
The allyl ether isomerisation of 61 was carried out using freshly sublimed potassium t- 
butoxide in dimethylsulphoxide at 50°C. Acid hydrolysis of the czs-prop-l-enyl ethers 
of 62 afforded the crystalline triol 63 in excellent yield.
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4.2,4 Phosphorylation of DL-l,2,,5-Tri-0-benzvl-/tgo-inositol (63).












As for compound 60, a P(III) approach to the phosphorylation of 63 was adopted. In this 
case the phosphitylation reagent used was bis(2-cyanoethoxy)-A,iV- 
diisopropylaminophosphine which had been activated as the tetrazolide. Conversion to 
the trisphosphite triester was judged by TLC. Oxidation to the trisphosphate triester was 
effected with excess m-chloroperoxybenzoic acid. Purification by flash chromatography 
afforded the pure fully protected trisphosphate 64 in 54% yield, and a proton-decoupled 
31P NMR showed two clear singlets at 5p -3.19 (IP) and -3.23 (2P) corresponding to the 
trisphosphate triester 64. ]H NMR and mass spectroscopic data further confirmed the 
identity of 64. The purity of 64 was judged by TLC and NMR.
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4.2.5. Deprotection and Purification of the Target Inositol Phosphate 65.
The final deprotection of 64 involved the removal of the six cyanoethyl groups 
protecting the phosphates and the three benzyl groups which would be cleaved to afford 
hydroxyls. Both the base-promoted elimination of the former and the reductive cleavage 
of the latter were achieved with sodium in liquid ammonia. Sodium was added to the 
distilled liquid ammonia at -78°C until the solution remained a deep blue colour due to 
solvated electrons of the sodium. The reaction was quenched with methanol after 
1.5min.
The deprotected trisphosphate 65 was purified by ion exchange chromatography as 
described for 60. After deprotection, the crude product contains large amounts of 
sodium salts and uncharged by-products which are easily separated from the highly 
charged inositol phosphate by the ion exchange column. The pure compound was 
quantified using a modified Briggs phosphate assay 244 as previously described for 60.
31P NMR confirmed the presence of three phosphate groups on the molecule showing
*2 i
heteronuclear Jhcop coupling. The identity of 65 was further confirmed by H NMR 
(Figure 4.16a). Peaks for (protonated) triethylamine are evident in this spectrum and in 
spectra of other triethylammonium salts. Assignment of the spectrum was facilitated byt 
the COSY spectrum (Figure 4.16b). The mass spectrum was also consistent with the 
structure.
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Figure 4.16.a. 'H NMR spectrum of 65.
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Figure 4.16.b. ‘H-'H COSY of 65.
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4.2.6. Design of DL-/fgfl-inositol-1.3.4-trisphosphorothioate (67).
To date, no inositol phosphate has demonstrated partial agonist activity in the rabbit 
platelet assay. However, three phosphorothioates, namely L-c/wro-inositol-2,3,5- 
trisphosphorothioate ( l l) ,120 L-/7zyo-mositol-l,3,4-trisphosphorothioate (15)119 and 
D-wryo-inositol-l,4,6-trisphosphorothioate (17),121 have been demonstrated to have 
partial agonist properties in this system.
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Another low intrinsic activity phosphorothioate, D-6-deoxy-/wyo-inositol-1,4,5- 
trisphosphorothioate (12) has been shown to exhibit partial agonist activity in SH-SY5Y 
cells119 but has not yet been evaluated in platelets.






(12) OPS = Phosphorothioate
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These partial agonists have certain structural features in common; they are modified at 
the equivalent positions C-3 or C-6 of Ins(l,4,5)P3 and are substituted with 
phosphorothioate groups in place of the three phosphates. These structural 
modifications appear to assist in triggering a substantial loss of agonist efficacy 
accompanied by a less significant loss of activity. What effects will reversing the 
orientation of both the C-3 and C-6 hydroxyls have together with the phosphorothioate 
pattern illustrated above ? To address this question, the design and synthesis of DL-neo- 





Evaluation of Ins(l,4,5)P3 receptor affinity and Ca2+ release activity is currently under 
investigation.
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4.2.7. Synthesis of DL-/fgo-inositol 1.3.4-trisphosphorothioate (67).
BnO BnO
)P(OBn)2I OH lQ P(O B n;
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Scheme 4.9. Synthesis of DL-«eo-inositol-l,3,4-trisphosphorothioate (67). 
i) (BnO)2PNPrI2, tetrazole; ii) S8; iii) Na / Liquid NH3.
Compound 63 was prepared in the synthesis of 65.
Phosphitylation of 63 was as for compound 60. The 31P NMR spectrum showed the 
appearance of signals at 5P 139.45 and 139.98, corresponding to the trisphosphite 
triester. A high resolution, low sweep width 31P NMR of the signals close to 5p 140 was 
able to resolve three signals, two of which belonged to a doublet, with a coupling 
constant of 4.0Hz. This arose from the 5JPP spin coupling between the P-atoms at 
positions C-3 and C-4, and was clear evidence that the compound contained a vicinal 
bisphosphite. Elemental sulphur was used to sulphoxidise the trisphosphite triester to 
the trisphosphorothioate triester 66. A 'H-^P-decoupled 31P NMR spectrum revealed 
that oxidation to the protected phosphorothioate had been accomplished with the 
signals around 8i> 140 being replaced by two singlets at 8i> 66.88 (IP) and 8i> 67.07 (2P).
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4.2.8. Deprotection and purification of the target Inositol Phosphorothioate 67.
Deprotection of the benzyl-protected trisphosphorothioate triester 66 was effected by 
sodium in liquid ammonia reduction, as described for the trisphosphate 64.
The deprotected trisphosphorothioate triester 67 was purified by ion exchange 
chromatography as previously described for 60. Detection of 67 within the ion exchange 
fractions collected and quantification of the compound was determined by a modified 
procedure of the Briggs phosphate assay as described for weo-inositol-1,3,4,6- 
tetrakisphosphate (60).244
The triethylammonium salt of 67 was obtained as a colourless glass in 61% yield. The 
proton-coupled 31P NMR spectrum (Figure 4.20) revealed two signals at 5P 44.47 (IP) 
showing a 3Jhcop = 10.7Hz, and a multiplet at 8P 41.89 (2P), corresponding to the 
trisphosphoro- thioate triester 67. The identity of 67 was further confirmed by lH NMR 
and mass spectroscopy.
Figure 4.20. 31P NMR spectrum of 67 (proton-coupled).
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4.3. Inversion of configuration of the 6-OH flanking the 4,5- 
bisphosphate system of Ins(l,4,5)P3.
4.3.1 Design of DL-gpi-inositol 1,3,6-trisphosphate 1831.
While the syntheses of 60 and 65 were in progress, L-myo-Ins( 1,3,4)P3 239 and D-myo- 
Ins(l,4,6)P3 240 were constructed in order to address the question of partial agonist 
activity exhibited by Ins(l,3,4,6)P4 previously described.
Figure 4.21. Binding orientations of D-myoIns(l,4,6)P3 and L-wyo-Ins(l,3,4)P3.
These two chiral trisphosphates can be regarded as simplified analogues of 
Ins(l,3,4,6)P4 (9) with the absence of different phosphate groups. This alteration forces 
each of the molecules to bind in only one orientation, the one that will mimic the 
orientation and positioning of the three phosphate groups in Ins(l,4,5)P3 (Fig. 4.17). D- 
myo-Ins(l,4,6)P3 will adopt this conformation at the expense of placing an axial 
hydroxyl group at the Ins(l,4,5)P3 position-3, and L-/wyo-Ins( 1,3,4)P3 by placing an 
axial hydroxyl at the Ins(l,4,5)P3 position-6 thus mimicking each of the binding 




Binding orientation of 
D-/»yo-Ins( 1,4,6)P3.
Binding orientation of 
L-myo-Ins( 1,3,4)P3.
I l l
structure of Ins( 1,4,5)P3 by two points, the inverted configuration at positions-3 and 6, 
and inverted configuration at pseudo position-2 for both analogues. It was rationalised 
that these two structures should be moved a step closer to the structure of Ins(l,4,5)P3 
by inverting the stereochemistry at position-2 of both compounds to give 14 and 83. 
Thus the only difference between Ins(l,4,5)P3 and each of 14 and 83 would be the 
inverted stereochemistry at positions-3 and 6. This would allow direct comparison of 
the biological characteristics of each compound with Ins(l,4,5)P3, attributing the 
differences to the modification of one stereogenic centre only.





















L-c/nro-Ins(2,3,5)P3 (14) was a potent agonist for the mobilisation of sequestered Ca2+ 
whereas L-c/z/ro-Ins(2,3,5)PS3 (11) was biologically evaluated and found to be the first 
partial agonist in rabbit platelets.120 DL-e/?/-Ins(l,3,6)P3 (83) was synthesised as part of 
the work covered in this thesis.
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D-myo-]ns( 1,4,6)P3 and L-myo-\ns( 1,3,4)P3 together with Ins(l,3,4,6)P3 were also 
evaluated for their abilities to displace specifically bound [3H]Ins(l,4,5)P3 from the 
Ins(l,4,5)P3 receptor on rat cerebellar membranes and their abilities to release Ca2+ in 
permeabilised platelets.240 All three analogues, however, were found to behave as full 
agonists in the platelet Ca2+ release assay and yet Ins(l,3,4,6)P3 had been previously 
demonstrated to behave as a partial agonist in SH-SY5Y cells.116,117 Both SH-SY5Y 
cells and platelets possess the type 1 Ins(l,4,5)P3 receptor 254,255 but, while 99% of the 
Ins(l,4,5)P3 receptors in SH-SY5Y cells are type 1, the abundance of this subtype in 
platelets is not known. It is possible then that the difference in activity of Ins( 1,3,4,6)P4 
in the two assays may be related to different receptors in the two cell types. Indeed, the 
different receptor subtypes have been shown to differentially recognise regioisomers of 
Ins(l,4,5)P3.62,63 It is, therefore, necessary to investigate the behaviour of all these 
compounds in SH-SY5Y cells before any conclusions about the structural basis of the 
partial agonist behaviour of Ins( 1,3,4,6)P4 can be proposed.
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Scheme 4.10. Attempted routes to the synthesis of 83 showing required products and 
side products.
(i) (CF3S02)20, pyridine, CH2C12, b). CsOAc, DMF; (ii) PMBC1, NaH, DMF; (iii) 
MeOH-lM HC1 9:1, 50°C, (iv) BnBr, NaH, DMF; (v) EtOH-1 M aq. HC1 2:1, reflux; 
(vi) pyridine-S03, DMSO, triethylamine; (vii) K-selectride, THF, 1%HC1, 45°C; (viii) 
NaBH4 , CH3CN, 20°C; (ix) (CH3C0)20, pyridine, DMAP; (x) BnBr, NaH, DMF; (xi) 
Pd/C, PTSA, EtOH-H20  11:1; (xii) a). (BnO)2PNPr12, tetrazole, CH2C12, b). 
C1C6H4C03H; (xiii) H2, Pd/C, 50psi.
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Compound (52) was a by-product from the synthetic route to DL-«eoinositol-l ,3,4- 
trisphosphate (65) and was the starting point for the synthesis of DL-e/?/-inositol-1,3,6- 
trisphosphate (83). The first step was to invert the configuration of the C-6-OH of 52 to 
give the axial 6-OAc. The OH of 52 was converted to the triflate in the usual manner 
but reaction with caesium acetate gave the diastereoisomer 68a as the sole product 
rather than the expected 68. Substitution had taken place with retention of configuration 
at C-6 (Scheme 4.10.). !H NMR showed the deshielded C-6 proton at 5h 5.05 as a triplet 
with 3Jhh = 8 .5Hz, indicating only axial-axial interaction between C-6-H and the vicinal 
protons C-5-H and C-l-H. The formation of 68a can be rationalised in two ways. 
Firstly, the reaction may have been S^l, with the acetate attacking from the less 
hindered face of the molecule. Secondly, there may have been transannular nucleophilic 
neighbouring group participation by the axial isopropylidene oxygen. (The triflate 
intermediate is assumed to have formed from TLC observations prior to reaction with 
acetate).




A plausible suggestion of why the reaction did not proceed via the SN2 route could be 
the steric hindrance of the isopropylidene ketal to the path of attack of the acetate 
nucleophile.
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Figure 4.23. Nucleophilic attack is hindered by the isopropylidene ketal.
Path of attack of AcO'
•All
With this reasoning in mind, it was decided that removing the ketal from 52 and using 
conformationally mobile groups to protect positions-2 and 3 might allow the 
nucleophilic attack by an SN2 mechanism to proceed. These protecting groups would 
need to be stable to a variety of reaction conditions as they would be required to protect 
these two positions until the end of the synthesis. Hence, the benzyl group was chosen 
to serve this function. Firstly, the C-6-OH of compound 52 needed to be blocked 
temporarily. Treatment with /?-methoxybenzyl chloride and sodium hydride in 
dimethylformamide afforded the />-methoxybenzyl ether 69 in good yield. Compound 
69 was then subjected to mildly acidic conditions to hydrolyse the isopropylidene ketal 
without cleaving the /?-methoxybenzyl ether. The diol 70 was obtained as an oil. The 
diol 70 was then benzylated to give the fully protected compound 71. Finally, acid 
hydrolysis of the p-methoxybenzyl ether gave the alcohol DL-l,4,5-Tri-0-allyl-2,3-di-0- 
benzyl-wyo-inositol 72 as a crystalline solid.
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The alcohol 72 was converted to the corresponding triflate as described for 52. 
Completion of the reaction was judged by TLC and the trifluoromethanesulphonate 
was not isolated. The crude material was treated with caesium acetate in 
dimethylformamide. TLC showed the complete conversion of the starting material into 
three products which were isolated by flash chromatography and characterised as 
compounds 73, 74 and 75.




















The desired e/?/-inositol analogue 75 was obtained in a very poor 6% yield. 
Displacement of the hydroxy substituent at C-6 with retention of stereochemistry had 
also occurred and the product 74 was isolated in 25% yield. The NMR spectra of 74 are 
shown in Figure 4.25. The main product however was a 1,4-anhydro derivative 73. 
Anhydro derivatives of this nature have been observed before in the attempt to 
introduce fluoro-substituents to the inositol ring with DAST, displacing a hydroxy 
substituent with inversion of configuration.
Compound 73 is likely to arise when a boat conformation can be adopted in which the 
benzyloxy-substituent at position C-3 is axial, with the triflate-activated hydroxyl at 
position C-6 equatorially oriented thereby allowing transannular nucleophilic attack by 
the benzyl oxygen. This underlines the danger of assuming simple chair forms for 
molecules of this type.
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Figure 4.25. *H NMR spectrum of 74, showing C-6-H (above) and l3C NMR spectrum 
showing the acetate carbonyl (below).
ll-IV li'Co








Figure 4.26.b. ‘H-'H COSY of 73.
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The structure of this molecule was confirmed by lU NMR spectroscopy and 
COSY. (See Figures 4.26.a. and 4.26.b.). The dihedral angle between C-6 -H and C-3-H 
is close to 90° and only a small coupling relationships are observed between these two 
protons and their vicinal neighbours C-2-H and C-l-H. The coupling observed by 
COSY between C-3-H and C-6 -H is attributed to W coupling. This is a four-bond 
coupling phenomenon mediated by orbital overlap which is at its most effective when 
the four bonds adopt a W arrangement. C-5-H is observed as a singlet with very small 
coupling to C-4-H and no coupling to C-6 -H. These results are best explained with a 
3D-molecular model where the angles between vicinal protons can be seen. 
Displacement of the triflate substituent at position C- 6  with inversion of 
stereochemistry could not be achieved in reasonable yield due to the competing 
formation of the 1,4-anhydro derivative 73 and the formation of the configurationally 
retained diastereoisomer 74 of the required product 75. Mechanisms for the formation 
of both of these compounds were taken to be as shown in Schemes 4.13 and 4.14. Note 
that a high energy boat conformation of the triflate intermediate is considered in both 









common intermediate (See Schemes 4.13 and 4.14). Carrying out the reaction at a 
lower temperature would perhaps decrease the number of triflate molecules in the boat 
conformation, thus reducing the amounts of 73 and 74 formed.


















The conversion of 72 to the corresponding triflate was carried out as before. Treatment 
of the crude triflate with caesiun acetate in DMF at 0-5°C afforded the required 
compound 75 in 42% yield, and the diastereoisomer 74 in 19% yield. No anhydro 
product was observed.
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(74) H5 (75) H,
These two compounds are easily distinguishable by NMR. The C-2 proton of 
compound 75 appeared as a deshielded triplet at 5h 5.69 with 3Jhh=2.4Hz, 
corresponding to two axial-equatorial proton interactions of similar magnitude. The C- 6  
proton of compound 74 appeared as a downfield triplet at §h 5.48 with 3Jhh =10.1Hz, 
suggesting that this proton was axially oriented and coupled to two vicinal axial 
protons.
The prediction that carrying out the reaction at a reduced temperature may allow an SN2 
mechanism to prevail proved true but the yield of the required fully-protected epi- 
inositol analogue 75 was still only moderate. The reaction was therefore repeated at 
reduced temperature as before but with an increased concentration of caesium acetate, 
in an attempt to increase the rate of formation of 75 over any competing reactions. The 
hygroscopic nature of the salt was also considered. To ensure that any water of 
crystallisation was not encouraging initial unimolecular nucleophilic substitution by 
increasing the polarity of the reaction mixture, the caesium acetate was crushed to a 
fine powder with a pestle and mortar, dried under vacuum at 100°C for 6 h, and used 
immediately. The yield of the required product 75 was slightly improved, from 42% to 
48%, but, more importantly, the yield of the diastereoisomer 74 was reduced from 19% 
to 11%. Due to the only moderate yield of the required analogue 75, an alternative 
strategy to its synthesis was contemplated.
124
4.3.3 Synthesis of DL-2-Q-acetvI-1.3.5-tri-(7-allvl-4.5-di-0-benzvl-gj9/-mositol (75) - 
An alternative route.
The strategy of Swem oxidation of 72 followed by borohydride reduction of the 
resulting inosose 76 (lH NMR spectrum: Figure 4.28), was investigated as an alternative 
route to the synthesis of 78, with subsequent acetylation to afford the fully-protected 
analogue 75.























Figure 4.29 shows the NMR spectra of 78. Here the couplings to C-2-H are ca. 3 Hz, 
indicating that this proton is equatorial, given that C-l-H and C-3-H are axial.
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Scheme 4.16. Mechanism of Swem oxidation of 72.
This method afforded the required inosose 76 in 65% yield. This procedure was 
repeated using sulphur trioxide-pyridine complex as the dimethylsulphoxide activator 
257 and the yield of the inosose 76 was increased to 80%.
The next step was to reduce the ketone 76 back to the alcohol with inversion of 
stereochemistry using a borohydride reagent. The reagent to be used would have to be 
carefully chosen to ensure that the ratio of diastereomeric products 72:78 would be in 
favour of 78. It was reasoned that a sterically bulky reagent should be used. Such a 
reagent would attack the carbonyl from the less hindered side of the inositol ring, 
resulting in preferential formation of the axial epimer 78. K-selectride
[KB(CH(CH3)C2H5)3H] was chosen. Note, however, that the presence of the ring 
carbonyl will distort 76 from the chair conformation.















K-selectride was added to a solution of the ketone 76 in tetrahydrofuran at -78°C. Three 
products were observed by TLC. These were isolated by flash chromatography and 
found to be 72 (9%), the aromatic 77 (55%) and 78 (21%). 5H NMR confirmed that 
compounds 72 and 78 were mono-alcohols and conversion of both compounds to their 
acetate esters 74 and 75, respectively, confirmed their respective stereochemistry.
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Figure 4.30. Conversion of the diastereoisomers 72 and 78 to their corresponding 














5h 5.48 5„ 5.69
3J = 10.1Hz 3J = 2.4Hz
The least polar product 77 was found to be a symmetrical aromatic compound by 
NMR (Figure 4.32) and was the major product isolated.





An explanation for the aromatisation of compound 76 would be to suggest that the K- 
selectride was too bulky in structure and the ketone 76 too sterically hindered at both 
faces to allow close approach of the K-selectride for hydride transfer. Poor yields of the 
two reduction products 72 and 78
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Figure 4.32. lH NMR spectrum of the aromatic compound 77.
(77)
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in the ratio 72:78, 1:2, illustrate that the borohydride was more hindered from 
approaching from the axial face of the ketone than from the equatorial.
Figure 4.33. Hindrance to the approach of K-selectride.
Axial attack is hindered by the 
substituents oriented above the 
plane of the ring.
e





H - B [ C H ( C H 3) C 2H 5 ] 3
Equatorial attack is hindered, 
to a lesser extent, by the vicinal 
axial protons to the carbonyl and 
the allyl substituent oriented below 
the plane of the ring.
Thus, unable to function as a hydride transfer agent, K-selectride can act as a base. Note 
that the axial protons a  to the carbonyl will be relatively acidic.
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Scheme 4.18. shows the mechanism by which the aromatisation can occur, the driving 
force being the formation of the low-energy aromatic ring. Repetition of the reaction at 
45°C gave only 77 in 90%yield.
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4.3.4 Reduction of DL-(2.4,5.6/3)-2,3,6-Tri-0-allyl-4,5-di-0-benzvl-2.3,4,5,,6- 
pentahvdroxvcvclohexanone 76 using sodium borohvdride.
The next stage was to consider the use of another borohydride, one that was less basic 
than K-selectride and that was less bulky in structure, so that its nature as a reducing 
agent would prevail. Sodium borohydride was the next borohydride of choice.
Inosose 76 was treated with NaBH4 in ethanol at 0°C. Two products were isolated and 
found to be the epimers 72 (29%) and 78 (59%). The yield of the required epimer was 
moderate but a higher degree of selectivity had been expected, as the axial face of the 
carbonyl was far more hindered than the equatorial. It seems that, even though the 
borohydride will preferentially approach the carbonyl via the least hindered equatorial 
path, it is also small enough to approach, to a lesser extent, from the highly hindered 
axial face. This analysis is based on the assumption that the molecule exists as close to 
the chair conformer depicted in Fig.4.31.
A procedure described by Roomer et al., 258 in which a similarly hindered fully 
protected inosose was reduced with 4 equivalents of sodium borohydride in acetonitrile 
at 0°C gave the axial hydroxyl epimer preferentially in a ratio of 1:10. When the 
experiment was carried out at 50°C, selectivity for the axial epimer was increased to 
1:16.
This method was used to reduce compound 76. The axial epimer 78 was indeed formed 
preferentially over the equatorial epimer 72 in the ratio 1:4. When the procedure was 
carried out at 50°C, only the required axial epimer 78 was isolated in 79% yield. The 
reason why acetonitrile should enhance the stereoselectivity of sodium borohydride is 
unclear. It may be that ligation of a molecule of acetonitrile (a Lewis base) to a 
molecule of borohydride occurs, forming a complex which is too sterically hindered to 
attack the ketone 76 from the axial face.
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4.3.5 Generation of the phosphorylation precursor DL-1.2,4-Tri-O-benzyl-gp/- 
inositol (80).
Having proved the stereochemistry of 78 by conversion to the corresponding acetate 
ester 75, the next step was to benzylate the alcohol 78 to the fully protected DL-1,3,6- 
Tri-0-allyl-2,4,5-tri-0-benzyl-e,/?/-inositol 79. Mono-benzylation of 78 afforded the fully 
protected e/?/-analogue 79 in good yield. Generation of the phosphorylation precursor 
triol 80 required the removal of the three allyl protecting groups from 79. This was 
achieved by their isomerisation using palladium on carbon, followed by acid hydrolysis 
of the intermediate enol ethers to give 80 (Scheme 4.10.).
4.3.6 Phosphorylation of DI^1.2.4-Tri-Q-benzvl-gpi-inositol (80).
Phosphitylation and subsequent oxidation of 80 was carried out as previously described 
for the alcohol 58 (scheme 4.10.). The starting material triol 80 was converted to two 
new products of similar polarities after phosphitylation. Oxidation afforded two 
products with similar polarities, which were isolated by flash chromatography. The 
more polar product was identified as the required trisphosphate 82 by *H NMR and 31P 
NMR spectroscopy at 55°C. The proton-decoupled 31P NMR (Figure 4.35) showed two 
singlets at 5p -1.50 (IP) and 8p -2.06 (2P) corresponding to the trisphosphate triester 82. 
The less polar product was difficult to identify. *H NMR revealed two of the ring 
protons at 6H 3.28 and 3.42 as doublets with 3Jhh spin couplings of 3.4Hz and 3.3Hz and 
two more ring protons at 6H 5.10 and 5.12 as singlets. No 3Jhcop spin couplings were 
observed. The 31P NMR spectrum showed two clear singlets at 5P -0.98 (IP), which is a 
usual value for a benzyl protected inositol phosphate ester, and an unusual value 8p 
-13.40 (IP). This value is well out of the range of chemical shift for a dibenzyl-
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protected inositol phosphate ester. An extensive literature search revealed that 8p -13.40 
relative to external 85% phosphoric acid was within the range for a mono-benzyl 
protected six-membered cyclic phosphate.259,260




/  OBn 
0
The above cyclic phosphate, for example, shows a signal at 5p -13.0 when taken in 
DMSO.259
From 'H NMR (Figure 4.36a), COSY (Figure 4.36b), 3IP NMR and mass spectroscopic 
data, the structure 81 was proposed for this unusual product.
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Figure 4.36.a. H NMR spectrum of 81
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Figure 4.36.b. 'H-'H COSY of 81.
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In reality, however, the structure is probably far from the neat boat-chair representation 
depicted in the diagram above. Steric repulsion between the benzyl groups at positions 
1,2 and 4 and the cyclic phosphate will cause distortion of the bicyclic structure so that 
each ring flattens somewhat giving two twisted “half-boat structures”. This structural 
deformation is clear from the coupling relationships between the vicinal protons of the 
inositol ring, in the 'H NMR spectrum.




NMR (Figure 4.36a) shows C-5-H and C-6-H as singlets at SH 5.10 and 5.12. The 
dihedral angle between these two protons and their respective vicinal neighbours (C-4- 
H and C-l-H) is close to 90°. No couplings are observed (Figure 4.36a). The dihedral 
angle between C-2-H and C-3-H also approaches 90°. C-2-H therefore appears as a 
doublet at 5h 3.94 with a 3Jhh =3 4Hz. C-l-H is a doublet at 8H 3.28 with 3Jhh = 3.4Hz. 
C-4-H is coupled only to C-3-H and is observed as a doublet at 5H 3.42, with a 3Jhh =
Bikj O (81)
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3.3Hz. These signals are further split by coupling constants too small to determine, 
where the dihedral angles between vicinal protons is close to 90°.
Having identified the structure of this by-product 81, it was necessary to find a plausible 
mechanism for its formation. Recall the structure of the starting material triol 80. 
Although it was expected that the preferred conformation of 80 would be the ring 
flipped chair with two equatorial benzyls and one axial, !H NMR coupling constants 
showed that the conformer present was the one depicted in the figure below.





Note that the region above the inositol ring is sterically congested. The three hydroxyl 
groups to be phosphorylated are oriented with two above the plane of the ring 
(positions-3 and 5), and one below (position-6). A rational assumption would be that 
phosphitylation will occur first at the most accessible position-6.









Consider that steric repulsion between the two axial benzyl groups at positions-2 and 4
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cause a change in conformation of the ring from the chair to a “twisted boat” 
conformer. Note also that the reaction medium will have been fairly basic due to the 
presence of diisopropylamine produced by the reaction of bis(benzyloxy)-7V,Af- 
diisopropylaminophosphine and tetrazole. Consider therefore, that base catalysed 
deprotonation occurs at one of the positions 3 or 5 and phosphitylation occurs at the 
other.
Figure 4.41, Suggested mechanism of cyclic phosphite formation.
Transannular nucleophilic attack with the elimination of a benzyloxy-substituent, will 
result in the formation of a six-membered cyclic phosphite. Subsequent oxidation then 
converts the two phosphite groups to phosphate groups.
Scheme 4.19. Oxidation of phosphite groups to phosphate groups.
In order to confirm the identity of 81, the benzyl groups were removed by 
hydrogenolysis. The resulting bisphosphate 84 was purified by ion exchange 









and quantified using a modified procedure of the Briggs phosphate assay,244 to give the 
pure compound 84 as a colourless glass.
The ]H NMR spectrum was not very informative, however, showing the inositol ring 
protons as two sets of multiplets which could not be resolved as separate signals. The 
downfield multiplet contained the deshielded three protons attached to the 
phosphorylated centres. The proton-coupled 31P NMR spectrum proved the identity of 
the bisphosphate 84 and therefore the identity of its precursor 81.
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3 J h c o p  = 9.9Hz
8p -9.56, triplet 
3JHCo p =  10.7Hz
The position-6 phosphate P-atom was observed as a doublet at 8P -0.98 with 3JHcop =  
9.9Hz, as would be expected for a deprotected inositol phosphate. The other signal 
observed was a triplet at 8P -9.56 with a 3JHcop = 10.7Hz. This 5P value is consistent for 
a deprotected 6-membered cyclic phosphate. The splitting pattern further illustrates that 
the P-atom couples to two protons, H-3 and H-5. Mass spectroscopic data were 
consistent with this structure.
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Figure 4.43.a. 31P NMR spectrum of 83 (proton-coupled above and proton-decoupled 
below).
OH






Figure 4.43.b. *H NMR spectrum of 83.
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4.3.7 Deprotection of DL-1.2.4-Tri-Q-benzvl-gp/-inositol-3.5,6-tris 
(dibenzvlphosphate)(82) and Purification of the deprotected trisphosphate triester 
(83).
Debenzylation of 82 was effected by hydrogenolysis as described for 59. Purification of 
the deprotected trisphosphate 83 was by ion exchange chromatography as for compound 
60. The triethylammonium salt of 83 was detected and quantified using a modified
« 4 4   ' 111  “11
procedure of the Briggs phosphate assay. The P- H-coupled P NMR spectrum of 
83 in deuterated methanol (Figure 4.43a) showed two signals at Sp 0.38 (2P, m) and 5p
2.07 (IP, doublet, 3Jhcop = 8. 1Hz), corresponding to the trisphosphate triester 83. The 
*11 NMR spectrum and the corresponding COSY spectrum are presented in Figures 
4.43b and 4.43c, respectively.
Figure 4.44. Energy minimised model of 
DL-<?/?/-inositol 1,3,6-trisphosphate (right) 




5.1. Conformational changes of the 4,5-bisphosphate moiety of 
Ins(l,4,5)P3 - In search for a partial agonist.
5.1.1 Design of DL-mvo-inositol-l,2,5-trisphosphate (89) and D-myo-inositol-2,3,5- 
irisphosphate (96) - Modification of the position-4 phosphate of the 4,5- 
bisphosphate system.
To date, all the inositol phosphates that show significant affinity for the Ins(l,4,5)P3 
receptor contain the 4,5-bisphosphate motif. This conformationally mobile system is 
known to be essential for receptor recognition and Ca2+ mobilisation and yet relatively 
little attention has been focused on the structural modification of this structure. Little is 
known about the way these two phosphates interact with the receptor in the series of 
events leading to the opening of the ion channel.




DL-6 -deoxy-6 -hydroxymethyl-scy//0 -inositol-1:7-cyclic-2,4-trisphosphate 261 was 
synthesised to investigate the effects of conformationally restricting one of the 
phosphates of the 4,5-bisphosphate system.
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Figure 5.2. DL-6-deoxy-6-hydroxymethyl-jcy//o-inositol 1:7 cyclic trisphosphate.261
OPCV
HO
This compound was shown to retain full agonist activity but with reduced potency. It 
seems therefore, that the path to an Ins(l,4,5)P3 receptor antagonist does not lie in the 
conformational restraint of the inositol ring nor of a phosphate group, at least not of the 
position-4 phosphate in the positive gauche orientation. Therefore, channel opening 
cannot require the inositol ring to flip and probably does not require a dramatic change 
in the orientation of the 4-phosphate.
Another C-4 modified analogue that has been reported is 3-deoxy-D-/wwco-inositol- 
1,4,5-trisphosphate.262




This compound was shown to inhibit [3H]Ins(l,4,5)P3 binding to rat cerebellar 
membranes containing a high density of Ins(l,4,5)P3 receptors, with a 3-order of 
magnitude potency lower than the affinity of Ins(l,4,5)P3. The authors262 therefore 
suggested that that the 4,5-trans relationship of the 4,5-bisphosphate system is a primary 
requirement for the binding of Ins(l,4,5)P3 to the receptor and this criterion has been 
maintained in the design of subsequent analogues with potential for partial agonist 
activity.
151
A more recent publication, where the binding (in bovine adrenal cortical membranes) 
and activity (in permeabilised Chinese hamster ovary cells) of the nine possible 
regioisomers of /wyo-inositol tetrakisphosphate at the Ins(l,4,5)P3 receptor were 
examined, showed that Ins(l,2,3,5)P4 had an approximately 200-fold lower potency for 
Ca2+ release compared with its affinity for the Ins(l,4,5)P3 receptor, i.e. EC5o/Ki.
All the other regioisomers showed 45Ca2+-releasing potencies comparable with their 
apparent binding affinities for the Ins(l,4,5)P3 receptor. These results suggested that 
Ins(l,2,3,5)P4 could be a useful lead compound for rational design of novel synthetic 
Ins (1,4,5) P3 analogues possessing structure-activity profiles with relatively high 
binding affinity but low intrinsic efficacy and hence partial agonists or even antagonists 
at the Ins (1,4,5) P3 receptor.
Figure 5.4. Binding orientation of Ins( 1,2,3,5)P4.
Binding orientation
Ins(l,2,3,5)P4 ofIns(l,2,3,5)P4. Ins(l,3,4,5)P4
Structure-activity modelling of this compound demonstrates that Ins(l,2,3,5)P4 can be 
visualised in a pseudo-Ins(l,4,5)P3 receptor binding conformation, mimicking the 
crucial 4,5-bisphosphate motif and also the position-1 phosphate of Ins(l,4,5)P3. This 
binding conformation also resembles that assumed by D-Ins(l,3,4,5)P4, with the 
exception that for Ins(l,2,3,5)P4, the 2-position phosphate (pseudo-4-position 
phosphate) of the vicinal phosphate pair is oriented axially rather than equatorially. The 
axial pseudo-4-phosphate does not appear to dramatically effect binding to the 
Ins(l,4,5)P3 receptor since Ins(l,2,3,5)P4 has an affinity similar to that of Ins( 1,3,4,5)P4. 
However, the ability of Ins(l,2,3,5)P4 to release 45Ca2+ from intracellular stores is
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approximately 5-fold lower suggesting that the modification in structure may 
significantly attenuate agonist efficacy.
This finding was the stimulus for the synthesis of DL-Ins(l,2,5)P3 (89) and its D- 
antipode D-Ins(2,3,5)P3 (96), since when visualised in a binding conformation 
possessing an axial pseudo-4-position phosphate, it would lack the pseudo-3-position 
phosphate known to reduce binding affinity.89,90 The hypothesis is that D-Ins(2,3,5)P3 
will have a more potent binding affinity for the Ins(l,4,5)P3 receptor than Ins(l,2,3,5)P4, 
but retain its Ca2+ release potency, thus making 96 a more potent partial agonist.
Figure 5.5. D-Ins(2,3,5)P3 - a potential partial agonist.
Binding conformation Binding conformation
o f Ins(l,2,3,5)P4. o f Ins(2,3,5)P3 (96).
5.2. Design of D-mvo-inositol-23.6-trisphosphate (100) and DIwtgo-inositol-1,2.4- 
trisphosphate (lll)-Modification of the position-5 phosphate of the 4.5- 
bisphosphate system.
As for the position-4 phosphate, little attention has been paid on the structural 
modification of the 5-position phosphate. Single phosphorothioate substitution is known 
to be well tolerated, resulting in a full agonist.94,95 The racemic 5-methylphosphonate 
and 5-difluoromethylphosphonate analogues of Ins(l,4,5)P3 have been reported as weak 
antagonists at the Ins(l,4,5)P3 receptor from preliminary biological data, but 
confirmatory results have not yet appeared.96,97
To complete this study, the syntheses of analogues (100 and 111) with inverted 
position-5 phosphates was carried out. D-Ins(2,3,6)P3 (100) is a regioisomer of
153
D-Ins(2,3,5)P3 (96), with the position-5 phosphate inverted instead of the position-4. 
DL-weo-Ins(l,2,4)P3 (111) is an analogue of Ins(l,4,5)P3 with the position-5 phosphate 
inverted.













Previous studies with single phosphorothioate substitution of each of the 4-position and
5-position phosphates of Ins(l,4,5)P3, have shown that chemical modification of the 5-
phosphate is more perturbing for Ins(l,4,5)P3 receptor binding than a similar
modification of the 4-phosphate.122 It may be, however, that structural modification of
the 5-phosphate, such as inversion of orientation, will still allow the phosphate to
interact with the receptor binding pocket, perturbing only the conformational change of
the receptor required for efficient gating of the intrinsic Ca2+ channel.
These compounds are currently under biological evaluation.
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5.2.1 Synthesis of DL-mvfl-inositol 1,2,5-trisphosphate (89),
Compound 89 was prepared via the racemic triol 87. Synthesis of 87 was by a route 



















Scheme 5.1. Synthesis of DL-myo-Ins( 1,2,5)P3.
(i) a). Bu2SnO, toluene; b). BnBr, CsF, DMF; (ii) EtOH-1 M aq. HC1 5:1, reflux;
(iii) a). (BnO)2PNPrI2, tetrazole, CH2C12; b). C lC^C O jH ; (iv) H2, Pd/C, 50psi.
5.2.2 Phosphorylation of DL-M^Tri-O-benzyl-mrfl-inositol (87).
Phosphitylation of the racemic triol 87 was carried out using the P(III) reagent 
bis(benzyloxy)-Af,jV-diisopropylaminophosphine and ///-tetrazole. The conversion to 
the trisphosphite triester was monitored by TLC. Oxidation of the corresponding 
trisphosphite to the trisphosphate triester 88 was effected with excess m-
chloroperoxybenzoic acid, and the protected compound 88 purified by flash
  1
chromatography. The purity of 88 was judged by TLC. The proton-decoupled P NMR
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Figure 5.7. 'H-‘H COSY of 86.
« L _
PPM













spectrum showed three signals at 8p -1.20, -1.56 and -1.78 corresponding to the 
trisphosphate triester 88. lH NMR further confirmed the identity of 88.









Figure 5.8.b NMR spectrum of 88.
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5.2.3 Peprotection and Purification of the target phosphate 89.
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The next step involved the removal of the nine benzyl protecting groups from 88 by 
hydrogenolysis. The crude trisphosphate triester 89 was purified by ion exchange 
chromatography as described for 60, and the triethylammonium salt of 89 was detected 
amongst the ion exchange fractions and quantified using a modified procedure of the 
Briggs phosphate assay.244 A proton-coupled 31P NMR spectrum taken in deuterated 
methanol showed three doublets at 8 P 0.12, 2.06 and 2.93, each showing 3J h c o p  spin 
coupling.
Figure 5.9.a. *H NMR spectrum of 89, showing W coupling C-l-H and C-2-P.
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Figure 5.10. Energy minimised model of 
DL-myoinositol 1,2,5-trisphosphate (89) 
left, and myoinositol 1,4,5-trisphosphate 
(right).
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5.3. D-ffijw-inositol 2,3,5-trisphosphate (96) and D-my^-inositol 2,3,6- 
trisphosphate (100).
5.3.1. Synthesis of D-mvo-inositoI-2.3«5-trisphosphate (961 and D-/nyo-inositol-2.3.6-- 
trisphosphate 1100).
The racemic diol 85 was resolved via synthesis of the corresponding diastereoisomeric 
*y-camphanate esters 90 and 91 as described by Desai et al.2S0









Isolation of the required diastereoisomer 90 was by crystallisation.
NMR, melting point, TLC and specific rotation data were in agreement with the 
literature values.250 In particular, the NMR spectrum (Figure 5.11) confirmed the 
absence of other diastereoisomers.
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Scheme 5.3. Synthesis of 96 and 100.
(i) l%NaOH-MeOH, reflux; (ii) a) Bu2SnO, toluene, b) BnBr, CsF, DMF (iii) EtOH- 
1 M aq. HC1 5:1, reflux; (iv) a). (BnO)2PNPri2, tetrazole, CH2C12, b). C lC ^C O jH ; (v) 
H2, Pd/C, 50psi.
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The diastereoisomer 90 was saponified to yield the enantiomerically pure diol 1D-1,4- 
di-O-benzyl-2,3-O-isopropylidene-/w>'0-inositol 92. 92 was then converted to the two 
phosphorylation precursor triols 94 and 98 by a tin-mediated mono-benzylation to 
afford the alcohols 93 and 97 in equal yield, and subsequent acid hydrolysis of the 
isopropylidene ketals of each of the alcohols to afford the triols 94 and 98 in good yield.
5.3.2. Phosphorylation of the chiral triols 94 and 98.
Phosphitylation of the triols 94 and 98 was carried out using bis(benzyloxy)-AT,AT- 
diisopropylaminophosphine and ///-tetrazole in dichloromethane. Oxidation of the 
corresponding trisphosphite triesters was effected by /w-chloroperoxybenzoic acid, to 
yield the trisphosphate triesters 95 and 99 respectively.
95 Gave the same [H NMR and 31P NMR spectroscopic data as the racemic material 88. 
Proton-decoupled 31P NMR of 99 showed three singlets at 6P -0.89, -0.98 and -2.25, 
corresponding to the trisphosphate triester 99 (Figure 5.12a). The corresponding *H 
NMR spectrum is given in Figure 5.12b.
5.3.3 Deprotection of 95 and 99. and purification of the target chiral trisphosphates
96 and 100.
Benzyl deprotection of the trisphosphates 95 and 99 was effected by hydrogenolysis.
The corresponding products 96 and 100 were purified by ion exchange chromatography, 
eluting with a gradient of triethylammonium hydrogencarbonate buffer. The 
triethylammonium salts of 96 and 100 were detected and quantified by a modified 
procedure of the Briggs phosphate assay.244 The NMR spectrum of 100 is given in 
Figure 5.13.
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5.4. DL-/!£0-inositol 1,2,4-trisphosphate (111).































Scheme 5.4. Synthesis of DL-weo-inositol- 1,2,4-trisphosphate (111).
(i) a). Bu2SnO, toluene, b). AllBr, CsF, DMF; (ii) (C6H5)3P, triiodoimidazole, imidazole, 
toluene; (iii) RuC13, NaI04, CH3CN/Et0Ac/H20; (iv) (CF3S02)20, pyridine, CH2C12; (v) 
MeOH-lMNaOH 5:1, reflux, (vi) BnBr, NaH, DMF; (vii) KOBu*, DMSO, 100°C; (viii) 
MeOH-1 M HC1 9:1, reflux; (ix) a). (BnO)2PNPri2, tetrazole, b). CfC(1H4CO;H; (x) H2, 
Pd/C, 50psi.
Figure 5.14. Energy minimised model of 
DL-weo-inositol 1,2,4-trisphosphate (111) 
left, and myo-inositol 1,4,5-trisphosphate 
(right).
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5.4.2 Synthesis of the key intermediate DL-6-0-allvl-l,4-di-0-benzyl-2,3-0- 
isoproDvlidene-m^-inositol (106).
The synthesis of the diol 85 was as previously described by Desai et al. 264 The vicinal 
diol was converted to the olefin 101 by a procedure described by Garegg et al. 265 This 
procedure involved the reaction of the diol 85 with triiodoimidazole, 









Scheme 5.5. Conversion of the diol 85 to the olefin 101.
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The olefin 101 was easily purified by flash chromatography and was isolated in good 
yield. The next step was to c/s-dihydroxylate the olefin 101. The two most common 
reagents for cw-hydroxylation of alkenes are potassium permanganate and osmium 
tetroxide, with the latter being more stereoselective and affording higher yields despite 
being costly and highly toxic. More recently, a “flash-dihydroxylation” method was 
reported by Shing et al.266, using ruthenium tetroxide. This procedure was reported to 
give rapid dihydroxylation of a variety of alkenes although its stereoselectivity was, at 
the time, still under investigation. Both of the possible diastereoisomeric products of the 
hydroxylation of 101 could be put to good use, so this method was of particular interest.
Figure 5.15. Possible products of dihydroxylation of 101.
OH
A sample of the olefin 101 was treated according to the published protocol, with 
sodium periodate and a catalytic amount of ruthenium chloride in a biphasic solvent 
system of ethyl acetate/acetonitrile/water at 0-5°C for 5min.
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Scheme 5.6. Mechanism of alkene dihydroxylation using ruthenium tetroxide.
The addition of the olefin 101 to the ruthenium tetroxide caused the rapid precipitation 
of the cyclic ruthenate ester. The ester was hydrolysed with aqueous sodium 
thiosulphate. When the reaction was run for 5min, only one major product was observed 
by TLC. This was isolated and identified by *H NMR (Figure 5.16a,b) as the c/s-diol 
102. It is thus apparent that ruthenium tetroxide, like osmium tetroxide, will attack a 
cyclic system from the less hindered side thereby yielding the more stable of the two 
possible cw-diols. The procedure was also run for 3min and 7min. In both instances, far 
lower yields of 102 were obtained. The shorter reaction time afforded much starting 
material together with a poor yield of the required diol 102. The longer reaction time 
afforded numerous minor products observed by TLC. These were not isolated but were 
assumed to be products of oxidative fission. Again the yield of 102 was poor.
The next stage of the synthesis was to allylate regioselectively the equatorially oriented 
hydroxyl group at position-6 over the axial one at position-5. As previously discussed, 
this can be effected via the formation of a stannylene derivative.
(102) OH
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The resulting tin complex reacted with caesium fluoride and allyl bromide in DMF to 
afford the mono-alkylated product 106 in 64% yield. (!H NMR spectrum: Figure 5.17). 
The overall yield for the conversion of the diol 85 to the alcohol 106 was merely 33%.
Scheme 5.7. Three step conversion of 85 to 106










An alternative strategy for this conversion was considered.
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Scheme 5.8. An alternative three-step conversion of 85 to 106.
The first step was to alkylate the hydroxyl group selectively at position-6 of the diol 85 
via its corresponding stannylene derivative. Regioselectivity between the two hydroxyl 
groups of 85 cannot be achieved due to their similar reactivities, and the regioisomeric 
alcohols 103 and 104 were afforded in a 1:1 ratio. Mono-allylation of 85 was effected 
via the formation of the dibutyl stannylene derivative of 85 in toluene as previously 
described, with the subsequent mono-alkylation using caesium fluoride and allyl 
bromide in DMF. The required alcohol 104 was obtained in a moderate 44% yield.
The next step was to invert the configuration at position-5 of the alcohol 104. 
Conversion of the alcohol to the corresponding triflate and subsequent displacement of
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the triflate group using caesium acetate in DMF inverted this stereocentre to give 105 in 
87% yield. The acetate was then saponified to yield the alcohol 106 in 93% yield.
The overall yield by this route was only 34% but was favoured over the 
olefin/dihydroxylation method for the following reasons;
1. Conversion of the diol 85 to the olefin 101 requires the use of triiodoimidazole which 
is not commercially available and has to be synthesised. This is time consuming.
2. Dihydroxylation of 101 to 102 requires the use of ruthenium tetroxide. Very little is 
documented about the toxicity of this reagent, so handling with extreme caution is 
necessary due to its high volatility and powerful oxidising potential.
3. Dihydroxylation requires attention, as the reaction occurs at a very fast rate. A minute 
more or less affects the product yield tremendously.
5.4.5 Generation of the phosphorylation precursor trio! DI l^,2,4~Tri-Q-benzvl-/ig<?~ 
inositol (109).
Mono-benzylation of the alcohol 106 afforded the fully protected analogue 107. 
Isomerisation of the single allyl group at position-3 of 107 gave the corresponding cis- 
prop-l-enyl ether 108 in excellent yield. Acid hydrolysis of the cw-prop-l-enyl group 
and the isopropylidene ketal of 108 in one pot afforded the triol 109 (Scheme 5.4.).
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Figure 5.18. 13C NMR spectrum of 107 (above), and 13C NMR spectrum of 108 
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5.4.6 Phosphorylation of DL-l,2,4-Tri-0-benzyl-/tgg-inositol (109).
Phosphitylation and subsequent oxidation of 109 was as previously described in Chapter 
4 for 58. The formation of the trisphosphite triester was judged by TLC, and m- 
chloroperoxybenzoic acid used to oxidise the phosphite groups to phosphate groups 
(110). The trisphosphate triester 110 was purified by flash chromatography. The purity 
of 110 was judged by TLC. A proton-decoupled 31P NMR spectrum of 110 showed 
three signals corresponding to the three phosphates at 6p -1.39, -1.54 and -1.89. Further 
confirmation of the identity of 110 was by NMR (Figure 5.19) and mass 
spectroscopy. The *H NMR signal for C-5-H is clearly seen downfield at 8 5.44; this 
proton is equatorial and C-5 bears a phosphate.
5.4.7. Deprotection of 110 and Purification of the target Inositol Phosphate 111. 
Removal of the nine benzyl groups of 110 was by hydrogenolysis over palladium on 
carbon at a pressure of 50psi, the usual method used in this work (See chapter 4). 
Purification of the deprotected trisphosphate 111 was by ion exchange chromatography 
as described in Chapter 4 for 60. The triethylammonium salt of 111 was detected 
amongst the ion exchange fractions and quantified by a modified Briggs phosphate
244assay.
A proton-coupled 31P NMR spectrum of 111 (Figure 5.20) taken in DzO showed two 
signals, a doublet at 5 P - 0 . 0 6  with 3J h c o p  =  7 . 1Hz, and a multiplet of two P-atoms at 5 P 
- 0 .22 .
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Figure 5.20. 31P NMR spectrum of 111 (proton-decoupled), above and ]H NMR
spectrum below.
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6.1. A short route to a//0-inositol (118), and the synthesis of a racemic 
a//0-inositol trisphosphate mimic of lns(l,4,5)P3.
6.1.1 a/fo-inositol-An overview.
a//o-Inositol (118), a non-natxural cyclitol, was synthesised for the first time by 
Dangschat and Fischer in 1939. 267,268 The fastest synthesis reported to date is by 
Mandel and Hudlicky234 and involves a three-step process in which the key step is 
potassium permanganate oxidation of (IS, 2S)-3-bromocyclohexa-3,5-diene-l,2-diol or 
its chloro- derivative.
Figure 6.1. (IS, 2S)-3-Bromocyclohexa-3,5-diene-l,2-diol.
,OH
OH
This synthesis however produces extremely carcinogenic materials and is not amenable 
to scale-up. The reported overall yield is 26%.
A more recent report269 demonstrates a seven-step stereoselective synthesis of alio- 
inositol in an overall yield of 45%, suitable for a multigram scale but relies on the bio­
oxidation of bromobenzene with toluene dioxygenase expressed in Escherichia coli, to 
give the bromodienediol mentioned above. The route described here is a five-step total 
chemical synthesis, amenable to scale-up, and uses easily available and cost-efficient 
reagents. The aim is to make tf//o-inositol easily accessible for the synthesis of allo- 
inositol trisphosphates, primarily for enzyme studies.
184


















Scheme 6.1. A short route to «//o-inositol (118).
(i) Aq. HI, reflux; (ii) (CH3)2C(OCH3)2, PTSA, DMF; (iii) (C6H5)3P, triiodoimidazole, 
imidazole, toluene, reflux; (iv) RuC13, NaI04, CH3CN/Et0Ac/H20; (v) HCl-EtOH, 16h.
The starting material of choice for the synthesis of tf//o-inositol was L-quebrachitol so
that should, it be required at a later stage to synthesise chiral 121, the synthetic route
could be slightly modified to ensure that chirality was retained throughout the synthesis.
The first step was the demethylation of L-quebrachitol by boiled in hydroiodic acid to
give L-c/z/ro-inositol (113). 113 was then treated with 2 equivalents of 2,2-dimethoxy-
propane and catalytic /?-toluenesulphonic acid in DMF to afford the c/s-diacetonide 114
([H NMR spectrum: Figure 6.2)
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in reasonable yield. (A c/s-acetonide is more stable than a /miw-acetonide and will thus 
form preferentially as the thermodynamic product). The olefin 115 was then formed by 
reaction of the diol 114 with triphenylphosphine, triiodoimidazole and imidazole, as 
described in the synthesis of DL-«eo-inositol-1,2,4-trisphosphate (111). Cis- 
dihydroxylation of the olefin 115 with ruthenium chloride, sodium periodate in a 
mixture of ethyl acetate-acetonitrile-water for 3min afforded two products. (Owing to 
the symmetry of 115, there is only one possible product of cw-dihydroxylation, 116).
Figure 6.3. c/s-Dihydroxylation of 115 gives only one product 116.
The more polar product was isolated and characterised as the a/Zo-inositol diol 116. The 
other product was found to be a ketone by-product, 117. The identity of this product
(116) (116)
was proved by 'H NMR, with the protons a  to the carbonyl shifted to §h 3.32-3.34 and
13C NMR, with the carbonyl signal appearing at 5C 204.33. Mass spectroscopic data was
also in agreement with this structure.
Figure 6.4. A side product of the dihydroxylation of 115.
(117)
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Acid hydrolysis of the diacetonide 116 afforded the hexol 118. At this stage of the 
synthesis chirality was lost. The overall yield of a/Zo-inositol was only 12% 
(unoptimised).
6.2. Design of DLr-a//fl-mositol-1.3,6-trisphosphate (121).
The role of the 2-, 3- and 6-position hydroxyl groups of Ins(l,4,5)P3 may be either to 
donate or accept hydrogen bonds from the receptor or to fix the conformation of the 
molecule by intramolecular hydrogen-bonding to its neighbouring phosphates. Inversion 
of configuration of a hydroxyl group is often equated with its deletion from the 
molecule in the prediction of receptor and metabolic enzyme interactions. Does this 
hypothesis hold true ? Will inverting the stereochemistry of a hydroxyl group disrupt its 
spatial position to such a great extent that it is unable to participate in hydrogen bonding 
with the receptor and enzyme binding sites ? Is the receptor and the metabolic enzymes 
so specific in their requirements for the conformation of the phosphates that a slight 
conformational modification will not be tolerated ?
Obviously if the hydroxyl is deleted it cannot participate in any of these interactions, 
but a hydroxyl with a reversed orientation may.
Already available are L-c/z/ro-Ins(2,3,5)P3, which can be visualised as Ins(l,4,5)P3 with 
the position-3 hydroxyl inverted, and scyllo-Ins(l,2,4)P3 which can be visualised as Ins 
(1,4,5) P3 with its position-2 hydroxyl inverted.
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3 4 M 5 0]O F ^
Ins(l,4,5)P3 L-c/?/ro-Ins(2,3,5)P3 scyllo-lns{ 1,2,4)P3
As part of this project, DL-e/>/-Ins( 1,3,6)P3 (83), the D-enantiomer of which is 
equivalent to Ins(l,4,5)P3 with the position-6 hydroxyl inverted, has been synthesised 
together with DL-weo-Ins(l,3,4)P3 (65) which can be visualised as Ins(l,4,5)P3 with all 
of its hydroxyls inverted
Here is described the synthesis of DL-<a//o-Ins( 1,3,6)P3 (121) which is equivalent to 
Ins(l,4,5)P3 with the position-3 and 6 hydroxyls inverted, completing a set of analogues 
available for biological evaluation.
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While this work was in progress, L-c/z/>*o-Ins(2,3,5)P3 and its phosphorothioate were 
found to be inhibitors of phosphatidylinositol 3-kinase (Ptdlns 3-kinase), the enzyme 
that phosphorylates the 3-position of the inositol head groups of phosphatidylinositol
[Ptdlns], phosphatidylinositol 4-monophosphate [Ptdlns (4)P] and phosphatidylinositol 
4,5-bisphosphate [Pt<Uns(4,5)P2], giving 3-phosphatidylinositol lipids which are not 
substrates for phospholipase C. 270 Evidence is accumulating that some or all of its 3- 
phosphoiylated lipid products (particularly PtdIns(3,4,5)P3) may have second messenger 
functions of their own.271 Inhibitors of Ptdlns 3-kinase may help to clarify the role of 
this enzyme and its products in metabolic cells.
OH OP
Figure 6.7. Criteria for Ptdlns 3-kinase inhibition.
Axial OH groups^ 
required for 
Ptdlns 3-kinase
inhibition. q H O F
L-c///roIns(2,3,5)P3 D-myo-Ins(l,4,6)P3
L-c/z/>o-Ins(2,3,5)P3 can be considered as Ins(l,4,5)P3 in which the equatorial 3-position 
hydroxyl group is replaced by an axial hydroxyl group. It may not be surprising that a 
structural alteration at the 3-position, which is the site of phosphorylation, should 
produce this effect, but D-Ins(l,4,6)P3 is not recognised. The only difference in these 
two structures is the orientation of the position-2 hydroxyl group. Therefore there seems 
to be a requirement for axial-hydroxyl orientation at both positions 2 and 3 for inositol 
phosphates to inhibit Ptdlns 3-kinase activity. In the light of this finding, DL-allo- 
Ins(l,3,6)P3 (121) may also be a Ptdlns 3-kinase inhibitor.
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6.2.1. Synthesis of DL-g//fl-inositoI-l«3,6-trisnhosphate (121) from g/to-inositol
a m
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Scheme 6.2. Synthesis of 121 from <z//oinositol (118).
(i) a). Bu2SnO, MeOH-toluene; b). CsF, BnBr, DMF; (ii) a). (BnO)2PNPri2, ///-tetra- 
zole, CH2C12; b). CIC6H4CO3H; (iii) H2, Pd/C, 50psi.
6.2.2. Regioselective Tri-O-benzvlation of q/to-inositol (118) via a dibutvlstannvlene 












Scheme 6.3. Regioselective benzylation of a/Zoinositol (118).
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The use of organotin derivatives in the selective activation of an equatorial hydroxyl 
group of a vicinal axial-equatorial pair and hence the selective alkylation of it has been 
previously discussed in Chapter 4. a//o-Inositol (118) has three axially oriented 
hydroxyl groups, each of which is vicinal to an equatorial hydroxyl group. Conversion 
of 118 to the corresponding tri-O-dibutylstannylene derivative with the subsequent 
treatment with caesium fluoride and benzyl bromide in DMF was considered to be the 
shortest and highest yielding route to the triol 119. Previous reports on the formation of 
tri-0-dibutylstannylene derivatives of cyclitols, namely myo-inositol 251 and L-chiro- 
inositol,171 have used acetonitrile as the solvent. Toluene is also commonly used, but 
<2//oinositol was found not to dissolve very well in either of these solvents even at the 
boiling point. A mixture of methanol-toluene 1:10 was found to dissolve ^//o-inositol 
under reflux. This was the solvent system employed for the stannylation of 118, with 
the use of a Soxhlet apparatus containing 3A molecular sieves to remove water. The 
resulting crystalline product was dried at 130°C under vacuum before proceeding with 
the benzylation, which involved the reaction with caesium fluoride and benzyl bromide 
in DMF. The reaction was monitored by TLC. After 8h, two main products were 
observed. These products were isolated by flash chromatography. The more polar of the 
two products was found to be the required triol 119, whose regiochemistry was proved 
by conversion to its corresponding trisphosphate 120, and a diol whose regiochemistry 
could not be identified at this stage either. Subsequent phosphorylation of the diol using 
bis(benzyloxy)-A,A-diisopropylaminophosphine and ///-tetrazole in dichloromethane, 
followed by oxidation with m-chloroperoxybenzoic acid, afforded a bisphosphate 
diester whose structure could only be narrowed down to either 124 or 125 by 'H NMR 
spectroscopy.
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Figure 6.8. Phosphorylation of an unidentified by-product. 
OBn OBn
OPO(OBn)2 tanO OBn
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(124) (125)
The identity of the precursor diol could therefore only be narrowed down to the 
corresponding diol structures 122 and 123.
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6.2.3. Phosphorylation of PI^l,3,6-Tri-0- benzyl-a/la-inositol (119).
Phosphorylation of 119 was carried out by phosphitylating the triol 119 using the P(III) 
reagent bis(benzyloxy)-Ar,A'-diisopropylaminophosphine and 7/7-tetrazole in dry 
dichloromethane, followed by oxidation of the resultant trisphosphite triester with m- 
chloroperoxybenzoic acid to give the trisphosphate triester 120. Purification of 120 was 
by flash chromatography. The purity of the compound was judged by TLC.
At this stage it was expected that the steric crowding caused by the axial phosphate 
esters at positions-2 and -4 would cause the ring to flip. The axial protected phosphate 
esters would thus adopt equatorial orientations and the less bulky benzyl groups would 
adopt axial orientations (120a). One and two-dimensional *H NMR spectra were 
required to identify the conformation of the trisphosphate triester. A NMR spectrum 
showed the protons attached to the phosphate bearing carbons, H-2, H-4 and H-5 to be 
downfield with respect to H-l, H-3 and H-6, suggesting that in fact they were 
equatorially oriented (conformation 120). The proton-decoupled 31P NMR spectrum 
showed three signals at 8p -1.52, -1.57 and -1.79, corresponding to the trisphosphate
120.
Figure 6.11. Expected “buckling” of inositol ring due to steric crowding.
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6.2.4. Peprotection of the benzyl-protected trisphosphate 120 and purification of 
the trisphosphate triester 121.
Scheme 6.4. Benzyl deprotection of 120.
OPO(OBn)2 OH
4lBnO OPO(OBn)2 [  9 P° 3'2QH
5^ ~ > v \^ O B n  
(BnO^OPO ° Bl
(120)
Benzyl deprotection of the trisphosphate triester 120 was carried out by hydrogenolysis
as for 59 (Chapter 4). The corresponding deprotected trisphosphate 121 was purified by
ion exchange chromatography as for 60 (Chapter 4) and the triethylammonium salt of
121 was detected from the ion exchange fractions and quantified by a modified
procedure of the Briggs phosphate assay. 244 A proton-coupled 31P NMR spectrum
showed two doublets at 5p 0.60 (IP), 3Jhcop = 9.3Hz and 5P 0.39 (2P), 3Jhcop = 9.3Hz
corresponding to the trisphosphate triester 121(Figure 6.12a). Two of the phosphates are
11
thus chemically and magnetically equivalent judging by their P NMR signal as a clean 
doublet. It is assumed that these are the phosphates at positions-1 and -6. The 
corresponding !H NMR spectrum is shown in Figure 6.12b.
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Figure 6.12.a. 31P NMR spectrum of 121 (proton-coupled) showing the magnetic 
equivalence of the two vicinal phosphates.
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Figure 6.12.b. lH NMR spectrum of 121
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OFR 3 9 9 . C5 MHz
OBSET 1 2 4 . 0 0 kHz
OBFIN 1 0 5 0 0 . 0 Hz
POINT 3 2 7 66
FREOU 5 0 0 0 . 0 Hz
SCANS 64
ACGTM 3 . 2 7 7 s e c
PD 1 . 9 5 2 s e c
PW1 5 . 9 u s
IRNUC 1H
CTEMP 2 1 . 8  c
SLVNT CD30D
EXR£F 0 . 0 0 ppm
BF 0 . 1 5 Hz
RGAIN 15
OPERATOR :
Figure 6.13. Energy minimised model 
of DL-tf//o-inositol 1,3,6-trisphosphate
(121) left, and myo-inositol 1,4,5- 
trisphosphate, right.
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6.3. A summary of the analogues synthesised and their respective 
relationships to Ins(l,4,5) P3.






Molecules synthesised as 
part o f this work.
OH OP 
DL-/?eo-Ins( 1,3,4)P3 * (65)
OH OP
L-c/j/>o-Ins(2,3,5 )P3 
Liu et a/. 120
D-Ins(2,3,5)P3*(96) 




















Tegge et a ll*
OH
^01
Not synthesised to date.
OP
DL-e/?/-Ins( 1,3,6)P3 * 
(83)
OH OP 




Figure 6.14. illustrates the trisphosphate analogues synthesised as part of this project 
and their relationships to Ins(l,4,5)P3 and to each other. The corresponding 
phosphorothioate of 65, 67, was also constructed as was 60, the neo-analogue of 
Ins(l,3,4,6)P4. These compounds are the first neo-inositol trisphosphorothioate and 
tetrakisphosphate reported to date.
Much work has been reported on the chemical modifications of the hydroxyl and 
phosphate substituents of Ins(l,4,5)P3 and the effects that these changes have on the 
interaction with the Ins(l,4,5)P3 receptor and the metabolic enzymes.78 
However, there has been little focus on the construction and biological evaluation of 
Ins(l,4,5)P3 mimics with single and multiple inversions of stereochemistry at each of 
the stereocentres of the molecule. The effects of stereocentre inversion at positions-2 
and -3 to give scj'//o-Ins(l,2,4)P3 (13) 80 and L-c/z/>o-Ins(2,3,5)P3 (14) 120 have been 
studied within the Potter Group (University of Bath), and are well documented in the 
literature.
The aim of this project was to provide a full set of trisphosphate analogues of 
Ins(l,4,5)P3, each of which would have the configuration at one of the six stereocentres 
reversed. The neo-inositol (111) and e/?/-inositol (83) phosphates reported, are the first 
configurational isomers of Ins(l,4,5)P3 of this type. The project was extended to the 
syntheses of various novel analogues with multiple configurational changes, 65, 89, 96, 
100 and 121. 121 is the first a//oinositol trisphosphate synthesised to date.
The work covered in this project provides a full set of analogues to complete this study.
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CHAPTER 7 EXPERIMENTAL
General information for experimental procedures.
Unless stated otherwise, inositol derivatives were racemic and are drawn in the 
D-configuration. Numbering at each stereogenic centre follows IUPAC 
recommendations.272,273
Thin layer chromatography (TLC) was performed on pre-coated plates (Merck TLC 
aluminium sheets silica 60 F254) and products were visualised by spraying with 
phosphomolybdic acid in methanol, followed by heating. Flash chromatography refers 
to the procedure developed by Still and co-workers 274, and was carried out on Sorbsil 
C60 silica gel. TLC was carried out for all compounds after each column 
chromatography purification, to ensure the purity of each compound. All benzyl- 
protected inositol phosphates were purified at least twice by flash chromatography. TLC 
in at least two different solvent systems ensured that they were as pure as possible 
before deprotection. The purity of deprotected inositol phosphates was judged by 
NMR and 31P NMR. Each inositol phosphate was isolated as the triethylammonium salt. 
Masses at this stage are not indicative of the amount of compound present. 
Quantification was by a modification of the Briggs phosphate assay.244 
The NMR spectra for the nuclei 31P, and 13C were recorded on GX270, GX400 or 
GLI EX400 spectrometers. Chemical shifts were measured in parts per million (ppm) 
relative to tetramethylsilane (TMS), deuterium oxide (D20), dimethylsulphoxide-cf, 
(ds-DMSO) or methanol-dj (CD3OD). The 31P NMR shifts were measured in ppm 
relative to external 85% phosphoric acid. Coupling constants, J were measured in hertz 
(Hz) and the following abbreviations are used; s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br. = broad, ex. = exchanged with D20  and Cq = quaternary
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carbon. Melting points (uncorrected) were determined using a Reichert-Jung Thermo 
Galen Kofler block, using two glass plates. Microanalysis was carried out at the 
University of Bath Microanalysis Service. Low resolution and high resolution mass 
spectra were recorded at the University of Bath Mass Spectrometry Service using +ve 
and -ve Fast Atom Bombardment (FAB) with 3-nitrobenzyl alcohol (NBA) as the 
matrix. Optical rotations were measured using an Optical Activity Ltd. AA-10 
polarimeter using 1cm or 5cm cells. All rotations were measured at ambient 
temperature. Ion-Exchange chromatography was performed on an LKB-Pharmacia 
Medium Pressure Ion Exchange Chromatograph using Sepharose Q Fast Flow by 
elution with a gradient of triethylammonium hydrogencarbonate (TEAB) buffer 
(between 0-1M, pH 8) as eluent. Qualitative and quantitative analysis of phosphate was 
performed using a modification of the Briggs phosphate assay.244 
Chemicals and anhydrous solvents were purchased from Aldrich and Fluka. Ether refers 
to diethyl ether, light petroleum refers to the boiling range 40-60°C. The term in vacuo 
refers to the removal of solvent on a cold finger rotary evaporator at ImmHg or below. 
Pyridine was dried by refluxing with sodium hydroxide pellets, followed by distillation, 
and stored over 5A sieves. Tetrahydrofuran (THF) was dried by passing through 
activated alumina to expel peroxide radicals, followed by distillation from sodium in 
the presence of benzophenone ketyl. Anhydrous dimethylsulphoxide, 
dimethylformamide and dichloromethane were purchased from Aldrich and stored over 
4A molecular sieves.
Potassium /-butoxide was purified by sublimation at 225°C/ImmHg. Sodium hydride 
was was used as a 60% dispersion in oil.
Bis(benzyloxy)-A,Ar-diisopropylaminophosphine was prepared by the method of Dreef 
etal. 275
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A mixture of myo-inositol (50g, 277mmol), 2,2-dimethoxypropane (85mL), PTSA 
(50mg, 2.6mmol) and DMSO (160mL) was stirred at 90°C imtil a clear solution was 
obtained, about 2h. The solution was cooled to room temperature, ethanol (200mL) and 
diethyl ether (lOOOmL) were added and stirring continued for a further 2h. 
Triethylamine (lOmL) was added and the mixture was stirred for 4h. The mixture was 
left to stand overnight, after which a white solid precipitated out of solution. This 
product was filtered, washed with methanol-water 1:5 (200mL), ether and dried. It was 
then dissolved in DMF (400mL) and filtered to remove any remaining wyo-inositol. The 
filtrate was reduced to a white solid and reciystallised from ethanol in lOg batches to 
give the title compound 50, (38.4g, 63%).
Mp: 183-184° C (from ethanol) (lit 182-184° C).250 
lU NMR (de-DMSO, 270MHz):
5 1.22 (3H, s, -CH3), 1.36 (3H, s, -CH3), 2.85 (1H, dt, J = 4.4Hz, 9.2Hz, C-5-H), 3.25- 
3.35 (2H, m, C-4-H and C-6-H), 3.45 (1H, m, C-l-H), 3.75 (1H, dd, J = 5.3Hz, 7.3Hz, 
C-3-H), 4.14 (1H, t, J = 4.8Hz, C-2-H), 4.70 (1H, d, J = 4.4Hz, D20  ex.,-OH), 4.74 (1H, 
d, J = 4.4Hz, D20  ex., -OH), 4.8 (1H, d, J = 4.4Hz, D20  ex., -OH), 4.84 (1H, d, J = 
4.8Hz, D20  ex., -OH).
MS: m/z (positive ion FAB, rel. intensity) 221[(M+H)+, 100%], 165(83%), 115(90%), 
87(50%).
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MS: m/z (negative ion FAB, rel. intensity) 373[(M+NBA)", 80%], 291(100%), 
184(80%).







A mixture of 50, (lOg, 45.4mmol), dibutyltin oxide (33.95g, 136.4mmol), 
tetrabutylammonium bromide (14.6g, 45.3mmol) and allyl bromide (60mL, 694mmol) 
in acetonitrile (300mL) was boiled under reflux under a Soxhlet apparatus containing 
3A molecular sieves, for 24h. The sieves were replaced with re-activated ones every 6h. 
Two major products were observed by TLC (diethyl ether-light petroleum 3:2), Rf 0.3 
and 0.4. The solution was allowed to cool and the solvents were evaporated under 
reduced pressure. The residue was partitioned between water and ether (200mL each) 
and the organic layer separated and stirred with sat. aq. sodium hydrogen carbonate 
(200mL) for lh, after which white solid tin derivatives precipitated out of solution. The 
mixture was filtered through Celite and the ethereal filtrate was dried over magnesium 
sulphate, filtered and concentrated under reduced pressure. The title products 51 and 52 
were isolated by column chromatography on silica gel (diethyl ether-light petroleum 
3:2) as yellow syrups.
Yields: 51, Rf 0.4, (4.6lg, 29% yield), 52, Rf 0.3, (4.92g, 32% yield).
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Analytical data for 51:
*H NMR (CDCI3,270MHz)
8 1.55 (3H, s, -CH3), 1.6 (3H, s, -CH3), 3.4 (1H, t, J = 9.7Hz, C-5-H), 2.25 (1H, br.s, 
D20  ex., -OH), 3.50-3.70 (2H, m, C-l-H or C-3-H and C-6-H or C-4-H), 4.07 (1H, t, J = 
9.6Hz, C-6-H or C-4-H), 4.15-4.40 (8H, m, C-3-H or C-l-H and C-2-H and 3x -CH2- 
allyl), 5.15-5.35 (6H, m, 3x =CH2 allyl), 5.85-6.00 (3H, m, 3x -CH= allyl).
13C NMR (CDC13, 68.70MHz)
8 27.70 (q, -CH3), 73.14, 74.65, 77.00, 78.93, 79.90, 81.39 (6d, inositol ring carbons),
72.26, 72.31,73.52 (3t, -OCHr ), 109.88 (s, Cq, (CH3)2-C-), 117.10, 117.30, 117.61 (3t, 
=CH2), 134.86,134.77 (2d, -CH= ).
MS: m/z (positive ion FAB, rel. intensity) 341[(M+H)+, 90%], 283(100%), 167(90%), 
97(85%).
Analytical data for 52: 
lH NMR (CDC13, 270MHz)
8 1.37 (3H s, -CH3) 1.53 (3H, s, -CH3), 3.15 (1H, t, J = 9.1Hz, C-5-H), 3.48-3.57 (2H, m, 
C-6-H and C-3-H), 3.91 (1H, t, J = 9.4Hz, C-4-H), 4.07 (1H, dd, J = 5.4, 12.8Hz, C-l- 
H), 4.43 (1H, t, J = 4.2Hz, C-2-H), 4.15-4.38 (6H, m, 3x -OCH2- allyl), 5.16-5.34 (6H, 
m, 3x =CH2 allyl), 5.88-6.03 (3H, m, 3x -CH= allyl), 2.69 (1H, br.s, D20  ex.,-OH).
13C NMR (CDC13, 68.70MHz)
8 25.79, 27.80 (2q, -CH3), 71.09, 73.69, 76.52, 79.04, 81.15, 81.93 (6d, inositol ring 
protons), 71.75, 72.68, 73.80 (3t, -OCH2- allyl), 110.13 (s, Cq, (CH3)2-C-), 116.90, 
117.12,118.00 (3t, =CH2 allyl), 134.73,134.99, 135.21 (3d, -CH= allyl).
MS: m/z (positive ion FAB, rel. intensity) 341[(M+H)+, 55%], 125(50%), 97(65%), 
81(100%).









A solution of 51 (4.5g, 13.2mmol) and dry pyridine (2.5mL), in dry dichloromethane 
(60mL) was placed under nitrogen and cooled to -78° C. Trifluoromethanesulphonic 
anhydride (1.73mL, 13.20mmol) was added dropwise over a period of 5min. The 
chloroform-acetone cooling bath was removed and the solution allowed to stir at room 
temperature for 2h. TLC (diethyl ether-light petroleum 1:1) showed one major product 
Rf 0.65. The dichloromethane solution was washed with cold 10%HCl(aq), cold 
NaHC03(sat.aq.), ice-water, dried over MgS04, filtered and concentrated to a deep 
orange syrup. The trifluoromethanesulphoxy-intermediate was not isolated. To 4.8g of 
the crude material in dry DMF (150mL) was added an excess of caesium acetate (4g, 
20.8mmol) and the mixture was stirred under nitrogen for 3h. One product was detected 
by TLC (diethyl ether-hexanes 1:1), Rf 0.4. The solution was concentrated in vacuo and 
the residue was partitioned between water and diethyl ether (lOOmL each). The organic 
layer was dried over MgS04, filtered and concentrated to a yellow oil. Purification by 
column chromatography (diethyl ether-hexanes 1:1) afforded the title compound 53, Rf 
0.6, (3.2g, 85%) as a colourless oil.
*H NMR (CDCI3, 270MHz)
5 1.52, 1.38, 2.08 (3s, -CH3), 3.45 (1H, dd, J = 2.7Hz, 9.1Hz, C-l-H), 3.76 (1H, dd, J = 
2.9Hz, 10.2Hz, C-3-H), 3.92 (1H, dd, J = 4.4Hz, 9.7Hz, C-4-H), 4.45 (1H, t, J = 4.8Hz,
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C-5-H), 4.0-4.35 (7H, m, C-6-H and 3x -OCH2 allyl) 5.14-5.36 (6H, m, 3x =CH2 allyl), 
5.82-6.04 (3H, m, 3x -CH= allyl), 5.61 (1H, t, J = 2.9Hz, C-2-H).
13C NMR (CDClj, 68.70MHz)
8 20.98,26.03,28.33 (3q, -CH3), 70.48, 71.40, 72.70 (3t, -OCH2-), 68.51,74.34, 75.02, 
76.04, 76.68, 77.65 (6d, inositol ring carbons), 109.57 (s, Cq, (CH3)2-C-), 117.10, 
117.38,117.58 (3t, 3x =CH2), 134.46,134.60,135.08 (3d, 3x-CH=), 170.08 (s, -C=0 ). 
MS: m/z (+ve ion FAB, rel. intensity) 383[(M+H)+, 68%], 325(100%), 207(55%).
MS: m/z (-ve ion FAB, rel. intensity) 535[(M+NBA)', 88%], 381[(M-H)', 20%]. 






Compound 53, (3.00g, 8.82mmol) was suspended in methanol-aq.NaOH(lM) 5:1 v/v 
(120mL) and heated under reflux for 45min. The solution was left to cool to room 
temperature and carbon dioxide was bubbled through until the pH reached 7.0. The 
methanol was evaporated under reduced pressure and the residue partitioned between 
water and dichloromethane. The organic layer was dried over MgS04, filtered and 
concentrated to give the title compound 54 as an oil, Rf 0.45, (diethyl ether-hexanes 
1:1), (2.8g, 93%).
'H NMR (CDC13, 270MHz)
8 1.36, 1.50 (6H, 2s, C(CH3)2), 3.42 (1H, dd, J = 2.7Hz, 7.0Hz, C-l-H), 3.68 (1H, dd, J 
= 3.1Hz, 9.3Hz, C-3-H), 4.02 (1H, dd, J = 4.2Hz, 9.3Hz, C-4-H), 4.12-4.28 (9H, m,
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C-2-H and C-6-H and C-5-H and 3x -CH2- allyl), 5.16-5.33 (6H, m,3x =CH2 allyl), 
5.84-6.01 (3H, m, 3x -CH- allyl).
13C NMR (CDC13,100MHz)
8 26.81, 29.08 (2q, -C(CH3)2), 72.51, 73.56, 73.50 (3t, 3x -CH2- allyl), 72.09, 75.31, 
76.45, 78.39, 78.60, 77.98 (6d, inositol ring carbons), 110.41 (s, Cq, C(CH3)2), 118.14, 
118.45,118.77 (3t,3x=CH2 allyl), 135.61,135.68,135.83 (3d, 3x-CH= allyl).
MS: m/z (+ve ion FAB, rel. intensity) 341[(M+H)+, 100%], 363[(M+Na)+, 25%], 
499(50%), 681 [(2M+H)+, 30%], 703[(2M+Na)+, 28%].









Compound 54, (2.5g, 7.35mmol), was suspended in a solution of ethanol-lM HC1 
5:lv/v (120mL) and heated under reflux for 30min to give a product by TLC Rf 0.2 
(ethyl acetate-dichloromethane 3:1). The solution was allowed to cool and the solvents 
were evaporated under reduced pressure. The residue was taken up in dichloromethane, 
washed with sat.aq. NaHC03 and sat. NaCl, dried over MgS04, filtered and 
concentrated to a crystalline solid. This was reciystallised from ethyl acetate-hexane to 
give the title compound 55 as white crystals, (2. lg, 95%).
Mp: 73-74° C (from ethyl acetate-hexane).
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]H NMR (CDC13j 270MHz).
5 2.57 (3H, br.s, D20  ex., 3x -OH), 3.56 (1H, dd, J =2.7Hz, 9.5Hz, C-3-H or C-4-H), 
3.63-3.70 (2H, m, C-l-H and C-6-H), 3.89 (1H, dd, J = 2.9Hz, 9.5Hz, C-3-H or C-4-H),
4.06-4.24 (8H, m, 3x -CH2- allyl and C-2-H and C-5-H), 5.14-5.31 (6H, m, 3x =CH2 
allyl), 5.87-5.99 (3H, m, 3x -CH- allyl).
13C NMR (CDCI3,100MHz)
6 71.05, 71.77, 71.95 (3t, -CH2- allyl), 69.19, 69.41, 76.67, 77.31, 77.40, 77.71 (6d, 
inositol ring carbons), 117.06, 117.14, 117.17 (3t, =CH2 allyl), 134.47, 134.73, 134.80 
(3d, -CH= allyl).
MS: (+ve ion FAB, rel. intensity) 601[(2M+H)+, 62%], 323[(M+Na)+, 70%], 
301[(M+H)+, 72%].
MS: (-ve ion FAB, rel. intensity) 599[(2M-H)\ 10%], 299[(M-H)\ 54%], 259[(M- 
CH2CH=CH2)\ 42%], 219(8%).











Compound 55, (3g, lO.Ommol) and dibutyltin oxide (3.73g, 15.0mmol) were suspended 
in toluene (200mL) and heated under reflux using a Dean and Stark apparatus for 2.5h. 
The solution was cooled and the toluene was evaporated under reduced pressure to give 
a crystalline tin complex, which was further dried at 130° C under reduced pressure for 
2h. DMF (200mL) and caesium fluoride (1.89g, 12.5mmol) were added and the
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suspension was stirred vigorously under nitrogen. Allyl bromide (1.20g, lO.Ommol) was 
added dropwise and the mixture left to stir at room temperature for 8h. TLC (diethyl 
ether) showed a single product Rf 0.7. The DMF was evaporated in vacuo and the solid 
residue taken up in dichloromethane (200mL). A saturated solution of NaHC03(aq) 
(200mL) was added and the mixture was stirred vigorously for 30min, during which the 
tin derivative precipitated. The suspension was filtered through Celite, which was 
washed with dichloromethane (2xl00mL). The organic layer was separated, washed 
with water, sat.NaCl, water (lOOmL each), dried over MgS04 and evaporated to 
dryness. The crude material was purified by flash chromatography (diethyl ether-light 
petroleum 1:1) to give the title compound 56 as a crystalline solid, Rf 0.34, (diethyl 
ether-light petroleum 1:1), (3.15g, 92% yield).
Mp: 45°C (from ethyl-acetate-hexane).
‘H NMR (CDCLj; 400MHz)
8 2.52 (2H, s, D20  ex., 2x -OH), 3.67 (4H, s, C-l-H, C-3-H, C-4-H, C-6-H), 4.19-4.22 
(10H, m, -OCH2- allyl and C-2-H and C-5-H), 5.15 (4H, dq, 2Jgem = 1.5Hz, 3JC15 = 
10.5Hz, = CH2 allyl), 5.18 (4H, dq, 2Jgei„ = 1.5Hz, 3J,rans = 12.1Hz, =CH2 allyl), 5.90- 
5.99, (4H, m, -CH= allyl).
13C NMR (CDC13,100MHz)
5 72.23 (t, -CH2- allyl), 76.88, 77.52 (2d, inositol ring carbons), 117.28 (t, =CH2 allyl), 
134.98 (d, -CH= allyl).
MS: m/z (+ve ion FAB, rel. intensity) 703[(2M+Na)+, 12%], 681[(2M+H)+, 15%], 
363[(M+Na)+,48%], 341[(M+H)+, 100%].
MS: Accurate mass (FAB)+ requires (M+H)+ = 341.1964.
MS: Accurate mass (FAB)+ found (M+H)+ = 341.1969.
Anal. Calcd forC18H280 6 (340); C, 63.51; H, 8.29. Found; C, 63.3; H, 8.30%.
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To a solution of the diol 56, (3.00g, 8.82mmol) in dry DMF (lOOmL), was added 
sodium hydride (1.30g, 54.0mmol) and the mixture was stirred at room temperature for 
lOmin. The solution was then cooled to 0° C and benzyl bromide (2.53mL, 21.20mmol) 
was added dropwise over a period of 5min. The cooling bath was removed and the 
mixture was left stirring at room temperature for 2h after which TLC (ethyl acetate- 
hexane 3:1) showed a major product Rf 0.7 and a minor product Rf 0.5. The excess 
sodium hydride was carefully destroyed with water and the mixture concentrated in 
vacuo. The residue was dissolved in dichloromethane (lOOmL), and the solution washed 
successively with water, 0.1M HC1, sat.aq.NaHC03, water (lOOmL each), dried over 
MgS04, filtered and evaporated under reduced pressure. The residue was purified by 
flash chromatography (ethyl acetate-hexane 1:1) to give 57 (Rf 0.45) as a crystalline 
solid (3.5g, 76%), and 57a (Rf 0.2) as a syrup (70mg, 2%).
Analytical data for 57:
Mp: 109-112°C (from ethyl acetate-hexane).
‘H NMR (CDCIj, 400MHz)
5 3.71 (4H, s, C-l-H, C-3-H, C-4-H and C-6-H), 4.0-4.19 (10H, m, 4x-CHr  allyl andC- 
2-H and C-5-H), 4.81 (4H, s, 2x -CH2Ph), 5.07 (4H. dd, 2Jgem = 1.5Hz, 3Jcis = 10.3Hz, 
=CH2 allyl), 5.22 (4H, dd, 2Jgem = 1.8Hz, 3Jttins = 15.3Hz, =CH2 allyl), 5.85-5.90 (4H, m, 
-CH= allyl), 7.21-7.62 (10H, m, 2x -Ph).
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,3C NMR (CDC13j 100MHz)
8 71.77 (t, -CH2- allyl), 74.53 (t, -CH2Ph), 75.66, 78.62 (2d, inositol ring carbons), 
115.89 (t, =CH2 allyl), 127.76, 128.0, 128.17 (3d, -CH2Ph), 135.41 (d, -CH= allyl), 
139.43 (s, Cq,-CH2Ph).
MS: m/z (+ve ion FAB rel. intensity) 543[(M+Na)+, 12%], 521[(M+H)+, 32%], 
519(40%), 91[(C7H7)+, 100%].
MS: Accurate mass (FAB)+ requires (M+H)+ = 521.2903.
MS: Accurate mass (FAB)+ found (M+H)+ = 521.2892.
Anal. Calcd for C32H40O6 (520); C,73.82; H, 7.74. Found; C, 73.4; H, 7.67%.
Analytical data for 57a:
*H NMR (CDCI3,400MHz)
8 3.63 (2H, dd, J = 2.4,9.8Hz, C-4-H and C-6-H), 3.76 (2H, dd, J = 3.1, 9.8Hz,
C-l-H and C-3-H), 4.01 (1H, t, J = 2.5Hz, C-5-H), 4.06-4.28 (9H, m, C-2-H and -CH2- 
allyl), 4.83 (2H, s, -CH2Ph), 5.15 (4H, dq, 2Jgem = 1.8Hz, 3Jcis = 6.4Hz and =CH2 allyl), 
5.30 (4H, dq, 2Jgem = 1.5Hz, = 11.3Hz, =CH2 allyl), 5.86-5.99 (4H, m, -CH= allyl),
7.24-7.72 (5H, m, -Ph, 3Jortho = 7.3Hz).
13CNMR(CDC13, 100MHz)
8 71.78, 71.97 (2t, -CH2- allyl), 74.38 (t, -CH2Ph), 77.00, 77.32, 77.62, 78.15 (4d, 
inositol ring protons), 116.17, 116.79 (2t, =CH2 allyl), 127.27, 127.82, 128.04 (3d, - 
CH2Ph), 135.06,135.19 (2d, -CH= allyl), 139.14 (s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB rel. intensity) 453[(M+Na)+, 70%], 431[(M+H)+, 79%],
91[(C7H7)+, 100%], 415(80%).













A mixture of 57 (200mg, 0.38mmol), PTSA (50mg, 0.26mmol) and 10% palladium on 
activated charcoal (10%, 150mg) in ethanol-water 1:12 (50mL) was heated under reflux 
for 12h. TLC (chloroform-acetone 20:1) showed one major product Rf 0.3 and 
debenzylated products on the baseline. The solution was filtered through Celite and the 
colourless filtrate was concentrated under reduced pressure to give a white solid. This 
residue was reciystallised from methanol to give the title compound 58 (90mg, 65%), as 
white crystals.
Mp: 190-194°C (from methanol).
*H NMR (CDC13,270MHz)
8 3.68 (4H, s, C-l-H, C-3-H, C-4-H, C-6-H), 3.70 (2H, s, 2x -OH), 4.63 (2H, s, C-2-H 
and C-5-H), 4.75 (4H, s, -CH2Ph), 7.23-7.41 (10H, m, -Ph).
13C NMR (CDCI3,100MHz)
8 70.51, 81.85 (2d, inositol ring carbons), 74.41 (t, -CH2Ph), 126.89, 126.97, 127.09 (d, 
-CH2Ph), 139.57 (s, Cq, -CH2Ph).
MS: m/z (+ve ion El, rel. intensity) 269[(M-C7H7)+, 25%], 91[(C7H7)+, 100%],
MS: m/z (+ve ion Cl, rel. intensity) 91[(C7H7)+, 93%], 181[(2C7H7-H)+, 100%], 
269(50%), 359(37%).
MS: Accurate mass (EI)+ requires (M-C7H7)+ = 269.1025.
MS: Accurate mass (EI)+ found (M-C7H7)+ = 269.1028.
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To a solution of bis(ben2yloxy)-Af,./V-diisopropylaminophosphine (765mg, 2.22mmol) in 
dry dichloromethane (lOmL) was added tetrazole (31 lmg, 4.43mmol). The mixture was 
stirred at room temperature for 15min before the tetrol 58 (lOOmg, 0.27mmol) was 
added. The mixture was left stirring for a further 30min, and was then cooled to -78° C 
using a C02(s) / acetone bath. m-CPBA (420mg, 2.44mmol) was added and the cooling 
bath removed. Stirring was continued for 5min before the mixture was diluted with 
dichloromethane (50mL). The clear solution was washed with 10% aq.Na2S20 5, 
sat.aq.NaHC03, water (50mL each), dried over MgS04, filtered and concentrated under 
reduced pressure. Purification by flash chromatography (chloroform-acetone 20:1) 
afforded the title compound 59, Rf0.65, (chloroform-acetone 20:1), (230mg, 61%) as a 
colourless oil.
NMR (CDCI3, 400MHz)
5 4.59 (2H, br.s, C-2-H, C-5-H), 4.95 (4H, s, -CH2Ph), 4.77-4.82 (4H, m, C-l-H, C-3-H, 
C-4-H, C-6-H), 4.93 and 4.94 (4H, AB, Jab = 11.9Hz, -PO(OCH2Ph)2), 4.95 and 4.96 
(4H, AB, Jab = 11.6Hz, -OP(OCH2Ph)2), 4.97 (4H, s, -PO(OCH2Ph)2), 4.99 (4H, s, - 
PO(OCH2Ph)2), 7.20-7.72 (50H, m, -CH2Ph).
13CNMR(CDC13, 100MHz)
8 69.40, 69.44, 69.64, 69.71 (4t, -PO(OCH2Ph)2), 76.17 (t, -CH2Ph), 76.71, 77.02 (2d, 
inositol ring carbons), 127.92, 127.97, 128.52 (3d, -Ph), 135.58, 135.66 (2s, Cq, 
-CH2Ph).
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31PNMR(CDC13, 162MHz) 5p-1.98(4P) 3IP-1H-decoupled.
MS: (+ve ion FAB, rel. intensity) 91[(C7H7)+, 100%], 181[(2C7H7-H)+, 12%], 
1401[(M+H)+, 75%], 1423[(M+Na)+, 12%].
MS; (-ve ion FAB, rel. intensity) 277[(OPO(OC7H7)*), 100%], 1310[(M-C7H7+H)\ 
30%].
Accurate mass (FAB)+ requires (M+H)+ = 1401.4060.
Accurate mass (FAB)+ found (M+H)+ = 1401.4058.




A solution of 59, (lOOmg, 71.0pmol) in ethanol-water 4:1 (50mL) was treated with 
hydrogen over Pd/C (10%, lOOmg) at room temperature at a pressure of 50psi for 18h. 
The suspension was filtered through Celite to remove the catalyst, 2mL of TEAB buffer 
pH 8.0 was added and the solvents were evaporated under reduced pressure at room 
temperature. The residue was made up to 200mL with de-ionised water and purified by 
ion-exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient 
of triethylammonium bicarbonate (TEAB) buffer (0-1M), pH 8.0. The 
triethylammonium salt of 60 eluted between 600-650mM, and was detected and 
quantified by the Briggs phosphate assay. 244 (52pmol, 73% yield). 
lHNMR(D20, 400MHz)
6 4.20 (2H, m, C-2-H and C-5-H), 4.59-4.67 (4H, m, C-l-H, C-3-H, C-4-H, C-6-H). 
31PNMR(D20, 162MHz) 5p -0.36 (br.s, 4P) (^P-'H-coupled).
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MS: m/z (+ve ion FAB, rel. intensity) 102[(C2H5)3NH+, 100%], 118(10%), 59(6%).
MS: m/z (-ve ion FAB, rel. intensity) 499[(M)', 100%], 998[(2M)', 26%], 158(20%), 
79(18%), 401(6%).
Accurate mass (FAB)’ requires (M-H)* = 498.9208.
Accurate mass (FAB)' found (M-H)' = 498.9207.
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7.2. Synthesis of DL-n^-inositol 1,3,4-trisphosphate (65)
7.2.1. DL-1.3.4-Tri-Oallvl-2.5.6-tri-0-benzvl-Meo-inositol (611 and DL-1.3.4-Tri-Q-





•Bn •Bn(55) (61) (61a)
A mixture of 55,(2.4g, 8.0mmol) and sodium hydride (1.27g, 71.6mmol) was stirred in 
diy DMF (60mL) for 15min. Benzyl bromide (3.35mL, 28.0mmol) was added dropwise 
over a period of 5min and the solution left stirring for 2h. TLC (diethyl ether-pentane 
1:4) showed one major product Rf 0.6 and a minor product Rf 0.4. The excess sodium 
hydride was destroyed with methanol (15mL) and the solvents were evaporated in 
vacuo to give a syrupy residue. The syrup was partitioned between water and diethyl 
ether and the ethereal extract was washed with 0.1M HC1 sat.aq.NaHC03 and water 
(lOOmL). The organic layer was dried over MgS04, filtered and concentrated. The 
remaining syrup was purified by flash chromatography (diethyl ether-pentane 1:5) to 
give compound 61, Rf0.45, the less polar product (3.8g, 83%) as a white solid, and the 
minor more polar product 61a, Rf0.3, (120mg, 4%) as an oil.
Analytical data for 61:
Mp: 45-47° C (from hexane).
'H NMR (CDClj, 270MHz)
5 3.83 (m, 4H, C-l-H, C-3-H, C-4-H and C-6-H), 4.03 (2H, m, C-2-H and C-5-H), 4.08- 
4.22 (6H, m, -CH2- allyl), 4.64 and 4.74 (2H, AB, Jab = 12.1,-OCH2Ph), 4.83 (2H, s, 
-OCH2Ph), 4.85 (2H, s, -OCH2Ph), 5.13 (3H, dq, 2Jgora = 1.6Hz, 3J*. = 10.6Hz, =CH2
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allyl), 5.3 (3H, dq, 2Jgem = 1.7Hz, 3J*  = 17.2Hz, =CH2 allyl), 5.84-5.99 (3H, m, -CH- 
allyl), 7.23-7.44 (15H, m, -OCH2Ph).
13C NMR (CDC13, 68MHz)
8 71.77, 72.94 (2t, -CHr  allyl), 74.53, 74.56 (2t, -OCH2Ph), 75.58, 75.76, 78.62, 78.67,
78.78, 78.83 (6d, inositol ring carbons), 115.95, 116.00 (2t, =CH2, allyl), 127.42, 
127.79, 128.03 (3d, -Ph), 135.40, 135.59 (2d, -CH= allyl), 139.09, 139.40 (2s, Cq, - 
OPh).
MS: m/z (+ve ion FAB, rel. intensity) 593[(M+Na)+, 18%], 571[(M+H)+, 45%], 
570(24%), 569(68%),
91[C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity 723[(M+NBA)\ 30%], 569[(M-H)', 5%].
Accurate mass (FAB4) requires (M+H)+ = 571.3059.
Accurate mass (FAB4) found for (M+H)+ =571.3057.
Analytical data for 61a:
!H NMR (CDCI3,400MHz)
8 2.47 (2H, s, D20  ex., 2x -OH), 3.52 (1H, dd, J = 2.4Hz, 9.8Hz, C-4-H or C-6-H), 
3.61(1H, dd, J = 2.4Hz, 9.8Hz, C-6-H or C-4-H), 3.78 (1H, dd, J = 3.4Hz, 9.8Hz, C-l-H 
or C-3-H), 3.96-4.24 (9H, m, -CH2- allyl, and C-2-H and C-5-H and C-l-H or C-3-H), 
4.79 and 4.83 (2H, AB, Jab= 11.7Hz, -CH2Ph), 5.15-5.34 (6H, m, =CH2 allyl), 5.85-5.99 
(3H, m, -CH- allyl), 7.21-7.41 (5H, m, -Ph,).
13C NMR (CDCI3,100MHz)
8 70.93, 71.98, 72.01 (3t, -CH2- allyl), 74.34 (t, -CH2Ph), 76.73, 77.90, 78.34, 78.56, 
79.57 (5d, inositol ring carbons), 116.29, 116.90, 117.28 (3t, =CH2 allyl), 127.41,
127.87, 128.16 (3d, -Ph), 134.60, 134.98,135.18 (3d, -CH= allyl), 138.95 (s, Cq, -Ph). 
MS: m/z (+ve ion FAB, rel. intensity) 413[(M+Na)+, 391[(M+H)+, 66%], 18%], 
91[(C7H7)+, 100%].
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A mixture of compound 61, (3.5g, 6.14mmol) and freshly sublimed potassium-/- 
butoxide (6.2g, 55.3mmol) in dry DMSO (60mL), was stirred at 100° C for 1.5h under 
an atmosphere of nitrogen. TLC (diethyl ether-pentane 1:6) showed conversion to a 
single product Rf 0.6 which was less polar than the starting material 61, Rf 0.3. The 
reaction mixture was left to cool, water (lOOmL) was added and the product was 
extracted with dichloromethane (4x lOOmL). The organic layer was dried over MgS04, 
filtered and purified by flash chromatography (diethyl ether-pentane 5:1, 5% 
triethylamine) to give the title compound 62, Rf0.6, (diethyl ether-pentane 1:6), (3.1g, 
5.4mmol, 88% yield) as fine white crystals.
Mp: 92-94° C (from hexane).
‘H NMR (CDC1,, 400MHz)
8 1.60 (6H, dd, J = 1.5, 6.8Hz, -CH3 propenyl), 1.66 (3H, dd, J = 1.5, 6.8Hz, -CH3 
propenyl), 3.92 (1H, dd, J = 2.9, 7.3Hz, inositol ring proton), 4.03-4.14 (5H, m, inositol 
ring protons), 4.37 (3H, m, =CHMe propenyl), 4.60 and 4.69 (2H, AB, Jab = 12.2Hz, 
-CH2Ph), 4.78 (2H, m, -CH2Ph), 4.81 (2H, s, -CH2Ph), 6.06 (2H, qd, J = 1.5, 6.3Hz, 
-OCH= propenyl), 6.15 (1H, m, -OCH= propenyl), 7.24-7.72 (15H, m, 3x -Ph).
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13C NMR (CDCI3,100MHz)
8 9.23,9.31,9.34 (3q, -OCH= propenyl), 72.57,74.45, 74.69 (3t, -CH2Ph), 75.89, 76.63, 
76.92, 77.45, 78.31, 78.89 (6d, inositol ring carbons), 98.49, 100.31, 101.64 (3d, =CH- 
propenyl), 127.21, 127.51, 128.32, 128.55, 128.69, 129.43, 129.69, 129.99 (8d, -Ph), 
137.98, 138.34,138.62 (3s, Cq, -Ph), 146.32,147.48, 147.82 (3d, -CH= propenyl).
MS: (+ve ion FAB, rel. intensity) 611(25%), 571[(M+H)+, 14%], 514(60%), 479(30%), 
91[(C7H7)+, 100%].
MS; (-ve ion FAB, rel. intensity) 723[(M+NBA)\ 75%], 569[(M-H)\ 14%], 
335(100%), 289(88%), 123(90%).













Compound 62, (3.0g, 5.26mmol) was suspended in a solution of methanol-lM aq.HCl 
2:1 (60mL) and stirred under reflux for 1.5h after which TLC (dichloromethane-ethyl 
acetate 1:1) showed a single product Rf 0.3. The solution was allowed to cool and the 
mixture was evaporated to dryness under reduced pressure. The remaining residue was 
taken up in dichloromethane (lOOmL), washed with sat.aq.NaHC03 and water (lOOmL 
each), dried over MgS04, filtered and concentrated to give a white solid. Purification by 
column chromatography (ethyl acetate-hexane 4:1) Rf 0.55, afforded the title compound 
63, (2.1g, 88%) as a crystalline solid.
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Mp: 169-170° C (from ethanol).
'H NMR (CDCIj, 270MHz)
8 2.25 (2H, br.s, D20  ex., -OH), 2.45 (1H, br.s, D20  ex., -OH), 3.80 (2H, m, inositol 
ring protons), 4.05-4.10 (4H, m, inositol ring protons), 4.60 and 4.74 (2H, AB, Jab = 
12.0Hz, -CH2Ph), 4.64 and 4.72 (2H, 2s, -CH2Ph), 4.69 and 4.76 (2H, 2s, -CH2Ph), 7.22- 
7.45 (15H, m,-CH2Ph).
13C NMR (CDC13, 68MHz)
5 71.31, 72.42,74.68 (3t, -CH2Ph), 72.16,72.19,73.41, 75.62, 76.31, 76.79 (6d, inositol 
ring carbons), 127.31, 127.61, 127.89, 128.32, 128.41, 128.62, 128.65, 128.89 (8d, - 
CH2Ph), 139.20,139.68,139.76 (3s, Cq, -Ph).
MS: (+ve ion FAB, rel. intensity) 473[(M+Na)+, 65%], 451[(M+H)+, 21%], 91[(C7H7)+, 
100%].
MS: (-ve ion FAB, rel. intensity) 603[(M+NBA)\ 100%], 449[(M-H)\ 60%], 188(40%). 
Anal.Calcd. for C27H30O6 (450); C, 71.98; H, 6.71. Found; C, 71.5; H, 6.68%.
7.2.4. DL-1.2.5-Tri-Q-benzvl-weoinositol 3.4,6-Trisfbis(2-cvanoethvl)phosphate1. (64)
OBn
J OPO(OCH2CH2CN)2  
BnOsA  t^O PO (O C H 2CH2CN)2
(NCCH2CH20)2 0 P O s 
(64)
To a solution of bis(2-cyanoethoxy)-diisopropylaminophosphine (358mg, 1.32mmol) in 
dry dichloromethane (lOmL), was added tetrazole (185.5mg, 2.64mmol). The mixture 
was stirred at room temperature for lOmin and the triol 63 was added. Stirring was 
continued for a further lh, after which TLC (ethyl acetate-dichloromethane 1:1) showed 






mixture was cooled to -78° C and m-CPBA (360mg, 2.09mmol) was added. Stirring 
was continued for 5min before the cooling was removed and the mixture was allowed to 
stir for a further 5min. Ethyl acetate (50mL) was added to the mixture and the solution 
was washed with 10% aq.sodium metabisulphite, sataq NaHC03 and satbrine (50mL 
each), dried over MgS04, filtered and concentrated to an oil. Purification by column 
chromatography (chloroform-acetone 20:1) Rf 0.56, afforded the trisphosphate triester 
64 as a colourless oil (120mg, 54%).
*H NMR (CDC13,270MHz)
8 2.71-2.84 (12H, m, 6x -CH2CN), 4.19-4.37 (15H, m, 6x -CHfiH2CN and C-l-H, C-2- 
H, C-5-H), 4.51 (1H, dd, J = 2.8, 9.4Hz, C-3/4/6-H), 4.72-4.90 (8H, m, -CH2Ph and C- 
3/4/6-H), 7.24-7.54 (15H, m, -Ph).
13C NMR (CDCI3,100MHz)
8 20.32, 20.47, 20.54, 20.61, 20.70, 20.80 (6t, -CH2CN), 63.33, 63.43, 63.72, 63.79, 
63.83, 63.88 (6t, -Ctf2CH2CN), 73.76, 75.88, 75.99 (3t, -CH2Ph), 76.83, 76.89, 76.94, 
77.00, 77.50, 78.00 (6d, inositol ring carbons), 117.36, 117.45, 117.50, 117.70, 117.74,
117.80 (6s, Cq, -CN), 128.49, 128.64, 128.77, 128.84, 128.88, 129.01, 129.08, 129.15, 
129.30, 129.41, 129.50, 129.56, 129.74, 129.88, 130.69 (16d, -Ph), 138.17, 138.90, 
138.94 (3s, Cq, -Ph).
31P NMR (CDCI3, 109MHz)
8P -3.19 (IP), -3.23 (2P). (^H -decoupled).
MS: m/z (+ve ion FAB, rel. intensity) 1009[(M+H)+, 40%], 91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 203[(NCCH2CH2O)2PO2\  45%], 1211(30%), 
1007[(M-H)\ <1%].




OPO(OCH2CH2CN)2  H( 
—OBn
Bn* OPO3
(NCCH2CH20 )2 0 P 0
(65)(64)
Ammonia (lOOmL) was condensed into a three-neck flask at -78° C. An excess of 
sodium was added to dry the liquid ammonia and the deep blue solution was stirred at - 
78° C for 30min. A small volume of the dry ammonia (30mL) was then distilled into a 
second three-neck flask and kept at -78° C. Sodium was added until the solution 
remained blue/black for lOmin. A solution of 64, (95mg, 94.2pmol) in dry dioxane 
(5mL), was added to the vigorously-stirring sodium-liquid ammonia mixture. After 60 - 
90sec. the reaction was carefully quenched with methanol, followed by de-ionised 
water. The ammonia and solvents were then evaporated under reduced pressure and the 
residue dissolved in de-ionised water (500mL) and purified by ion-exchange 
chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient of 
triethylammonium hydrogen carbonate buffer (0-1M), pH 8.0. The glassy 
triethylammonium salt of 65 eluted between 540-600mM buffer and was detected and 
quantified by the Briggs phosphate assay.244 (36pmol, 38% yield).
!HNMR (D20,400MHz)
5 3.81 (1H, dd, J = 2.0, 10.2Hz, C-6-H), 4.10-4.24 (4H, m, C-l-H, C-2-H, C-3-H, C-4- 
H), 4.28 (1H, br.s, C-5-H).
31P NMR (D20 , 162MHz) 5p -0.18 (IP, d, J = 8.6Hz), 8P -0.32 (2P, m)
(1H-3 ^ -coupled).
MS: m/z (-ve ion FAB, rel. intensity) 838[(2M)', 55%], 419[(M)', 85%], 
97[(H2P04)\ 20%].
MS: Accurate mass (FAB)' requires (M-H)' = 418.9545.
MS: Accurate mass (FAB)' found (M-H)‘ = 418.9549.
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7.3. Synthesis of DL-/ie0 -inositol 1,3,4-trisphosphorothioate (67).






To a solution of bis(benzyloxy)-7V,ALdiisopropylaminophosphine (460mg, 1.33mmol) in 
dry dichloromethane (5mL), was added tetrazole (140mg, 2.0mmol). The mixture was 
stirred at room temperature for lOmin. The triol 63 (lOOmg, 0.22mmol) was added and 
stirring continued for a further 30min. Dry pyridine (3mL) and sulphur (lOOmg, 
3.13mmol) were added and the mixture was stirred for 18h. The solvents were 
evaporated under reduced pressure, and the residue was purified by column 
chromatography (ethyl acetate-hexane 1:4) to give 66, Rf 0.45, (141mg, 50%) as an oil. 
*H NMR (CDCI3,400MHz)
5 3.91 (1H, dd, J = 2.1, 10.1Hz, C-l-H), 4.39 (1H, t, J = 2.8Hz, C-5-H), 4.43 and 4.49 
(2H, AB, Jab = 11.9Hz, -CH2Ph), 4.69 and 4.78 (2H, AB, Jab = 116Hz, -CH2Ph), 4.72 
(3H, m, C-2-H and -CH2Ph), 4.89-5.1 (15H,m, C-3-H and C-4-H and C-6-H and 
-CH2Ph), 7.22-7.48 (45H, m, 9x -Ph).
13C NMR (CDCI3, 100MHz)
8 69.46, 69.50, 69.74,69.79, 69.83, 69.95, 70.10, 72.61 (8t, -CH2Ph and 
-OPS(OCH2Ph)2), 75.33, 75.50, 75.83, 76.79, 76.85, 77.21 (6d, inositol ring carbons), 
127.55, 128.16, 128.23, 128.27, 128.38, 128.41 (6d, -CH2Ph and -OPS(OCH2Ph)2), 
135.66, 135.69, 135.73,135.78, 135.82, 135.86, 137.80, 138.55, 138.58 (9s, Cq,
-CH2Ph and -OPS(OCH2Ph)2).
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3IP NMR (CDClj, 162MHz)
8P +66.88 (IP), +67.07 (2P), (3'P-‘H-decoupIed).
5P +66.8 (IP, sextet, J = 9.5Hz), 67.07 (2P, br.s) (3,P-'H-coupled).
MS: m/z (-ve ion FAB, rel. intensity) 1277[(M-H)', 64%], 1186[(M-C7H7-H)', 10%], 
293 [(OPS(OC7H7)2)", 100%], 95(47%).
Anal.Calcd for C e ^ O u ? ^ ;  C, 64.78; H, 5.44. Found; C, 65.0; H, 5.45%.
7.3.2. DL-flgo-inositol 1.3.4-trisphosphorothioate. (67)
Compound 66 was deprotected as described for compound 65. Purification was by ion- 
exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient of 
triethylammonium hydrogen carbonate buffer (0-1M), pH 8.0. The triethylammonium 
salt of 67 eluted between 800-900mM buffer and was detected and quantified using the 
Briggs phosphate assay.244 (43pmol, 61 % yield).
’H NMR (D20, 400MHz)
(1H, t, J = 2.4Hz, C-5-H), 4.60-4.69 (m, C-l-H and H20).
31PNMR(D20, 162MHz)
5P +44.47 (IP, d, J = 10.8Hz), +41.89 (2P, m) (’H-3 ^ -coupled).
MS: m/z (+ve ion FAB, rel. intensity) 468[(M+H)+, <1%], 102[(C2H5)3NH+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 466[(M-H)\ 100%], 432(10%), 371(80%), 
330(5%), 113[(H2P03S)', 10%], 95(17%).
0 P S 0 22►PS(OBn>2




6 3.84 (1H, dd, J = 2.9, 10.2Hz, C-6-H), 4.23-4.35 (3H, m, C-l-H, C-2-H, C-3-H), 4.54
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MS: Accurate mass (FAB)" requires (M-H)" = 466.8860. 
MS: Accurate mass(FAB)" found (M-H)" = 466.8871.
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7.4. Synthesis of DL-epi-inositol 1,3,6-tris phosphate. (83)





■ O A 1 1
AllO 5AllO 1AllO 5 
(52) (68a)(68)
To a solution of 52 (3.0g, 8.82mmol) and dry pyridine (2mL) in dry dichloromethane 
(50mL), was added trifluoromethanesulphonic acid (1.15mL, 8.82mmol) dropwise over 
a period of 5min at -78° C, under nitrogen. The cooling bath was removed and the 
solution was stirred at room temperature for 2h. TLC (ether-light petroleum 1:1) 
showed only one product Rf 0.60. The dichloromethane solution was diluted with 
dichloromethane (50mL), washed with ice-10% HCl(aq), ice-sat.aq.NaHC03, ice-water 
(50mL each), dried over MgS04 and concentrated under reduced pressure to a deep red 
syrup. The trifluoromethanesulphonoxy analogue was not purified. Dry DMF (60mL) 
and caesium acetate (3.38g, 17.64mmol) were added to the residue, and the mixture 
stirred under nitrogen at room temperature for 3h. TLC (ether-light petroleum 1:1) 
showed a single product Rf 0.30. The solution was concentrated in vacuo and the syrupy 
residue partitioned between ether and water (lOOmL each). The ethereal phase was 
separated, dried over MgS04, filtered and concentrated to a yellow syrup. Purification 
of the crude material by column chromatography (ether-light petroleum 1:1) afforded 
the diastereoisomer 68a, Rf 0.33, (2.63g, 78%).
'H NMR (CDClj, 400MHz)
5 1.36 and 1.54 (6H, 2s, 2x -CH3), 2.09 (3H, s, -CH3 acetyl), 3.32 (1H, t, J = 8.8Hz, C-5- 
H), 3.58-3.69 (2H, m, C-l-H and C-3-H), 4.05-4.33 (7H, m, 3x -CH2- allyl and C-4-H),
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4.42 (1H, dd, J = 4.0, 5.5Hz, C-2-H), 5.05 (1H, t, J = 8.5Hz, C-6-H), 5.12-5.32 (6H, 
m,3x =CH2 allyl), 5.80-5.98 (3H,m,3x-CH= allyl).
I3C NMR (CDC13, 100MHz)
8 21.69, 26.34, 28.26 (3q, -CH3), 72.59, 73.43, 73.47 (3t, -CH2- allyl), 72.59, 74.34, 
74.42, 75.08 (4d, inositol ring carbons), 110.79 (s, Cq, CMe2), 117.30, 117.50, 117.70 







Compound 52 (7.55g, 22.2mmol) and sodium hydride (1.06g, 44.4mmol) were 
dissolved in dry DMF (150mL). / 7-Methoxybenzyl chloride (6.1mL, 44.98mmol) was 
added dropwise at room temperature over a period of 15min, and the mixture was 
stirred for 2h. TLC (ether-light petroleum 1:2) showed one product Rf 0.2. The excess 
sodium hydride was destroyed with methanol (20mL) and the solvents were evaporated 
under reduced pressure. The remaining syrup was partitioned between ether and water 
(200mL each) and the organic phase was washed with 0.1M HC1, sat.aq.NaHC03 and 
water (lOOmL each). The ethereal solution was dried over MgS04, filtered and 
concentrated. The remaining syrup was purified by flash chromatography (ether-light 
petroleum 2:1) to afford the title compound 69, Rf 0.47, as a syrup (7.15g, 70%).
'H NMR (CDCI3,400MHz)
S 1.36 and 1.55 (6H, 2s, -CH3), 3.21 (1H, t, J = 9.1Hz, C-5-H), 3.56 (1H, dd, J = 2.4,
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7.0Hz, C-l-H or C-3-H), 3.77 (3H, s, -OCH3), 3.79 (1H, t, J = 8.8Hz, C-4-H), 4.03 (1H, 
t, J = 8.9Hz, C-6-H), 4.20-4.4.41 (7H, m, C-2-H and -CH2- allyl), 4.72 (2H, 2s, , - 
OCH2QH4OCH3), 5.12-5.32 (6H, m, =CH2 allyl), 5.87-6.03 (3H, m, -CH= allyl), 6.86 
(2H, d, J = 8.5Hz, PMB 3,5-H), 7.31 (2H, d, J = 8.5Hz, PMB 2,6-H).
13C NMR (CDClj, 68MHz)
25.78, 27.73 (2q, -(CHj^, 55.12 (q, -PhOCH3), 72.49, 72.94, 73.67, 74.04 (4t, -OCH2 
allyl and -OCH2PhOCH3), 74.53, 76.85, 78.86, 80.38, 81.81, 82.10 (6d, inositol ring 
carbons), 109.72 (s, Cq, CMe2), 113.60, 113.70 (2d, -Ph-), 116.70, 117.47 (2t, =CH2 
allyl), 129.72 (d, -Ph-), 130.76 (s, Cq, -OCH2PhOCH3), 134.88, 135.18 (2d, -CH= allyl), 
159.19 (s, Cq, -CH2PhOCH3).
MS: m/z (+ve ion FAB, rel. intensity) 921[(2M+H)+, 10%], 483[(M+Na)+, 70%], 
461[(M+H)+, 15%], 459(100%).
Anal. Calcd for C26H360 7; C, 67.82; H, 7.88. Found; C, 67.9; H, 7.95.











Compound 69 (6.0g, 13.04mmol) was suspended in a solution of methanol-lM HC1 
9:lv/v (200mL) and was stirred at 50° C for 30min. TLC (ether-light petroleum 2:1) 
showed the complete conversion of the starting material 69, Rf 0.4, to a product on the 
baseline. The pH of the solution was adjusted to 7.0 using triethylamine and the mixture 
was allowed to cool to room temperature before the solvents were evaporated under 
reduced pressure. The remaining oil was taken up in dichloromethane and the solution 
was washed with sat.NaCl(aq), water (lOOmL each), dried over MgS04, filtered and
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concentrated. Purification by flash chromatography (ether-light petroleum 4:1) afforded 
the title diol 70 as an oil, Rf 0.55, (4.9g, 89%).
!H NMR (CDC13, 400MHz)
5 2.60 (2H, br.s, D20  ex., 2x -OH), 3.21 (1H, t, J = 9.5Hz, C-5-H), 3.26 (1H, dd, J = 2.7, 
9.8Hz, C-l-H or C-3-H), 3.38 (1H, dd, J = 2.4, 9.5Hz, C-3-H or C-l-H), 3.61 (1H, t, J = 
9.5Hz, C-4-H), 3.78 (3H, s, OCH3), 4.17-4.41 (7H, m, -CH2- allyl and C-2-H), 4.75 and
4.80 (2H, AB, = 10.1Hz. -CH2Ph-), 5.15-5.31 (6H, m, =CH2 allyl), 5.91-6.86 (3H, 
m, -CH= allyl), 6.85 (2H, d, J = 8.6Hz PMB 3,5-H), 7.10 (2H, d, J = 8.8Hz, PMB 2,6- 
H).
13C NMR (CDC13, 68MHz)
6 55.12 (q, -PhOCH3), 71.69, 72.39, 74.22, 75.55 (4t, -CH2- allyl and -CH2PhOMe),
69.26, 79.52, 80.65, 81.07, 82.74 (5d, inositol ring carbons), 113.68 (d, -Ph-), 116.52, 
117.08, 117.41 (3t, =CH2 allyl), 129.72 (d, -Ph-), 130.80 (s, Cq, -Ph-), 134.52, 134.97, 
135.08 (3d, -CH= allyl), 159.13 (s, Cq, -Ph-).
MS: m/z (+ve ion FAB, rel. intensity) 443[(M+Na)+, 98%], 419(30%), 420(7%), 
121[(CH2C6H40CH3)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 537[(M+NBA)*, 95%], 419[(M-H)', 100%]. 
Accurate mass (FAB)'requires (M-H)‘ = 419.2069.












A mixture of the diol 70 (lO.Og, 23.80mmol) and sodium hydride (1.71g, 71.42mmol) in 
dry DMF (300mL) was stirred at room temperature under nitrogen for 15min. The 
solution was cooled to -78°C and benzyl bromide (6.8mL, 57.1 mmol) was added 
dropwise over a period of 15min. The cooling bath was removed and the mixture was 
stirred for 3h at room temperature. TLC (ether-pentane 3:7) showed one main product 
Rf 0.4. The excess sodium hydride was carefully destroyed with methanol (30mL) and 
the solvents were evaporated under reduced pressure. The residue was partitioned 
between ether and water (300mL each), and the organic phase was washed with 0.1M 
HCl(aq), sat.aq.NaHC03 and water (200mL each). The ethereal solution was dried over 
MgS04, filtered and concentrated to a syrupy residue. Purification by column 
chromatography (ether-pentane 1:3) afforded the title compound 71, Rf 0.25, (11.98g, 
84%), as a syrup.
*H NMR (CDC13, 270MHz)
8 3.17 (1H, dd, J = 2.0, 10.1Hz, C-l-H or C-3-H), 3.23 (1H, t, J = 8.9Hz, C-5-H), 3.27 
(1H, t, J = 2.0,9.0Hz, C-l-H or C-3-H), 3.74 (3H, s, OCH3), 3.87 (1H, t, J = 9.5Hz, C-4- 
H or C-6-H), 3.91 (1H, t, J = 9.9Hz, C-4-H or C-6-H), 3.97 (1H, t, J = 2.2Hz, C-2-H),
4.07-4.34 (3H, m, -CH2- allyl), 4.57 and 4.67 (2H, ABq, Jab = 11.1Hz, -CH2Ph), 4.71 
and 4.78 (2H, ABq, = 12.1Hz, -CH2Ph), 4.85 (2H, s, -CH2ArOCH3), 5.14-5.33 (6H, 
m, =CH2 allyl), 5.85-5.94 (3H, m, -CH= allyl) 6.83 and 6.86 (2H, d, -C ^O M e, J = 
8.2Hz,), 7.26-7.42 (14H, m, -ArOCH3 and -Ph).
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l3C NMR (C D C I3 , 6 8 MHz)
8 55.17 (q, -OCH3), 71.34,72.69, 72.98,74.64 (4t, -CH2PhOMe and -CH2Ph and -CH2- 
allyl), 76.65, 76.89, 77.92, 78.73, 81.45, 82.66 (6d, inositol ring carbons), 113.71 (d, - 
Ph-), 116.57, 117.09, 117.38 (3t, =CH2 allyl), 127.24, 127.47, 128.66, 129.78, 129.89,
129.92 (6d, -Ph- and -Ph), 130.61 (s, Cq, -Ph-), 134.55,134.99, 135.07 (3d, -CH= allyl), 
138.95, 139.01 (2s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 623[(M+Na)+, 25%], 601[(M+H)+, 15%], 
599(35%), mKCHjQHUOCHjf, 100%], 91[(C7H7)+, 52%].
MS: m/z (-ve ion FAB, rel. intensity) 753[(M+NBA)', 100%].













Compound 71 (lO.Og, 16.66mmol) was suspended in a solution of ethanol-lM aq.HCl 
2:1 v/v (300mL) and stirred under reflux for 3h. TLC (ether-pentane 3:7) showed a 
single product Rf 0.27. The solution was allowed to cool to room temperature and the 
solvents evaporated under reduced pressure. The remaining solid residue was taken up 
in dichloromethane (200mL) and washed with sat.aq.NaHC03 and water (lOOmL each). 
The solution was dried over MgS04, filtered and concentrated. Purification by flash 
chromatography (ether-pentane 1:1) afforded the crystalline compound 72, Rf 0.45, 
(6.93g, 86%).
Mp: 34-36°C (from ether-hexane).
]H NMR (CDCI3 ,270MHz)
8 2.53 (1H, d, D20  ex., -OH), 3.07 (1H, dd, J = 2.2,9.9Hz, C-l-H or C-3-H), 3.18 (1H, t, 
J =9.2Hz, C-5-H), 3.29 (1H, dd, J = 2.4,9.9Hz, C-3-H or C-l-H), 3.84 (1H, t, J = 9.3Hz, 
C-4-H), 3.92-4.07 ((4H, m, C-2-H, C-6-H and -CH2- allyl), 4.25-4.41 (4H, m,
-CH2- allyl), 4.60 and 4.66 (2H, AB, Jab = 11.7Hz, -CH2Ph), 4.80 (2H, s, -CH2Ph), 5.13- 
5.33 (6H, m, =CH2 allyl), 5.80-6.05 (3H, m, -CH= allyl) 7.25-7.39 (10H, m, -Ph).
13C NMR (CDCI3, 68MHz)
8 71.09, 72.96, 73.96, 74.14, 74.48 (5t, -CH2Ph and -CH2- allyl), 72.34, 73.52, 79.67,
80.87, 81.20, 82.83 (6d, inositol ring carbons), 116.52, 116.71, 117.38 (3t, =CH2 allyl), 
127.35, 127.51, 127.59, 127.69, 127.77, 128.13, 128.36 (7d, -Ph), 132.62, 134.50, 
135.36 (3d, -CH= allyl), 138.49, 138.83 (2s, Cq, -Ph).
MS: m/z (+ve ion FAB, rel. intensity) 481[(M+H)+, 26%], 91[(C7H7)+, 100%].
MS : m/z (-ve ion FAB, rel. intensity) 633[(M+NBA)', 100%].
Accurate mass requires (M+H)+ = 481.2590.
Accurate mass found (M+H)+ = 481.2586.
Anal. Calcd for C29H360 6; C, 72.48; H, 7.55. Found; C, 72.2; H, 7.57%.
7.4.6. Attempted synthesis of 75 from 72 via an Sm2 mechanism.
(72) (73) (74) (75)
To a solution of 72 (l.Og, 2.1mmol) and dry pyridine (2mL) in diy dichloromethane 
(30mL) at -78°C under nitrogen, was added trifluoromethanesulphonic anhydride 
(0.3mL, 2.1mmol) dropwise over a period of 5min. The cooling bath was removed and 
the solution was stirred at room temperature for 2h. TLC (ether-pentane 3:7) showed
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total conversion of the starting material alcohol 72 to a product on the baseline. The 
dichloromethane solution was washed with 10% HCl(aq), sat.aq.NaHC03, water (30mL 
each), dried over MgS04, filtered and concentrated at room temperature to a dark red 
syrup. The trifluoromethanesulphoxy-intermediate was not purified.
To 1.30g of the crude material in dry DMF (50mL) was added caesium acetate (0.8g, 
4.16mmol) and the mixture stirred at room temperature under nitrogen for 2h. TLC 
(ethyl acetate-hexane 1:4) showed the formation of three products Rf 0.29, 0.60, 0.68. 
The solution was concentrated in vacuo and the residue was partitioned between ether 
and water (lOOmL each). The organic phase was separated and dried over MgS04, 
filtered and concentrated under reduced pressure. Purification of the residue by column 
chromatography (ethyl acetate-hexane 1:4) afforded the following oils;
Rf 0.29, 73 (329mg, 41%) DL-3,6-Anhydro-l,4,5-tri-(9-allyl-2-0-benzyl-wyo-inositol), 
Rf0.60, 74 (275mg, 25%), DL-6-O-acetyl-1,4,5-tri-O-allyl-2,3-di-0-benzyl-m>Y)-inositol, 
Rf 0.68,75 (70mg, 6%), the title compound.
Analytical data for 73:
*H NMR (CDC13,400MHz)
6 3.30 (1H, d, J = 1.8Hz, C-6-H), 3.71 (1H, m, C-l-H), 3.72 (1H, d, J = 6.1Hz, C-3-H), 
3.79-4.15 (6H, m, -CHr  allyl), 4.17 (1H, d, J = 6.1Hz, C-2-H), 4.42 (1H, s, C-5-H), 4.50 
(1H, dd, J = 1.5, 5.2Hz, C-4-H), 4.58 and 4.69 (2H, ABq, Jab = 12.2Hz, -CH2Ph), 5.10- 
5.30 (6H, m, =CH2 allyl), 5.74-6.00 (3H, m, -CH= allyl), 7.25-7.38 (5H, m, -Ph).
13C NMR (CDCI3, 100MHz)
5 70.65, 71.97, 72.48, 73.52 (4t, -CH2Ph and -CH2- allyl), 77.00, 79.43, 80.56, 83.93, 
83.96, 84.97 (6d, ring carbons), 117.98,118.18, 118.31 (3t, =CH2 allyl), 128.31, 128.66,
128.93 (3d, -Ph), 134.44, 134.77, 135.24 (3d, -CH= allyl), 138.72 (s, Cq, -Ph).
MS: m/z (+ve ion FAB, rel. intensity) 745[(2M+H)+, 24%], 373[(M+H)+, 72%], 
91[(C7H7)+, 100%].
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MS: m/z (-ve ion FAB, rel. intensity) 525[(M+NBA)", 32%], 633(100%), 646(95%). 
Accurate mass (FAB)+ requires (M+H)+ = 373.2015.
Accurate mass (FAB)+ found (M+H)+= 373.2029.
Analytical data for 74:
‘H NMR (CDClj, 400MHz)
5 2.04 (3H, s, -CH3), 3.17 (1H, dd, J = 2.1, 10.1Hz, C-l-H or C-3-H), 3.25 (1H, t, J = 
9.8Hz, C-5-H), 3.26 (1H, dd, J = 2.1,9.8Hz, C-3-H or C-l-H), 3.91 (1H, t, J = 9.5Hz, C- 
4-H), 3.97 (1H, t, J = 2.1Hz, C-2-H), 3.85-4.39 (6H, m, -CH2- allyl), 4.58 and 4.64 (2H, 
ABq, Jab = 11.6Hz, -CH2Ph), 4.81 and 4.83 (2H, ABq, Jab = 12.2Hz, -CH2Ph), 5.09- 
5.28 (6H, m, =CH2 allyl), 5.48 (1H, t, J = 9.8, 10.1Hz, C-6-H), 5.73-6.01 (3H, m, -CH= 
allyl), 7.22-7.40 (10H, m, -Ph). 
l3C NMR (CDCIj, 100MHz)
8 21.75 (q, -CHj), 71.69,73.37,74.44, 74.60,75.08 (5t, -CH2Ph and -CH2- allyl), 73.74,
73.94.74.09.78.70, 80.98, 81.59 (6d, inositol ring carbons), 117.08, 117.16, 117.34 (3t, 
=CH2 allyl), 127.93, 128.09, 128.18, 128.37, 128.51, 128.70, 128.95 (7d, -Ph), 135.08,
135.70, 135.92 (3d, -CH= allyl), 139.01, 139.28 (2s, Cq, -Ph), 170.48 (s, Cq, C=0). 
Analytical data for 75:
*H NMR (CDCI3,400MHz)
8 2.06 (3H, s, -CH3), 3.23 (1H, t, J = 2.4Hz, C-3-H), 3.26 (1H, dd, J = 2.5, 7.3Hz, C-l-H 
or C-5-H), 3.27 (1H, dd, J = 2.9, 7.3Hz, C-5-H or C-l-H), 4.00 (1H, t, J = 10.3Hz, C-6- 
H), 3.88-4.17 (7H, m, -CH2- allyl and C-4-H), 4.62 and 4.68 (2H, ABq, Jab = 12.2Hz, 
-CH2Ph), 4.82 and 4.85 ( 2H, ABq, = 12.2Hz, -CH2Ph), 5.11-5.30 (6H, m, =CH2 
allyl), 5.69 (1H, t, J = 2.4Hz, C-2-H), 5.80-6.02 (3H, m, -CH= allyl), 7.22-7.43 (10H, m, 
-Ph).
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13C NMR (CDC13) 1 OOMHz)
8 21.12 (q, -CH3), 70.13,71.45,73.62,74.63,75.54 (5t, -CH2Ph and -CH2- allyl), 75.93, 
76.70,77.34,78.14,78.84, 79.91(6d, inositol ring caibons), 116.23, 116.95, 116.98 (3t, 
=CH2 allyl), 127.04, 127.52, 127.70, 127.96, 128.29, 128.41 (6d, -Ph), 134.38, 134.83, 
135.13 (3d, -CH= allyl), 138.64, 139.46 (2s, Cq, -Ph), 171.13 (s, Cq, C=0).
MS: m/z (+ve ion FAB, rel. intensity) 545[(M+Na)+, 35%], 523[(M+H)+, 90%], 
91[(C7H7)+, 100%].
Accurate mass (FAB)+ requires (M+H)+ = 523.2695.
Accurate mass (FAB)+ found (M+H)+ = 523.2695.
7.4.7. Attempted synthesis o f  DL-2-0-acetvl-Tri-0-allvl-4.5-di-0-benzvl-epz-inositol (75) 
from 72 via an Sm2 mechanism at 0°C.
The above procedure was repeated, and the same quantities of reactants were used. The 
trifluoromethanesulphoxy-intermediate was prepared exactly as before. TLC (ether- 
pentane 1:1) before and after work-up showed the same product Rf 0.50. Dry DMF and 
caesium acetate were added as before but the reaction mixture was cooled to 0-5 °C and 
was stirred at this temperature for 2.5h. TLC (ethyl acetate-hexane 1:4) showed only 
two products Rf 0.60 and 0.68. Work-up and purification as before afforded the 
following products;
Rf 0.60, 74 (463mg, 19%)
Rf 0.68, 75 (216mg, 42%).
Analytical data for 74 and 75 as above.
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7.4.8. Attempted synthesis of DL-2-0-acetvl-Tri-0-allvl-4.5-di-0-benzvl-ep/-inositol 
(75) from 72 via an Sm2 mechanism at 0°C with an increased concentration of 
nucleophile.
The above procedure was repeated at 0°C as described. The caesium acetate (1.6g, 
8.3mmol) was crushed in a pestle and mortar and dried under vacuum for 6h at 100°C 
before being used for the reaction. Work-up of the reaction and purification as 
previously described afforded the following yields;
75 (530mg, 48%).
74 (126mg, 11%).
Analytical data for 74 and 75 as above.
7.4.9 DL-(2.4.5.6/3V2.3.6-Tri-0-allvl-4.5-di-0-benzvl-2.3.4.5.6-pentahvdroxvcvclohex- 




OA11• O A 1 1
AllO 5
(76)
A solution of oxalyl chloride, (2.0M solution in dichloromethane, 2.85mL, 5.72mmol), 
in dichloromethane (5mL) was added to stirring dichloromethane (20mL) under 
nitrogen. The solution was cooled to -60°C. Anhydrous DMSO (0.8mL, 11.44mmol) in 
dichloromethane (3mL) was added dropwise, via a syringe, to the cooled solution over a 
period of 15min. Stirring was continued for a further 20min at -60°C. The alcohol 72 
(2.5g, 5.2mmol) in dry dichloromethane (15mL) was then added dropwise to the cold 
stirring solution, over a period of lOmin. with the temperature maintained at -60° C. 
Stirring was continued for a further 0.5h before triethylamine (20mL) was added 
dropwise and the mixture was stirred for 5min before the cooling bath was removed.
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Water (50mL) was added to the reaction mixture and stirring continued for lOmin. TLC 
(chloroform-acetone 20:1) showed one main product Rf 0.6.
Dichloromethane (lOOmL) was added to the solution and the organic phase was 
separated. The aqueous layer was extracted with dichloromethane (2x50mL) and the 
combined organic fractions washed with satNaCl(aq), 1% HCl(aq), 10% NaHC03(aq) 
and water (lOOmL each). The solution was dried over MgS04, filtered and concentrated 
to an oil. Purification by flash chromatography (ethyl acetate-hexane 2:1) afforded the 
title inosose 76, Rf 0.4, as an oil (0.98g, 65%).
!H NMR (CDC13,400MHz)
5 3.68 (lH,dd, J = 2.1, 9.5Hz, C-4-H), 3.86 (1H, d, J = 9.2Hz, C-2-H), 3.95 (1H, d, J =
1.2Hz, C-6-H) 4.00 (1H, t, J = 9.2Hz, C-3-H), 4.10 (1H, t, J = 2.1Hz, C-5-H), 3.85-4.39 
(10H, m, -CH2- allyl and 4x ring protons), 4.60 and 4.66 (2H, ABq, Jab = 11.9Hz, 
-CH2Ph), 4.76 and 4.83 (2H, ABq, = 12.2Hz, -CH2Ph), 5.14-5.33 (6H, m, =CH2 
allyl), 5.83-6.02 (3H, m, -CH= allyl), 7.18-7.51 (10H, m, -Ph).
I3C NMR (CDCI3,100MHz)
8 71.41, 72.69, 72.84, 73.57, 74.68 (5t, -CH2Ph and -CH2- allyl), 75.63, 77.24, 79.82, 
81.47, 82.24 (5d, inositol ring carbons), 116.69, 117.61, 117.73 (3t, =CH2 allyl), 127.41,
127.61, 127.72, 127.94, 128.09, 128.40 (6d, -Ph-), 134.06, 134.43, 135.14 (3d, -CH= 
allyl), 138.11,138.16 (2s, Cq, -Ph), 201.53 (s, Cq, C=0).
MS: m/z (-ve ion FAB, rel. intensity) 501[(M+Na)+, 66%], 479[(M+H)+, 18%], 
91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 631[(M+NBA)\ 100%], 438[(M-CH2CHCH2+H)\ 
5%].
Accurate mass (FAB)+requires (M+H)+ = 479.2433.
Accurate mass (FAB)+ found (M+H)+ = 479.2464.
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IR(CC1„) 1751cm'1 (C=0).
7.4.10. Oxidation of 72 using pyridine-SO? complex and DMSO to give 76.
A solution of 72 (1.5g, 1.12mmol) in dry DMSO (7.5mL, 106mmol) and triethylamine 
(7.5mL, 53mmol) was cooled to -60° C under nitrogen. A solution of pyridine-S03 
complex (1.5g, 9.42mmol) in dry dimethyl sulphoxide (lOmL) was added dropwise to 
the cooled solution, via a syringe, over a period of lOmin. The cooling bath was 
removed and the solution allowed to stir under room temperature for 45min. TLC (ethyl 
acetate-hexane 2:1) indicated the conversion of the starting material alcohol 72, Rf 0.2, 
to a new product Rf 0.5. The solution was poured into water (50mL) and extracted with 
ether (4xlOOmL). The ethereal extract was separated and washed with 1M HC1, 
satbrine, sat.aq.NaHC03, dried over MgS04 and concentrated. Purification by flash 
chromatography (ethyl acetate-hexane 3:1) afforded the title inosose 76, Rf 0.46, as an 
oil (1.98g, 80%).
Analytical data for 76 as above.
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7.4.11. Attempted synthesis of DL-L3,6-Tri-0-allvl-4.5-di-0-benzvl-ep/-inositol 78 bv 
the reduction of 76 using K-Selectride(potassium tri-sec-butvlborohvdride) in THF.
►Bn
iBn ►Bn►Bn
I All I All►All
Bnl BnlBnl AH0‘ OA11
OA11 •O A 1 1►All
AllO AllO 1
(78) (72)(76) (77)
The inosose 76 (l.Og, 2.1 mmol) was dissolved in freshly distilled THF (50mL) and the 
solution was cooled to -78°C under nitrogen. K-Selectride, 1M in THF, (3.2mL, 
3.13mmol) was added dropwise and the solution stirred for 5min before the cooling 
bath was removed. The reaction mixture was stirred at room temperature for 3h. 1% 
HC1 (2mL) was added to the solution and the mixture was stirred for 5min before being 
extracted with ethyl acetate (3xlOOmL). TLC (chloroform-acetone 20:1) showed 
conversion of the starting material inosose 76, Rf 0.5, to three products Rf 0.8, 0.45, 
0.36. The combined extracts were washed with sat.aq.NaHC03, water (lOOmL each), 
dried over MgS04, filtered and concentrated. Purification by column chromatography 
(chloroform-acetone 20:1) afforded the following products;
Rf 0.80, 77 (360mg, 55%) as white crystals.
Rf 0.45, 72 (87mg, 9%) as an oil.
Rf 0.36, 78 (214mg, 21%) as white crystals.
Analytical data for 72 as previously described.
Analytical data for 77:
Mp: 76-79°C (from hexane).
‘H NMR (CDCl,, 400MHz).
5 4.55 (4H, td, J = 1.2, 5.5Hz, -CH2- allyl), 4.95 (2H, s, -CH2Ph), 5.19 (1H, s, D20  ex.,
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-OH), 5.25-5.39 (4H, m, =CH2 allyl), 5.99-6.08 (2H, m, -CH= allyl), 6.26 ( 2H, s, Ar-H), 
7.24-7.41 (5H, m, -Ph).
13C NMR (CDC13,100MHz)
8 70.26 (t, -CH2- allyl), 70.81 (t, -CH2Ph), 94.98, 95.31 (2d, -allyl-O-C-C-H), 118.14 (t, 
=CH2 allyl), 127.55, 127.97,128.56 (3d, -Ph), 130.29,137.03 (2s, Cq, -C-OMe), 133.10 
(d, -CH= allyl), 146.28 (s, Cq, C-O-allyl), 151.88 (s, Cq, -C-OH).
MS: m/z (+ve ion FAB, rel. intensity) 312(85%), 313[(M+H)+, 42%], 91[(C7H7)+, 
100%].
Accurate mass (FAB)+ requires (M+H)+ = 313.1439.
Accurate mass (FAB)+ found (M+H)+ = 313.1426.
Anal. Calcd for C19H20O4; C, 73.06; H, 6.45, Found; C, 73.1; H, 6.39%.




8 3.14 (1H, dd, J = 3.0, 9.9Hz, C-1-H/C-5-H), 3.18 (1H, t, J = 2.7Hz, C-3-H), 3.27 (1H, 
dd, J = 2.4, 9.8Hz, C-5-H/C-1-H), 4.01 (1H, t, J = 9.8Hz, C-H-6), 4.12-4.43 (8H, m, - 
CH2- allyl, C-2-H and C-4-H), 4.62 and 4.70 (2H, ABq, Jab = 11.6Hz, -CH2Ph), 4.81 
and 4.84 (2H, ABq, = 11.3Hz, Ph), 5.13-5.32 (6H, m, =CH2 allyl), 5.86-6.05 (3H, m, 
-CH= allyl), 7.24-7.70 (10H, m, -CH2Ph).
13C NMR (CDCI3, 100MHz)
8 69.44, 71.50, 73.09, 74.68, 75.45 (5t, -CH2Ph and -CH2- allyl), 69.38, 74.26, 76.71, 
78.91, 80.26, 80.57 (6d, inositol ring carbons), 116.44, 116.98, 117.26 (3t, =CH2 allyl), 
127.54, 127.61, 127.76, 128.12, 128.27, 128.36 (6d, Ph), 134.41, 135.16, 135.53 (3d, - 
CH= allyl), 137.78, 138.45 (2s, Cq, Ph)
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MS: m/z (+ve ion FAB, rel. intensity) 481[(M+H)+, 90%], 91[(C7H7)+, 100%].
Accurate mass requires (M+H)+ = 481.2590.
Accurate mass found (M+H)+ = 481.2567.
Anal. Calcd for C29U360 6; C, 72.48; H, 7.55. Found; C, 72.3; H, 7.61%.
7.4.12. Attempted synthesis of DL-1.3.6-Tri-0-aHvl-4.5-di-0-benzvl-eg>f-inositol 78 bv 
the reduction of 76 using K-Selectridefpotassium tri-sec-butvlborohvdride) in THF at 
45° C.
The procedure was repeated as described above. The quantities of reactants were as 
before. After the K-Selectride was added and stirring continued for 5min, the cooling 
bath was removed and the mixture was gently warmed to 45°C over a period of lh. The 
mixture was stirred at this temperature for a further 2.5h. TLC (chloroform-acetone 
20:1) showed only one major product Rf 0.8, the aromatic derivative 77 (590mg, 90%). 
Analytical data for 77 as described above.
7.4.13. Reduction of DL-(2A5,6/3)-2,3,6-Tri-0-allyl-4,5-di-0-benzvl-2,3A5,6-penta- 
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A mixture of 76 (1.50g, 3.13mmol) and sodium borohydride (0.47g, 12.52mmol) in 
ethanol (50mL) was stirred at 0°C for lOmin. The ice/water bath was removed and the 
solution was stirred at room temperature for 2h. TLC (chloroform-acetone 20:1) showed 
two major products Rf 0.28 and 0.40. Water (20mL) was added to the mixture and the 
solvents were evaporated under reduced pressure. The residue was partitioned between
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ether and water and the organic phase was separated and dried over MgS04, filtered and 
concentrated under reduced pressure to give an oil. Purification by flash 
chromatography (chloroform-acetone 20:1) afforded the two diastereoisomers 72, the 
less polar product (442mg, 29%), as an oil, and 78, the more polar product (890mg, 
59%), as white crystals.
Analytical data for 72 and 78 as described above.
7.4.14. Reduction of DL-(r2.4.5.6/3)-2.3.6-Tri-Q-allvl-4.5-di-Q-benzvl-2.3.4.5.6-penta- 
hvdroxvcvclohexanone 76 using sodium borohydride in acetonitrile.
To a solution of 76 (l.Og, 2.09mmol) in acetonitrile (150mL) at 0°C was added NaBH4 
(316mg, 8.4mmol). The mixture was stirred for lOmin before the cooling bath was 
removed and stirring continued for a further 2h at room temperature. Water (5mL) was 
added and TLC (chloroform-acetone 20:1) showed the conversion of the starting 
material inosose 76, Rf 0.6 to two main products Rf 0.28 and 0.40. Water (20mL) was 
added and the acetonitrile was evaporated under reduced pressure. The residue was 
extracted with ether (3xlOOmL) and the combined ethereal solutions were dried over 
MgS04, filtered and concentrate to an oily residue. Purification by flash 
chromatography (chloroform-acetone 20:1) afforded the isomeric alcohols 72, Rf 0.4, 
(175mg, 17%) and 78, Rf0.28, (723mg, 72%).
Analytical data for 72 and 78 as described above.
7.4.15. Reduction of DL-(2A5,6/3)-2,3,6-Tri-0-allvl-4.5-di-0-benzvl-2.3A5,6-penta- 
hydroxvcvclohexanone 76 using sodium borohydride in acetonitrile at 50°C
The above procedure was repeated on the same scale. After the addition of sodium 
borohydride, the cooling bath was removed and the mixture was slowly heated to 50°C 
over a period of 0.5h. This temperature was maintained and the reaction allowed to
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proceed for a further 2h. Water was added as before, and TLC (chloroform-acetone 
20:1) showed only one major product Rf 0.28 and a minor product Rf 0.4. Work-up and 
purification of the reaction afforded the desired compound 78 (795mg, 79%).








The alcohol 78 (400mg, 0.83mmol) was suspended in dry pyridine (50mL). Acetic 
anhydride (0.15mL, 1.66mmol) was added to the solution followed by DMAP (50mg). 
The solution was stirred at room temperature for 6h. TLC (chloroform-acetone 20:1) 
showed complete conversion of the starting material alcohol 78, Rf 0.28 to a new 
product Rf 0.65. Purification by flash chromatography (ethyl acetate-hexane 1:5) 
afforded the title compound 75, Rf 0.58, as an oil (386mg, 0.74mmol, 89% yield). 












A mixture of 78 (1.38g, 2.87mmol) and sodium hydride (0.2g, 8.62mmol) was stirred in 
dry DMF (50mL) for 15min. Benzyl bromide (0.4mL, 3.45mmol) was added dropwise 
over a period of 5min and the solution was stirred for 3h. TLC (ether-light petroleum
3:2) showed one major product Rf 0.7. Purification by flash chromatography (ether-light 
petroleum 1:2) afforded the title compound 79, Rf 0.42, as a syrup (1.42g, 86%).
*H NMR (CDC13,400MHz)
5 3.10 (1H, t, J = 2.4Hz, C-3-H), 3.15 (1H, dd, J = 2.7, 9.8Hz, C-l-H or C-5-H), 3.23 
(1H, dd, J = 2.7, 9.8Hz, C-5-H or C-l-H), 3.88 (2H, m, -CH2- allyl), 4.08 (1H, t, J = 
2.0Hz, C-2-H or C-4-H, 4.09-4.14 (4H, m, C-2-H or C-4-H and -CHr  allyl), 4.18 (1H, t, 
J = 9.8Hz, C-6-H), 4.36 (2H, m, -CH2- allyl), 4.62 and 4.66 (2H, ABq, Jab = 119Hz, - 
CH2Ph), 4.84-4.94 (4H, m, -CH2Ph), 5.09-5.32 (6H, m, =CH2 allyl), 5.78-6.04 (3H, m, - 
CH= allyl), 7.20-7.42 (15H, m, -CH2Ph).
13C NMR (CDCI3,100MHz)
6 70.07, 71.60, 72.52, 73.77, 74.47 (5t, -CH2Ph and -CH2- allyl), 75.10, 75.18, 78.28,
79.12, 80.48 (5d, inositol ring carbons), 116.05,116.23,116.49 (3t, =CH2 allyl), 126.83, 
127.29, 127.40, 127.64, 127.71, 127.84, 128.15 (7d, -CH2Ph), 134.44, 135.20, 135.69 
(3d, -CH= allyl), 138.77, 139.48 (2s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 593[(M+Na)+, 68%], 571[(M+H)+, 68%], 
91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 723[(M+NBA)\ 100%], 479[(M-C7H7)+, 22%]. 
Anal. Calcd for C36H420 6; C, 75.76, H; 7.42. Found; C, 75.4; H, 7.67%.







A mixture of 79 (1.3g, 2.28mmol), palladium on activated charcoal (10%, 300mg) and 
PTSA (O.lg, 0.52mmol) was suspended in a mixture of ethanol-water 1:11 (60mL) and 
stirred under reflux for 24h. TLC (chloroform-acetone 30:1) showed a single product, Rt
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0.5. The pH of the solution was adjusted to 7.0-8.0, the catalyst was filtered off through 
Celite and the filtrate was concentrated under reduced pressure. The residue was taken 
up in dichloromethane, washed with water, satbrine, dried over MgS04, filtered and 
evaporated to dryness. The residue was purified by flash chromatography (chloroform- 
acetone 30:1) to give the title compound 80, Rf 0.5, (0.85g, 82%) as a viscous syrup.
’H NMR (CDCIj, 400MHz)
8 2.55 (1H, br.s, D20  ex., -OH), 2.68 (1H, br.s, D20  ex., -OH), 3.00 (1H, br.s, D20  ex., - 
OH), 3.30 (1H, dd, J = 2.4, 8.8Hz, C-l-H), 3.53 (1H, m, C-5-H), 3.69 (1H, m, C-3-H), 
3.91 (1H, t, J = 3.4Hz, C-4-H), 3.99 (1H, t, J = 3.4Hz, C-2-H), 4.23 (1H, t, J = 9.3Hz, C- 
6-H), 4.52 and 4.90 (2H, ABq, Jab = 11.7Hz, -CH2Ph), 4.70 and 4.77 (2H, ABq, Jab = 
11.7Hz,-CH2Ph),4.71 and5.01 (2H, ABq, Jab = 11.2Hz,-CH2Ph), 7.20-7.51 (15H,m,- 
CH2Ph).
13C NMR (CDCIj, 100MHz)
8 72.71,74.98,75.51 (3t, -CH2Ph), 68.81,70.06,72.71,72.91, 77.21, 77.92 (6d, inositol 
ring carbons), 127.23, 127.37, 127.44, 127.79, 127.99, 128.34, 128.38, 128.66 (8d, Ph), 
137.78, 138.62,138.66 (3s, Cq, Ph).
MS: m/z (+ve ion FAB, rel. intensity) 923[(2M+Na)+, 60%], 901[(2M+H)+, 25%], 
451[(M+H)+, 15%], 91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 899[(2M-H)', 80%], 603[(M+NBA)', 100%], 
449[(M-H)’, 30%], 359[(M-C7H7)‘, 15%].
Accurate mass requires (M+H)+ = 451.2120.
Accurate mass found (M+H)+ = 451.2137.












To a solution of bis(benzyloxy)-W,.Ar-cliisopropylaminophosphine (460mg, 1.33mmol) in 
dry dichloromethane (lOmL) was added tetrazole (140mg, 2.0mmol). The mixture was 
stirred at room temperature for lOmin. 80 (lOOmg, 0.22mmol) was added and the 
mixture was stirred at room temperature for lh. Water (3mL) was added and stirring 
continued for 5min before the solution was cooled to -78°C. m-CPBA (500mg, 
2.89mmol) was added and the cooling bath was removed. The solution was stirred at 
room temperature for a further 45min before being diluted with dichloromethane 
(50mL). TLC (chloroform-acetone 20:1) showed complete conversion of the starting 
material triol Rf 0.25 to one major product Rf 0.40 and a minor less polar product Rf 
0.45. The solution was washed with 10% Na2S20 5(aq), sat.NaHC03(aq), sat.brine 
(50mL each), dried over MgS04, filtered and concentrated to a clear oil. Purification by 
column chromatography (chloroform-acetone 20:1) afforded the title trisphosphate 
triester 82, Rf 0.40, (140mg, 52%) as an oil, and a cyclic phosphate analogue by­
product 81, Rf 0.45, (60mg, 31%) as an oil.
Analytical data for 81:
]H NMR (CDC13,400MHz)
5 3.28 (1H, d, J = 3.4Hz, C-l-H), 3.42 (1H, d, J = 3.3Hz, C-4-H), 3.94 (1H, d, J = 3.4Hz, 
C-2-H), 4.29 and 4.37 (2H, ABq, Jab = 11.7Hz, -CH2Ph), 4.39 and 4.41 (2H, ABq, Jab =
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11.7Hz, -CH2Ph), 4.56-4.64 (2H, m, C-3-H and l/2ABq, -CH2Ph), 4.82-4.92 (7H, m, - 
OPO(OCH2Ph)2 and -PO(OCH2Ph) and l/2ABq, -CH2Ph), 5.10 (1H, s, C-5-H or C-6-H), 
5.12 (1H, s, C-6-H or C-5-H), 7.16-7.51 (30H, m, -CH2Ph).
31P NMR (CDCIj, 109MHz)
8P -0.98 (IP, s ), -13.40 (IP, s ) 3lP-‘H-decoupled.
MS: m/z (+ve ion FAB, rel. intensity) 1748[(2M+Na)+, 62%], 901[(M+K)+, 10%], 
885[(M+Na)+, 55%], 863[(M+H)+, 20%],91[(C7H7)+, 100%],
MS: m/z (-ve ion FAB, rel. intensity) 1015[(M+NBA)‘, 60%], 861[(M-H)‘, 55%], 
771[(M-C7H7)", 10%].
Analytical data for 82
'H NMR (CDCIj, 400MHz) at 55°C.
8 4.52 and 4.60 (2H, ABq, Jab = 11.7Hz, -CH2Ph), 4.65 and 4.73 (2H, ABq, Jab =
11.2Hz, -CH2Ph), 4.60-4.70 (2H, m, 2x inositol ring protons), 4.83-5.02 (17H, m, - 
CH2Ph and -OPO(OCH2Ph)2 and 3x inositol ring protons), 5.25 (1H, dt, J = 7.0, 9.3Hz, 
C-6-H), 7.12-7.24 (45H, m, -CH2Ph).
13C NMR (CDC13,100MHz) at 55°C.
6 68.81, 68.94, 69.40, 69.45, 69.98, 70.04, 70.18, 70.61, 71.17 (9d, -CH2Ph and - 
OPO(OCH2Ph)2), 72.05, 72.38, 75.03, 76.37, 78.32, 78.63 (6d, inositol ring carbons),
127.02, 127.06, 127.17, 127.79, 127.92, 128.27, 128.41, 128.80, 128.91, 129.05 (lOd, - 
Ph), 135.44, 135.47, 135.64, 135.73, 135.80, 135.91, 135.97, 136.06, 137.50 (9s, Cq, 
Ph).
31P NMR (CDCI3, 162MHz)
8P -1.50 (IP, s ), -2.06 (2P, s ) 31P-1H-decoupled.
MS: m/z (+ve ion FAB, rel. intensity) 1231[(M+H)+, 85%], 91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 1384[(M+NBA-H)\ 65%], 1139[(M-C7H7)\
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45%].
Accurate mass requires (M+H)+ = 1231.3882.
Accurate mass found (M+H)+ = 1231.3893.
Anal. Calcd for (1230); C, 67.31; H, 5.65. Found; C, 66.8; H, 5.67%.
7.4.20. DL-epf-inositol 1.3.6-trisphosphate. (83)
A solution of 82 (lOOmg, 81.3p.mol) in ethanol-water 4:1 (50mL) was treated with 
hydrogen at room temperature over Pd/C (10%, lOOmg) at 50psi for 24h. The 
suspension was filtered through Celite to remove the catalyst, TEAB buffer (2mL, pH 
8.0) was added and the solution was concentrated at room temperature under reduced 
pressure. The residue was made up to 200mL with de-ionised water and purified by ion- 
exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient of 
TEAB buffer (0-1M), pH 8.0. The triethylammonium salt of 83 eluted between 420- 
480mM buffer, and was detected and quantified using the Briggs phosphate assay. 244
2 IOPO(OBii)2|




*H NMR (CD3OD, 400MHz)
5 3.57 (1H, dd, J = 2.9, 9.3Hz, C-l-H), 4.06 (1H, t, J -  2.9Hz, C-5-H), 4.08 (1H, dd, J =
2.9, 6.3Hz, C-3-H), 4.24 (1H, m, C-2-H), 4.42 (1H, m, C-4-H), 4.54 (1H, q, J = 9.3Hz,
C-6-H).
31P NMR (CD3OD, 162MHz)
5p 0.38 (2P, m), +2.07 (IP, d, J = 8.1Hz,).
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MS: m/z (-ve ion FAB, rel. intensity), 838[(2M)', 10%], 579(10%), 419[(M)", 100%]. 
Accurate mass (FAB)* requires (M-H)" = 418.9545.
Accurate mass (FAB)* found (M-H)' = 418.9550.
7.4.21. DL-gp/-inositol-3.5-cvclic.6-bisphosphate. (841
A solution of 81 (50mg, 58pmol) in ethanol-water 1:4 (50mL) was treated with 
hydrogen at room temperature over Pd/C (10%, lOOmg) at 50psi for 20h. The 
suspension was filtered through Celite to remove the catalyst, 3mL TEAB buffer pH 8.0 
was added, and the solution was concentrated at room temperature under reduced 
pressure. The remaining residue was made up to 200mL with de-ionised water and 
purified by ion-exchange chromatography on Q Sepharose Fast Flow Resin, eluting with 
a gradient of TEAB buffer (0-1M), pH 8.0. The triethylammonium salt of 111 eluted 
between 380-410mM buffer, and was detected and quantified using the Briggs 
phosphate assay 244 (32pmol, 50% yield).
‘H NMR (D20, 400MHz)
8 3.80-3.94 (3H, m, C-l-H and C-2-H and C-4-H), 4.45-4.54 (3H, m, C-3-H and C-5-H 
and C-6-H).
31PNMR(D20 , 162MHz)
8p -0.98 (IP, d, J = 9.9Hz, C-6-P), -9.56 (IP, t, J = 10.7Hz, C-3,5-P).
MS: m/z (-ve ion FAB, rel. intensity) 643[(2M+H)', 15%], 321 [(M)\ 55%].
Accurate mass (FAB)' requires (M-H)' = 320.9776.
Accurate mass (FAB)' found (M-H)' = 320.9821.
OPO(OBn)2
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7.5. Synthesis of DL-wyo-Inositol 1,2,5-trisphosphate. (89)
7.5.1. DL-1 A6-Tri-0-benzvl-2<3-0-isopropvlidene-77m?-inositol. (86)





A mixture of 50, (lO.Og, 45.4mmol), dibutyltin oxide (33.95g, 136.4mmol), 
tetrabutylammonium bromide (14.6g, 45.3mmol) and benzyl bromide (90mL, 
756mmol) in acetonitrile (300mL) was heated under reflux using a Soxhlet apparatus 
containing 3A molecular sieves, for 18h. The Soxhlet apparatus was removed, 
triethylamine (50mL) added and the solution heated under reflux for a further lh to 
destroy the excess benzyl bromide. TLC (ether-light petroleum 2:1) showed two major 
products Rf 0.7 and 0.8. The solution was left to cool and the solvents were evaporated 
under reduced pressure. The residue was partitioned between ether and water (300mL 
each) and the organic phase was separated and decanted into a stirred solution of 
sat.aq.NaHCC>3 (300mL). Stirring was continued for lh and precipitation of a solid tin 
derivative was observed. The suspension was filtered through Celite, and the ethereal 
filtrate was dried over MgS04, filtered and concentrated to a yellow syrup. Flash 
chromatography (ether-light petroleum 1:2) of the crude residue gave the title 
compound 86, the less polar product Rf 0.5, (8.56g, 17.46mmol, 38% yield) as a solid, 
and the 1,4,5-tri-O-benzylated isomer 86a, Rf0.42, in 36% yield.
Mp: 80-82°C (from ethyl acetate-light petroleum). Lit.264 80-81°C.
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]H NMR (CDCI3,400MHz)
8 1.35,1.51 (6H, 2s, -CH3), 2.66 (1H, s, D20  ex., -OH), 3.50 (1H, t, J = 8.4Hz, D20  ex., 
C-5-H), 3.64-3.72 (2H, m, C-3-H and C-6-H), 3.81 (1H, t, J = 8.2Hz, C-4-H), 4.10 (1H, 
dd, J = 5.7, 6.8Hz, C-l-H), 4.29 (1H, dd, J = 3.8, 5.7Hz, C-2-H), 4.68-4.92 (6H, m, 
-CH2Ph), 7.26-7.39 (15H, m, -CH2Ph).
13C NMR (CDCI3,100MHz)
8 25.71, 27.69 (2q, -CH2Ph), 73.09, 73.31, 76.70, 78.91, 80.65, 81.65 (6d, inositol ring 
carbons), 109.89 (s, Cq, CMe2), 127.72, 127.79, 127.88, 127.97, 128.03, 128.40, 
128.45, 128.49 (8d, -CH2Ph), 138.05, 138.29, 138.47 (3s, Cq, -CH2Ph)
MS: m/z (+ve ion FAB, rel. intensity) 491[(M+H)+, 30%], 513[(M+Na)+, 65%], 
489(70%), 399[(M-C7H7)+, 20%], 475[(M-CH3)+, 10%], 91[(C7H7)+, 100%],
181[(2C7H7-H)+, 15%].
MS: m/z (-ve ion FAB, rel. intensity) 643[(M+NBA)', 100%], 489[(M-H)', 26%]. 
Accurate mass (FAB)+ requires (M+H)+ = 491.2433.
Accurate mass (FAB)+ found (M+H)+ = 491.2427.






Compound 86 (4.0g, 8.16mmol) was suspended in a solution of ethanol-lM HCl 5:1 v/v 
(150mL) and stirred under reflux for lh to give a product Rf 0.3 (ether-light petroleum 
2:1). The solution was evaporated to dryness and the product was purified by flash 
chromatography (ether-light petroleum 2:1) to give the title compound 87 as a 
crystalline solid (3.55g, 96%).
Mp: 83-86° C (from ethyl acetate-light petroleum). Lit.144 83-84° C.
'H NMR (CDCb, 270MHz)
8 2.62-2.72 (3H, m, D20  ex., 3x -OH), 3.34-3.95 (5H, m, C-l-H, C-3-H, C-4-H, C-5-H, 
C-6-H), 4.18 (1H, t, J = 3.8Hz, C-2-H), 4.68-5.03 (6H, m, -CH2Ph), 7.27-7.48 (15H, m, 
-Ph).
MS: m/z (+ve ion FAB, rel. intensity) 451[(M+H)+, 28%], 449(40%), 473[(M+Na)+, 
70%], 91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 603[(M+NBA)‘, 90%], 449[(M-H)', 72%]
Anal. Calcd for C27H,0O6 ; C, 71.98; H, 6.71. Found for C27H30O6.H2O (468); C, 69.2; 
H, 6.84.






To a solution of bis(benzyloxy)-Af,7V-diisopropylaminophosphine (9920mg, 2.66mmol) 
in dry dichloromethane (lOmL) was added tetrazole (280mg, 4.0mmol). The mixture 
was stirred at room temperature for lOmin. 87 (200mg, 0.44mmol) was added and 
stirring continued for lh.TLC (ether-light petroleum 2:1) showed complete conversion 
of the starting material triol to the trisphosphite triester Rf 0.8. Water (5mL) was added 
and stirring continued for a further 5min. before the solution was cooled to -78° C. 
m-CPBA (l.Og, 5.8mmol) was added to the mixture and the cooling bath removed. 
Stirring was continued for a further lOmin. before the solution was diluted with 
dichloromethane (50mL). The solution was washed with 10% Na2S20 5(aq), 
sataq.NaHCCb, sat.NaCl(aq), water (50mL each), dried over MgSC>4, filtered and
concentrated to a colourless syrup. Purification by column chromatography 
(chloroform-acetone 30:1) afforded the title trisphosphate triester 88, Rf 0.45, (350mg, 
64% yield), as an oil. 
lR  NMR (CDC13,400MHz)
6 3.48 (1H, m, C-l-H), 3.83 (1H, t, J = 9.8Hz, C-6-H), 3.94 (1H, t, J = 9.8Hz, C-4-H), 
4.39 (1H, t, J = 9.7Hz, C-5-H), 4.45 (1H, d, 1/2AB, = 10.7Hz,
-CH2Ph), 4.49 (1H, t, J = 9.3Hz, C-3-H), 4.64-5.09 (17H, m, -CH2Ph and - 
PO(OCH2Ph)2), 5.37 (1H, td, J = 8.3Hz, 4JPH <1, C-2-H), 6.99-7.52 (45H, m, -Ph).
13C NMR (CDCI3,68MHz)
5 54.71, 58.72, 69.15, 69.54, 72.26, 75.46, 75.54 (7t, -CH2Ph and -PO(OCH2Ph)2), 
74.60, 76.17, 77.21, 78.67, 79.27, 81.03 (6d, inositol ring carbons), 127.40, 127.51,
127.61, 127.66, 127.71, 12787, 127.92, 128.07. 128.18, 128.21, 128.31, 128.44, 128.50, 
128.62 (14d, -CH2Ph and -PO(OCH2Ph)2), 132.70, 135.83, 135.95, 136.63, 137.83, 
137.99 (6s, Cq, -CH2Ph and -PO(OCH2Ph)2).
31P NMR (CDCI3, 162MHz)
5P -1.20 (IP, s ), -1.56 (IP, s ), -1.78 (IP, s ) (^H -decoupled).
MS: m/z (+ve ion FAB, rel. intensity) 1231[(M+H)+, 80%], 1253[(M+Na)+, 30%], 
91[(C7H7)+, 100%], 181(10%), 271(5%).
MS: m/z (-ve ion FAB, rel. intensity) 1383[(M+NBA)\ 80%], 1139[(M-C7H7)\ 45%]. 
Accurate mass requires (M+H)+ = 1231.3927.
Accurate mass found (M+H)+ = 1231.3935.
Anal. Calcd for (1230); C, 67.31; H, 5.65. Found; C, 67.0; H, 5.66%.
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A solution of 88 (lOOmg, 81.3jimol) in ethanol-water 4:1 (50mL) was treated with 
hydrogen at room temperature over Pd/C (10%, lOOmg) at a pressure of 50psi for 18h. 
The suspension was then filtered through Celite to remove the catalyst, 2mL TEAB 
buffer was added, and the solution was concentrated in vacuo at room temperature. The 
remaining residue was made up to 300mL with de-ionised water and purified by ion- 
exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient of 
TEAB buffer (0-1M), pH 8.0. The triethylammonium salt of 89 eluted between 480- 
530mM, and was detected and quantified by the Briggs phosphate assay 244 (45pmol, 
55% yield).
*HNMR (D20, 400MHz)
8 3.49 (1H, dd, J = 2.1, 9.5Hz, C-3-H), 3.79-3.92 (3H, m, C-4-H, C-5-H and C-6-H), 
4.05 (1H, dt, J = 2.1, 9.2Hz, C-l-H), 4.86 ( 1H, dt, J = 2.7, 8.8Hz, C-2-H).
31PNMR(D20, 162MHz)
8P +1.77 (IP, d, 3Jph = 7.0Hz, -CH-0-P032'), +3.26 (IP, d, 3JPH = 6.4Hz), +3.62 (IP, d, J 
= 8.8Hz, -CH-O-PO32').
MS: (+ve ion FAB, rel. intensity) 102[(C2H5)3NHf, 100%], 255(40%), 301(18%), 
522(28%), 623(40%).
MS: (-ve ion FAB, rel. intensity) 419[(M)“, 100%], 97(5%), 838[(2M)\ 15%].
Accurate mass requires (M)‘ = 418.9545.
Accurate mass found (M)' = 418.9537.
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7.6. Synthesis of D-mjw-inositol 2,3,5-trisphosphate. (96)
Resolution of DL-3,6-Di-O-benzyl-l,2-(Msopropylidene-my0-inositol. (85)
7.6.1. D-L4-Di-0-benzvl-5.6-di-0-IY-y6>-carnphanovH-2.3-0-isopropvlidene-mvo-
inositol (90) and L-1.4-Di-0-benzvl-5.6-di-0-IY-yft>-camphanovll-23-0-isopropvlidene- 








The title compounds were prepared as described by Desai et a l250 
A solution of the racemic diol 85 (6.5g, 16.0mmol) and (-)-^y-camphanic acid chloride 
(lO.Og, 46.0mmol) in dry pyridine (350mL) was stirred at room temperature for 18h 
under nitrogen. The solution was cooled in an ice-water bath, water (2mL) was added, 
and the solution stirred at room temperature for 30min. The solution was diluted with 
water (200mL) and the products extracted with ether (2x200mL). The ethereal extract 
was washed successively with 1M HC1, sat.NaCl and sat.aq.NaC03, dried over MgS04, 
filtered and concentrated to give the mixture of diastereoisomers 90 and 91 as a solid 
residue. Rerystallisation from ether-light petroleum 2:1 gave the pure diastereoisomer 
90 (3.0g, 7.75mmol, 48% yield). 91 remained in solution.
Analytical data of 90:
'H NMR (CDC13> 270MHz)
5 0.86 (3H, s, -CH3, camphanate), 0.91 (3H, s, -CH3, camphanate), 0.99 (3H, s, -CH3, 
camphanate), 1.00 (3H, s, -CH3, camphanate), 1.07 (3H, s, -CH3, camphanate), 1.09 
(3H, s, -CH3, camphanate), 1.32 (3H, s, -CH3 acetonide), 1.57 (3H, s, -CH3, acetonide),
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1.18-1.25 (2H, m, -CH2 camphanate), 1.70-1.98 (4H, m, -CH2 camphanate), 2.28-2.36 
(2H, m, -CH2 camphanate), 3.83 (1H, t, J = 5.1Hz, C-4-H), 3.95 (1H, dd, J = 3.5,9.2Hz, 
C-l-H), 4.30 (1H, dd, J = 5.1,6.8Hz, C-3-H), 4.41 (1H, dd, J = 3.3,6.8Hz, C-2-H), 4.68 
and 4.77 (2H, AB, Jab = 11.9Hz, -OCH2Ph), 4.70(2H, s, -CH2Ph), 5.25(1H, t, J = 6.6Hz, 
C-5-H), 5.62 (1H, dd, J = 6.8, 9.2Hz, C-6-H), 7.26-7.35 (10H, m, -Ph).
Mp: 148-149°C (from ether-light ptroleum). Lit.25®148-150°C.











The bis-(-)-6>-camphanate 90 (6.55g, 8.5mmol) was heated under reflux with sodium 
hydroxide (2.0g) in methanol (200mL) for lh. Solid carbon dioxide was added, the 
solvent evaporated under reduced pressure and the residue was extracted with 
dichloromethane (2x 200mL). The extract was washed with water (2xl00mL), dried 
over MgS04 and concentrated. Recrystallisation from ethyl acetate-light petroleum 
afforded the chiral diol 92, (4.05g, 5.68mmol, 71%), as white crystals.
Mp: 80-84° C (from ethyl acetate-light petroleum). Lit.250 80-83° C.
[a]D18 -4.3° (cl.03, CHC1,). Lit.25® [a]D25 -4.0° (cl, CHC1,).
NMR data as for racemic material 85.










A mixture of 92 (4.0g, lO.Ommol) and dibutyltin oxide (3.73g, lS.Ommol) was 
suspended in toluene (300mL) and was stirred under reflux for 2.5h, using a Dean and 
Stark apparatus to remove water. The solution was allowed to cool to room temperature 
and the toluene evaporated under reduced pressure to give the crystalline tin complex. 
The residue was further dried at 130° C under vacuum for 2h. DMF (150mL) and 
caesium fluoride (3.79g, 25.0mmol) were added and the solution was stirred vigorously 
under nitrogen. Benzyl bromide (2.38mL, 20.0mmol) was added dropwise over a period 
of 15min and the reaction stirred at room temperature under nitrogen for 12h. TLC 
(ether-light petroleum 2:1) showed two major products Rf 0.7 and 0.8. Triethylamine 
(lOmL) was added and stirring continued for a further 2h to destroy the excess benzyl 
bromide. The solvents were evaporated in vacuo and the residue was distributed 
between dichloromethane and sat.aq.NaHC03 (300mL each). The solution was stirred 
at room temperature for 30min. and the precipitated tin derivative was filtered off 
through Celite. The Celite was washed with dichloromethane (2xl00mL). The organic 
phase was separated and washed with water, sat.NaCl, water (200mL each), dried over 
MgS04, filtered and concentrated. The remaining residue was purified by flash 
chromatography (ether-light petroleum 1:2) to give 93, the less polar product, Rf 0.45, 
(2.55g, 52%) as an oil, and 97, Rf0.39, (2.03g, 41%) as a crystalline solid.
259
Analytical data for 93:
NMR spectroscopic data as for the racemic material 86.
Mass spectroscopic data as for the racemic material 86.
[cc]D24 +6.2° (cl, CHCI3). L it250 [cx]D +5.9° (cl.25, CHClj).
Analytical data for 97:
Mp: 57-60° C (from ether-hexane). Lit.250 57-58° C.
[<x]D24 +23.9° (cl.02, CHC13). Lit.250 [a]D +23.4° (cl, CHClj).
'H NMR (CDCI3,270MHz)
5 1.34, 1.48 (6H, 2s, -CH3), 2.62 (1H, s, D20 ex., -OH), 3.29 (1H, t, J = 9.0Hz, C-5-H), 
3.56 (1H, dd, J = 3.8, 9.9Hz, C-3-H), 3.70 (1H, dd, J = 6.6, 9.0Hz), 4.04 (1H, t, J = 
9.5Hz, C-4-H), 4.12 (1H, t, J = 5.3, 6.6Hz, C-l-H), 4.30 (1H, dd, J = 4.0, 5.1Hz), 4.68- 
4.90 (6H, m, -CH2Ph), 7.26-7.42 (15H, m, -CH2Ph).
13C NMR (CDCI3,68MHz)
8 25.81, 27.84 (2q, -CH3), 72.73, 73.64, 75.10 (3t, -CH2Ph), 71.69, 73.96, 76.82, 79.33, 
81.72, 82.36 (6d, inositol ring carbons), 109.03 (s, Cq, CMe2), 127.64, 127.79, 127.98,
128.07, 128.13,128.33,128.49,128.52 (8d, -CH2Ph), 138.04, 138.45 (3s, Cq, -CH2Ph). 
MS: m/z (+ve ion FAB, rel. intensity) 491[(M+H)+, 25%], 489(68%), 513[(M+Na)+, 
38%], 399[(M-C7H7)+, 15%], 91[(C7H7)+, 100%], 181[(2C7H7-H)+, 15%].
MS: m/z (-ve ion FAB, rel. intensity) 643[(M+NBA)\ 100%], 979[2M-H)‘, 20%], 
489[(M-H)', 35%].
Accurate mass requires (M+H)+ = 491.2433.
Accurate mass found (M+H)+ = 491.2416.
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7.6.4. ID-1 A6-Tri-0-benzvl-/wyo-inositol. (94)
BnO BnO
(93) (94)
The chiral alcohol 93 (2.0g, 4.08mmol) was suspended in a solution of ethanol-1M aq. 
HC1 5:1 v/v (50mL) and was stirred under reflux for 30min to give a product Rf 0.3 
(ether-light petroleum 2:1). The solution was allowed to cool and the solvents were 
evaporated under reduced pressure. The residue was taken up in dichloromethane 
(50mL), washed with sat. aq. NaHC03, sat. aq. NaCl, dried over MgS04, filtered and 
concentrated to a white solid residue. Recrystallisation of the residue from ether-light 
petroleum afforded the title triol 94 as a crystalline solid. (1.65g, 89%).
Mp: 69-71°C (from ethyl acetate-light petroleum). Lit.26471-71°C.
[a]D22 -11.0° (cl. CH2C12). L it" 4 [a]D -11.3° (cl. CH2C12).
NMR and Mass spectroscopic data as for the racemic material 87.
7.6.5. D-l,4.6-Tri-0 -benzvl-7wvo-inositol-2.3.5-tris(dibenzvlphosphate).(95)
The chiral triol 94 (200mg, 0.44mmol) was phosphitylated as described for the racemic 
material 87. Oxidation and purification as before afforded the title trisphosphate triester 
95 as a colourless oil (378mg, 69%).





[a]D23 -2.0° (cl, CHClj).
Anal. Calcd for C69Hf,90 15P3 (1230); C, 67.31; H, 5.65. Found; C, 66.9; H, 5.70%.
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The chiral trisphosphate triester 95 (80mg, 65pmol) was deprotected and purified as 
described for the racemic material 88, to give 96 as the glassy triethylammonium salt, 
(42pmol, 64% yield).
[<x]D24 = +1.7° (c = 3.1. MeOH).
NMR data as for the racemic material 89.
Accurate mass requires (M-H)' = 418.9545.
Accurate mass found (M-H)" = 418.9526.
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The chiral alcohol 97 (2.0g, 4.08mmol) was suspended in a solution of ethanol-1M HC1 
5:1 v/v (lOOmL) and stirred under reflux for 30min to give a product Rf 0.25 (ether-light 
petroleum 2:1). The solution was allowed to cool to room temperature and the solvents 
were evaporated under reduced pressure. The residue was taken up in dichloromethane 
(50mL), washed with sat.aq.NaHC03, sat.NaCl, water (50mL each), dried over MgS04, 
filtered and evaporated to dryness. The solid residue was recrystallised from ether-light 
petroleum 1:1 to give the crystalline title triol 98 (1.63g, 88%).
Mp: 106-108°C (from ethyl acetate-light petroleum). Lit.264 106-107°C.
[a]D22 -3.0° (cl, CH2C12). Lit. 264[a]D -3.3° (cl, CH2C12).
'H NMR (CDClj, 270MHz)
5 2.49 (3H, br.s, D20  ex., -OH), 3.23-4.24 (6H, inositol ring protons), 4.70-5.01 (6H, m, 
-CH2Ph), 7.31-7.52 (15H, m, -Ph).
MS: m/z (+ve ion FAB, rel. intensity) 451[(M+H)+, 20%], 473[(M+Na)+, 32%], 
91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 603[(M+NBA)‘, 95%], 449[(M-H)", 68%]. 
Accurate mass requires (M+H)+ = 451.2076.
Accurate mass found (M+H)+ = 451.2075.
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5 ,  OBn
(98) (99)
To a solution of bis(benzyloxy)-A^A^-diisopropylaminophosphine (920mg, 2.66mmol) in 
dry dichloromethane (lOmL), was added tetrazole (280mg, 4.0mmol). The mixture was 
stirred at room temperature for 15min. 98 (200mg, 0.44mmol) was added and stirring 
continued for 0.5h. TLC (chloroform-acetone 20:1) showed one major product Rf 0.2. 
Water (5mL) was added and stirring continued for a further 5min before the solution 
was cooled to -78° C. m-CPBA (1.2g, 6.95mmol) was added, the cooling bath removed 
and the mixture was stirred for lOmins. The solution was diluted with dichloromethane 
(50mL) and then washed with 10% Na2S20 5, sat.aq.NaHC03, sat.NaCl (50mL each), 
dried over MgS04, filtered and concentrated to a colourless oil. Purification by column 
chromatography (chloroform-acetone 20:1) gave the title trisphosphate triester 99, Rf 
0.2, (369mg, 68%), as an oil..
[ct]D23 = -4.5° (c = 1.1, CHClj).
'H NMR (CDClj, 270MHz)
6 3.51 (1H, dt, J = 2.2, 11.2Hz, C-l-H showing W coupling to C-2-phosphate), 3.54
showing W coupling to C-2-phosphate, C-3-H), 4.42-5.12 (19H, m, -CH2Ph and
(1H, t, J = 10.1Hz, C-5-H), 3.95 (1H, t, J = 10.1Hz, C-4-H), 4.40 (1H, dt, J = 2.2, 9.0Hz,
-OPO(OCH2Ph)2 and C-6-H), 5.41 (1H, td, J = 2.2, 9.0Hz, C-2-H), 7.01-7.41 (45H, m,
-CH2Ph and -OPO(OCH2Ph)2).
13C NMR (CDCI3, 100MHz)
8 69.09, 69.16, 69.22, 69.25, 69.47, 69.54, 69.60, 74.63, 74.67 (9t, -CH2Ph and 
-OPO(OCH2Ph)2), 75.58, 76.17, 76.70, 77.30, 78.69, 79.27 (6d, inositol ring carbons), 
127.41, 127.52, 127.59, 127.63, 127.66, 127.87, 127.92, 128.08, 128.12, 128.18, 
128.21, 128.30, 128.43, 128.51, 128.62 (15d, -CH2Ph and -OPO(OCH2Ph)2), 135.58, 
135.66, 135.82, 135.89, 135.95, 136.02, 136.59, 137.80, 135.98 (9s, Cq, -CH2Ph and 
-OPO(OCH2Ph)2).
31P NMR (CDCI3,162MHz)
8p-0.89 (IP, s ), -0.98 (IP, s ), -2.25 (IP, s ). (^P^H-decoupled)
MS: m/z (+ve ion FAB, rel. intensity) 1231[(M+H)+, 80%], 1253[(M+Na)+, 35%], 
91[(C7H7)+, 100%], 181[(2C7H7-H)+, 20%].
MS: m/z (-ve ion FAB, rel. intensity) 1383[(M+NBA)’, 65%], 1276(15%), 1139[(M- 
C7H7)\ 40%], 277[(OPO(OC7H7)2\  100%].
Anal. Calcd for (1230); C, 67.31; H, 5.65. Found; C, 67.0; H, 5.71%.




The trisphosphate triester 99 (lOOmg, 81.3jumol) was deprotected as described for 
compound 88. Purification by ion exchange chromatography on Q Sepharose Fast Flow 
Resin as before, gave the glassy triethylammonium salt of 100 which eluted between 
450-500mM TEAB buffer. (49.5pmol, 61% yield).
[a]D24 =+1.17° (c = 5.1, MeOH).
'H NMR (D A  270MHz)
8 3.16 (1H, t, J = 9.0Hz, C-4-H or C-5-H), 3.39 (1H, m, C-l-H), 3.53 (1H, t, J = 9.4Hz, 
C-4-H or C-5-H), 3.75 (1H, dt, J = 7.8, 9.0Hz, C-6-H), 3.96 (1H, q, J = 9.0Hz, C-3-H), 
4.59 (1H, dt, J = 9.0Hz, C-2-H).
31PNMR(D20, 109MHz)
8P +1.22 (IP, d, J = 7.1Hz, -CH-O-POj2 ), +2.17 (IP, d, J = 9.5Hz, -CH-0-P032‘), +2.70 
(IP, d, J = 7.1Hz, -CH-O-POj2*).
MS: m/z (-ve ion FAB, rel. intensity) 419[(M)\ 100%], 572(3%), 838[(2M)\ 7%]. 
Accurate mass requires (M-H)‘ = 418.9545.
Accurate mass found (M-H)‘ = 418.9535.
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The title compound was prepared as previously described by Desai e t.a l264 
A mixture of 50, (20g, 90.8mmol), dibutyltin oxide (46g, 185mmol), tetrabutyl- 
ammonium bromide (59.2g, 183mmol), benzyl bromide (36mL, 300mmol) in 
acetonitrile (500mL) was stirred under reflux using a Soxhlet apparatus containing 3A 
molecular sieves, for 8h. TLC (diethyl ether) of the clear solution showed complete 
conversion of 50 into a major product Rf 0.5 and minor products Rf 0.75 and 0.85. The 
Soxhlet was removed, triethylamine (80mL) was added and reflux continued for a 
further lh to destroy the excess benzyl bromide. The solution was cooled, the solvents 
were evaporated and the residue distributed between diethyl ether (200mL) and water 
(200mL) and the title compound crystallised out. The mixture was stirred for 20min to 
ensure crystallisation was complete and the product filtered off and washed with water 
and ether to give 85 as a crystalline solid (22.6g, 62%).
Mp: 162-164°C (from ether); L it“ 4161-163°C.
'H NMR (CDC13,270MHz)
5 1.34 (3H,s, -CCHj), 1.49 (3H, s -CCH3), 2.74 (2H, br.s, D20  ex., -OH), 3.36 (1H, t, J 
= 9.5Hz, C-5-H), 3.50-3.56 (2H, m, C-3-H and C-6-H), 3.94 (1H, t, J = 9.5Hz, C-4-H), 
4.11 (1H, dd, J = 5.1, 7.0Hz, C-l-H), 4.29 (1H, t, J = 4.9Hz, C-2-H), 4.67 and 4.93 (2H, 
ABq, Jab = 11.5Hz, -CH2Ph), 4.78 (2H, s, -CH2Ph), 7.26-7.41 (10H, m, -CH2Ph).
I3C NMR (CDCIj, 68MHz)
8 25.93, 28.02 (2q, -CH3), 72.63, 73.33 (2t, -CH2Ph), 71.51, 74.00, 76.98, 79.25, 81.96 
(5d, inositol ring carbons), 109.97 (s, Cq, CMe), 127.79, 128.02, 128.11, 128.39, 128.52 
(5d, -CH2Ph), 137.80, 138.09 (2s, Cq, -CH2Ph).
7.8.2. DL-1.4-Di-0-benzvl-2.3-0-isopropvlidenecvclohex-5-ene-1.2.3.4-tetrol. (101)
2,4,5-Triiodoimidazole was prepared as previously described by Garegg et a l 265 
■Iodine (76. lg, 0.3mol) was stirred in hexane (1.5L) at room temperature for 0.5h. Water 
(1.5L) and imidazole (6.81g, 0.1 mol) were added and stirring continued. Sodium 
hydroxide (24g) in water (300mL) was added gradually in small portions whenever 
precipitation occurred. After stirring for 24h, the solution was filtered and the hexane 
decanted and discarded. The pH of the water layer was brought to 5.0 by the gradual 
addition of concentrated hydrochloric acid to the stirred solution. The resulting pale 
yellow precipitate was filtered off, washed thoroughly with water and recrystallised 
from ethanol-water to give 2,4,5-triiodoimidazole (35.3g, 76% yield) as pale yellow 
crystals. Mp:190-194°C. Lit. 265 190-192°C
A mixture of 85 (3g, 7.5mmol), triphenylphosphine (7.87g, 30.0mmol),
triiodoimidazole (5.0g, 11.25mmol) and imidazole (l.Og, 15.0mmol) in toluene 
(300mL) was heated under reflux for 3h. TLC (ether) revealed one major product, 
which was visualised using a potassium permanganate dip, Rf 0.9. The mixture was 
allowed to cool, toluene (200mL) was added and the solution was decanted into a 
stirring solution of sat.aq.NaHC03 (500mL). Any residue in the reaction vessel was 
dissolved in a little acetone (30mL) and the solution added to the hydrogencarbonate
2,4,5-1 moaoimiaazoie. (85) (101)
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solution. The mixture was stirred for a further 20min and the transferred to a separating 
funnel. The organic phase was washed with 10% sodium thiosulphate solution, 
sat.aq.NaHC03, water (500mL each), dried over MgS04, filtered and concentrated 
under reduced pressure. The residue was dissolved in 20mL toluene and gently warmed 
to dissolve any triphenylphosphine oxide. The solution was then loaded onto a flash 
chromatography column, and eluted with ethyl acetate-toluene 1:2 to afford the purified 
compound 101, Rf 0.4, (2.20g, 80%) as an oil.. 
lH NMR (CDC13,270MHz)
8 1.34 and 1.41 (6H, 2s, -CH3), 4.08 (1H, m, C-2-H or C-3-H, showing complex 
homoallylic coupling), 4.32 (1H, m, C-3-H or C-2-H showing complex homoallylic 
coupling), 4.43-4.77 (6H, m, C-l-H and C-4-H and -CH2Ph), 6.05 (1H, m, C-6-H), 6.15 
(1H, m, C-5-H), 7.21-7.40 (10H, m, -Ph).
13C NMR (CDClj, 68MHz)
8 24.65, 26.17 (2q, -CH3), 70.72, 71.37 (2t, -CH2Ph), 72.18, 75.60, 76.56, 77.19 (4d, 
cyclohexene ring carbons), 109.37 (s, Cq, -CMe), 127.69, 127.81, 127.94, 128.05, 
128.41 (5d, -CH2Ph and =CH), 132.70, 134.00 (2s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 367[(M+H)+, 55%], 389[(M+Na)+, 17%], 
91[(C7H7)+, 100%], 181[(2C7H7-H)+, 42%].
Accurate mass requires (M+H)+ = 367.1909.








To a vigorously stirred solution of the alkene 101 (l.Og, 2.73mmol) in ethyl acetate- 
acetonitrile (15mL-15mL) at 0-5°C, was added a solution of RuC13(H20)3 (37mg, 
0.18mmol) and NaI04 (866mg, 4.05mmol) in distilled water (5mL). The two-phase 
mixture was stirred vigorously for 5min and quenched with sat.aq.Na2S20 3 (20mL). The 
aqueous phase was separated and extracted with ethyl acetate (3x30mL). The combined 
organic fractions were dried over MgS04, filtered and concentrated under reduced 
pressure. Purification of the residue by flash chromatography (ether-light petroleum 
3:1) afforded the title diol 102, Rf0.45, (0.75g, 69%).
Mp: 116-120°C (from ethyl acetate-hexane).
'H NMR (CDCI3, 400MHz)
8 1.31, 1.37 (6H, 2s, -CH3), 2.25 (2H, s, D20  ex., -OH), 3.46 (1H, dd, J = 6.7, 2.7Hz, 
C-4-H), 3.91 (1H, dd, J = 2.8, 9.2Hz, D20  ex., C-6-H), 3.98 (1H, dd, J = 4.0, 9.2Hz, 
C-l-H), 4.18 (1H, t, J = 2.8Hz, D20  ex., C-5-H), 4.27 (1H, dd, J = 6.7, 5.1Hz, C-3-H), 
4.36 (1H, dd, J = 4.0, 5.2Hz, C-2-H), 4.66-4.98 (4H, m, -CH2Ph), 7.26-7.51 (10H, m, 
-Ph).
I3C NMR (CDClj, 100MHz)
8 25.84, 27.94 (2q, -CH3), 71,79, 72.54 (2t, -CH2Ph), 73.31, 76.35, 76.71, 77.04, 78.05, 
78.76 (6d, inositol ring carbons), 109.65 (s, Cq, CMe2), 127.92, 128.07, 128.18, 128.45,
128.56, 128.65 (6d, -CH2Ph), 137.74, 137.92 (2s, Cq, -CH2Ph).
MS: m/z (-ve ion FAB, rel. intensity) 553[(M+NBA)', 100%], 399[(M-H)', 58%].
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MS: m/z (+ve ion FAB, rel. intensity) 401[(M+H)+, 15%], 423[(M+Na)+, 12%], 
181[(2C7Hr H)+, 10%], 91[(C7H7)+, 100%].
Accurate mass requires (M+H)+ = 401.1964.
Accurate mass found (M+H)+ = 401.1960.













A mixture of 85 (3.0g, 7.50mmol) and dibutyltin oxide (2.8g, 11.25mmol) was 
suspended in toluene (200mL) and heated under reflux for 2.5h whilst removing water 
with a Dean and Stark apparatus. The solution was cooled and the toluene evaporated 
under reduced pressure. The remaining crystalline tin complex was further dried at 
130°C under vacuum for 2h. DMF (150mL) and caesium fluoride (2.85g, 18.76mmol) 
was added and the solution stirred vigorously under nitrogen. Allyl bromide (1.17g, 
15.0mmol) was added dropwise and the reaction left to stir at room temperature for 8h. 
TLC (ether) showed complete conversion of the starting material diol Rf 0.5, to two 
major products Rf 0.8 and 0.9. The solvents were evaporated in vacuo and the residue 
distributed between sat.aq.NaHC03 (300mL) and dichloromethane (300mL). The 
solution was stirred for 30min and the precipitated tin derivative filtered through Celite. 
The Celite was washed with dichloromethane (2xl00mL). The organic phase was 
separated and washed with water, sat.NaCl, water (200mL each), dried over MgS04, 
filtered and evaporated to dryness. The remaining residue was purified by flash
271
chromatography (ether-light petroleum 2:1) to give 103, the more polar product (1.3g, 
39%), and 104, the less polar product (1.45g, 44%), as oils.
Analytical data for 103:
!H NMR (CDC13,270MHz)
5 1.33 and 1.32 (6H, 2s, -CH3), 2.25 (1H, s, D20  ex., -OH), 3.08 (1H, t, J = 9.2Hz, 
C-5-H), 3.46 (1H, dd, J = 3.9, 9.9Hz, C-l-H), 3.54 (1H, dd, J = 6.8, 9.0Hz, C-3-H), 3.91 
(1H, t, J = 9.5Hz, C-6-H), 4.00 (1H, t, J = 6.8Hz, C-4-H), 4.11-4.31 (3H, m, C-2-H and 
-CH2- allyl), 4.61-4.78 (4H, m, -CH2Ph), 5.12-5.24 (2H, m, =CH2), 5.80-5.95 (1H, m, 
-CH=), 7.18-7.35 (10H, m, -Ph).
13C NMR (CDCI3,68MHz)
6 25.78, 27.96 (2q, -CH3-), 72.65, 73.61, 73.87 (3t, -CH2- ally!, and -CH2Ph), 76.72, 
79.17, 81.24, 82.23 (4d, inositol ring carbons), 109.80 (s, Cq, CMe2), 117.14 (t, =CH2 
allyl), 127.56, 127.90, 128.23, 128.44 (5d, -CH2Ph), 134.88 (d, -CH= allyl), 137.94, 
138.27 (2s, Cq, -CH2Ph).
Analytical data for 104:
!H NMR (CDCI3, 270MHz)
6 1.33 and 1.34 (6H, 2s, -CH3), 2.23 (1H, Br.s, D20  ex., -OH), 3.43 (1H, t, J = 9.5Hz, 
C-5-H), 3.59-3.71 (3H, m, C-l-H, C-4-C, C-6-H), 4.06 (1H, t, J = 6.8Hz, C-3-H), 4.21- 
4.39 (3H, m, C-2-H, -CH2- allyl), 4.68-4.91 (4H, m, -CH2- allyl), 5.16-5.33 (2H, m, 
=CH2 allyl), 5.89-6.03 (1H, m, -CH= allyl), 7.24-7.36 (10H, m, -Ph).
13C NMR (CDC13, 68MHz)
6 25.63, 27.60 (2q, -CH3), 73.01, 73.20, 73.43 (3t, -CH2- allyl and -CH2Ph), 74.51, 
76.53, 78.81, 78.98, 81.55 (5d, inositol ring carbons), 109.76 (s, Cq, CMe2), 117.00 (t, - 
CH= allyl), 127.59, 127.76, 127.90, 128.28, 128.32 (5d, -CH2Ph), 138.01, 138.22 (2s, 
Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 441[(M+H)+, 67%], 463[(M+Na)+, 43%], 
91[(C7H7)+, 100%].
Accurate mass requires (M+H)+ = 441.2277.












A solution of 104 (3.40g, 7.72mmol), dry pyridine (4mL) in dry dichloromethane 
(20mL), was cooled to -78° C and trifluoromethanesulphonic anhydride (1.30mL, 
7.72mmol) was added dropwise over a period of lOmin. under nitrogen. The cooling 
system was then removed and the solution was left to stir for 2h at room temperature. 
TLC (ether) showed the conversion of the starting material alcohol Rf 0.8 to a single 
product Rf 0.6. The dichloromethane solution was washed with ice-sat.aq.NaHC03, ice- 
water, ice-sat.NaCl (20mL each), dried over MgS04, filtered and concentrated to a 
yellow syrup. Toluene (20mL) was then added and evaporated under reduced pressure 
to remove any traces of pyridine. The trifluoromethanesulphoxy-intermediate was not 
isolated. Caesium acetate (2.96g, 15.45mmol) and dry DMF were added to the crude 
material and the mixture stirred at room temperature under nitrogen for 3h. TLC (ether- 
hexane 2:1) showed a single product Rf 0.7. The solution was concentrated in vacuo, 
and the residue partitioned between ether and water (lOOmL each). The organic phase 
was dried over MgS04, filtered and concentrated under reduced pressure to give a
273
yellow oil. Purification by column chromatography (ether-light petroleum 2:1) afforded 
the title compound 105, Rf 0.65, as an oil (3.25g, 87%). 
lH NMR (CDC13,270MHz)
5 1.32, 1.33 (6H, s, -CH3), 2.09 (3H, s, -COCH3), 3.45 (1H, dd, J = 2.8,7.9Hz, C-4-H or 
C-6-H), 3.75 (1H, dd, J = 2 6, 9.9Hz, C-6-H or C-4-H), 3.94 (1H, dd, J = 4.4, 9.9Hz, 
C-l-H or C-3-H), 4.10-4.20 (3H, m, -CH2- allyl and C-l-H or C-3-H), 4.31 (1H, t, J = 
4.5Hz, C-2-H), 4.80 and 4.75 (2H, AB, Jab = 12.3Hz, -CH2Ph), 4.56 and 4,73 (2H, AB, 
Jab  = 12.3Hz, -CH2Ph), 5.18-5.36 (2H, m, =CH2 allyl), 5.70 (1H, t, J = 2.8Hz, C-5-H), 
5.87-5.99 (1H, m, -CH= allyl), 7.27-7.42 (10H, m, -CH2Ph).
13C NMR (CDCI3, 68MHz)
6 20.98 (q, -COCH3), 25.97 and 28.10 (2q, -CH3), 71.11, 71.51, 73.51 (3t, -CH2Ph and 
-CH2- allyl), 74.38, 75.23, 76.25, 76.44, 77.64 (5d, inositol ring protons), 109.48 (s, Cq, 
CMe2), 117.15 (t, =CH2 allyl), 127.71, 127.97, 128.31, 128.39 (4d, -CH2Ph), 134.00 (d, 
-CH= allyl), 137.62, 138.48 (2s, Cq, -CH2Ph), 170.08 (s, Cq, -COMe).
MS: m/z (+ve ion FAB, rel. intensity) 483[(M+H)+, 78%], 505[(M+Na)+, 25%], 
91[(C7H7)+, 100%].
Accurate mass requires (M+H)+ - 483.2382.





Compound 105 (3.0g,6.22mmol) was suspended in methanol-lM aq.NaOH 5:1 
(lOOmL) and stirred under reflux for lh, after which TLC (ether-hexane 2:1) showed the
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complete conversion of the starting material 105, Rf 0.7, to a single product Rf 0.4. The 
solution was allowed to cool to room temperature and carbon dioxide was bubbled 
through until a pH 7.0 was reached. The methanol was evaporated under reduced 
pressure and the residue partitioned between water and dichloromethane. The organic 
phase was dried over MgS04, filtered and concentrated to give a clear yellow oil. 
Purification by column chromatography (ether-hexane 2:1) afforded the title alcohol 
105, Rf 0.42, as an oil (2.55g, 93%). 
lH NMR (CDC13,400MHz)
8 1.32 and 1.39 (6H, 2s, -CMe2), 2.37 (1H, s, D20  ex., -OH), 3.45 (1H, dd, J = 2.4, 
6.7Hz, C-4-H or C-6-H), 3.69 (1H, dd, J = 2.7, 9.5Hz, C-6-H or C-4-H), 4.08 (1H, dd, J 
= 4.0, 9.5Hz, C-l-H or C-3-H), 4.18 (1H, t, J = 2.4, 2.8Hz, C-5-H), 4.21-4.31 (4H, m, 
C-2-H and C-l-H or C-3-H and -CH2- allyl), 4.68-4.85 (4H, m, -CH2Ph), 5.17-5.33 (2H, 
m, =CH2 allyl), 5.90-6.00 (1H, -CH= allyl), 7.22-7.51 (10H, m, -Ph).
13C NMR (CDCI3,100MHz)
8 25.82, 28.01 (2q, -CH3), 71.85, 72.54, 73.40 (3t, -CH2Ph and -CH2- allyl), 74.35, 
75.69, 77.23, 77.50, 77.77, 78.60 (6d, inositol ring carbons), 109.38 (s, Cq^  -CMe2), 
117.18 (t, =CH2 allyl), 127.77, 127.85, 128.07, 128.36, 128.40 (5d, -CH2Ph), 134.89 (d, 
-CH= allyl), 138.01 (2s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 441[(M+H)+, 51%], 463[(M+Na)+, 31%], 
91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 593[(M+NBA)', 199%], 746[(M+2NBA)', 62%]. 
Anal. Calcd for C26H320 6 (440); C, 70.89; H, 7.32. Found; C, 70.7; H, 7.44%.
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7.8.7. Synthesis of DL-6-0-Allyl- 1.4“di-0-benzvl-2.3-0-isopropylidene-weo-inositol 







A mixture of 102 (3.0g, 7.50mmol) and dibutyltin oxide (2.8g, 11.25mmol) was 
suspended in toluene (200mL) and heated under reflux for 2.5h whilst removing water 
with a Dean and Stark apparatus. The solution was cooled to room temperature and the 
toluene was evaporated under reduced pressure. The remaining crystalline tin complex 
was further dried at 130° C in vacuo for 2h. DMF (150mL) and caesium fluoride (2.85g, 
18.76mmol) was added and the solution was stirred vigorously under nitrogen. Allyl 
bromide (1.17g, 15.0mmol) was added dropwise, and the solution left to stir at room 
temperature for 8h. TLC (ether-hexane 2:1) showed a single product Rf 0.4. The 
solvents were evaporated in vacuo and the residue distributed between sat.aq.NaHC03 
and dichloromethane (300mL each). The solution was stirred for 30min. at room 
temperature and the precipitated tin derivative was filtered off through Celite. The 
Celite was washed with dichloromethane (2x lOOmL). The organic phase was separated 
and washed with water, sat.NaCl, water (200mL each), dried over MgS04, filtered and 
concentrated under reduced pressure. Purification of the remaining residue by flash 
chromatography (ether-hexane 2:1) afforded the title compound 106, Rf 0.4, (2.75g, 







A mixture of 106 (2g,4.55mmol) and sodium hydride (327mg, 13.63mmol) was stirred 
in dry DMF (50mL) for 15min. Benzyl bromide (0.65mL, 5.46mmol) was added 
dropwise, and the solution left to stir for 2h under nitrogen. TLC (ether-hexane 2:1) 
showed complete conversion of the starting material alcohol 106, Rf 0.4, to a single 
product Rf 0.7. The excess sodium hydride was destroyed with methanol (15mL) and 
the solvents evaporated under reduced pressure. The residue was partitioned between 
ether and water (200mL each), and the ethereal phase washed with 0.1M HC1 (50mL), 
sat.aq.NaHC03 (lOOmL) and water (lOOmL). The solution was dried over MgS04, 
filtered and evaporated to dryness to give a syrup. Purification by column 
chromatography (ether-hexane 1:1) afforded the title compound 107, Rf0.25, (1.95mg, 
81%), as an oil.
'h  NMR (CDClj, 400MHz)
5 1.32, 1.38 (6H, 2s, -CH3), 3.40 (1H, m, inositol ring proton), 3.64 (1H, dd, J = 1.8, 
9.7Hz, inositol ring proton), 3.99 (1H, t, J = 2.1Hz, inositol ring proton), 4.08-4.30 (5H, 
m, -CH2- and 3x inositol ring protons), 4.56-4.85 (6H, m, -CH2Ph), 5.15-5.34 (2H, m, 
=CH2 allyl), 5.88-5.98 (1H, m, -CH= allyl), 7.12-7.50 (15H, m, -Ph).
13C NMR (CDCli, 100MHz)
5 26.06,28.31 (2q, -CH,), 71.70,72.00,73.39,73.81 (4t, -CH2Ph and -CH2 allyl), 74.39, 
75.85, 76.04, 78.47, 78.96, 79.20 (6d, inositol ring protons), 109.16 (s, Cq, CMe2), 
116.38 (t, =CH2 allyl), 127.37, 127.52, 127.65, 127.81, 128.08, 128.12, 128.29 (7d, 
-CH2Ph), 135.16 (d, -CH= allyl), 138.36, 138.60, 138.86 (3s, Cq, -CH2Ph).
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MS: (+ve ion FAB, rel. intensity) 531[(M+H)+, 88%], 553[(M+Na)+, 26%], 91[(C7H7)+, 
100%].
MS: (-ve ion FAB, rel. intensity) 683[(M+NBA)\ 100%], 349[(M-2C7H7+H)', 36%], 
259[(M-3C7H7+2H)‘, 58%].
Anal. Caled for C33H38O6 (530); C, 74.69; H, 7.22. Found; C, 74.6; H, 7.18%.









A mixture of compound 107 (1.50g, 2.83mmol) and freshly sublimed potassium 
t-butoxide (952mg, 8.50mmol) in dry dimethylsulphoxide (50mL) was stirred at 100°C 
for 2h under an atmosphere of nitrogen. TLC (ether-pentane 1:2) revealed a single 
product Rf 0.55 which was slightly less polar than the starting material 107, Rf 0.5. The 
reaction was left to cool to room temperature, water (lOOmL) was added, and the 
product was extracted with dichloromethane (2xl00mL). The combined organic 
extracts were dried over MgS04, filtered and concentrated under reduced pressure. The 
crude residue was purified by flash chromatography (ether-pentane 1:3, 5% 
triethylamine), to afford the title compound 108, Rf 0.3, (1.29g, 2.43mmol, 86% yield). 
‘H NMR (CDClj, 270MHz)
S 1.32, 1.36 (6H, 2s, -CH3), 1.68 (3H, dd, J = 1.6, 6.8Hz, -CH, propenyl), 3.44 (1H, m, 
inostol ring proton), 3.95 (1H, dd, J = 2.2, 9.9Hz, inositol ring proton), 4.04 (1H, t, J = 
2.2Hz, inositol ring proton), 4.17 (1H, dd, J = 4.0, 9.9Hz, inositol ring proton), 4.28 (2H,
m, 2x inositol ring protons), 4.44 (1H, q, J = 6.6Ez, =CH- propenyl), 4.62-4.84 (6H, m, 
-CH2Ph), 6.16 (1H, qd, J = 1.7,6.2Hz, -CH= propenyl), 7.25-7.41 (15H, m, -Ph).
13C NMR (CDC13,68MHz)
8 9.45 (q, -CHj propenyl), 26.04, 28.23 (2q, -CH3), 71.54, 73.26, 74.17 (3t, -CH2Ph), 
74.32, 74.99, 76.70, 76.91, 78.41, 78.87 (6d, inositol ring protons), 100.41 (d, -CH= 
propenyl), 109.32 (s, Cq, CMe2), 127.44, 127.55, 127.61, 127.77, 128.18, 128.30 (6d, - 
CH2Ph), 138.25, 138.33,138.73 (3s, Cq, -CH2Ph), 145.95 (d, =CH- propenyl).
MS: (+ve ion FAB, rel. intensity) 531[(M+H)+, 32%], 553[(M+Na)+, 78%], 439(37%), 
91[(C7H7)+, 100%].
Accurate mass requires (M+H)+ = 531.2701.
Accurate mass found (M+H)+ = 531.2702.









Compound 108 (l.Og, 1.88mmol) was suspended in a solution of 1M aq. HCl-methanol 
1:9 v/v (50mL) and stirred under reflux for lh. TLC (ether-pentane 1:2) showed 
complete conversion of the starting material Rf 0.55 to a more polar product on the 
baseline. The mixture was allowed to cool to room temperature and the solvents were 
evaporated under reduced pressure. The residue was taken up in dichloromethane 
(lOOmL), washed with sat. aq. NaHC03 and water (50mL each), dried over MgS04, 
filtered and evaporated to dryness. The remaining material was purified by column
chromatography (ethyl acetate-hexane 4:1) to give the title triol 109, Rf 0.65, (0.68g,
80%).
Mp: 160-162°C (from ethyl acetate-hexane). 
'H NMR (DMSO, 270MHz)
8 3.55 (2H, m, C-l-H and C-4-H), 3.69 (1H, m, D2Q ex., C-3-H or C-6-H), 3.80 (1H, m,
D20  ex., C-6-H or C-3-H), 3.96 (1H, t, J = 2.2Hz, C-2-H), 4.02 (1H, d, J = 3.4Hz, D20
ex.,C-5-H), 4.53-4.84 (9H, m, -CH2Ph and D20  ex., 3x -OH), 7.22-7.44 (15H, m, -Ph).
I3C NMR (DMSO, 68MHz)
5 68.75, 69.54, 69.57, 78.44, 78.63 (5d, inositol ring carbons), 70.57, 71.45, 74.27 (3t,
-CH2Ph), 127.04, 127.14, 127.24, 127.49, 127.64, 128.00, 128.03, 128.14 (8d, -CH2Ph),
139.38, 139.82 (2s, Cq, -CH2Ph).
MS: m/z (+ve ion FAB, rel. intensity) 451[(M+H)+, 7%], 473[(M+Na)+, 19%], 
91[(C7H7)+, 100%].
MS: m/z (-ve ion FAB, rel. intensity) 603[(M+NBA)', 100%], 359[(M-C7H7)\ 44%], 
269[(M-2C7H7+H)', 20%], 449[(M-H)\ 50%].
Accurate mass requires (M+H)+ = 451.2075.
Accurate mass found ((M+H)+ = 451.2094.
Anal. Calcd for C27H30O6 (450); C, 71.97; H, 6.72. Found; C, 71.4; H, 6.73%.
7.8.11. DL-1.2.4-Tri-0-benzvl-weo-inositol 3,5.6-Tris(dibenzvlphosphate) (110).
To a solution of bis^enzyloxy^A^A-diisopropylaminophosphine (920mg, 2.66mmol) in 





stirred at room temperature for lOmin. 109 (200mg, 0.44mmol) was added and stirring 
continued for lh. TLC (ethyl acetate) showed complete conversion of the starting 
material triol Rf 0.3 to a single product Rf 0.7. Water (5mL) was added and after being 
stirred for a further 5min the solution was cooled to -78° C. m-CPBA (500mg, 
2.89mmol) was added. The cooling system was removed and the mixture was allowed 
to stir for lOmin before diluting with dichloromethane (50mL). TLC (ethyl acetate) 
showed complete conversion of the trisphosphite Rf 0.7 to the trisphosphate Rf 0.65. 
The solution was washed with 10% aq.Na2S20 5, sat.aq.NaHC03, sat.NaCl, water (50mL 
each), dried over MgS04, filtered and concentrated to a clear syrup. Purification by 
column chromatography (chloroform-acetone 30:1) gave the trisphosphate triester 110, 
Rf0.35, (398mg, 73%) as a colourless syrup.
*H NMR (CDC13, 270MHz)
5 3.80 (1H, dd, J = 2.4, 10.1Hz, C-4-H), 4.00 (1H, dd, J = 2.2, 10.1Hz, C-l-H), 4.35 
(1H, t, J = 2.2Hz, C-2-H), 4.42-5.12 (20H, m, -CH2Ph and C-3-H and C-6-H), 5.43 (1H, 
dt, J = 2.4, 8.8Hz, C-5-H), 7.05-7.30 (45H, m, -Ph).
13C NMR (CDC13, 100MHz)
5 69.14, 69.22, 69.27, 69.36, 69.42, 72.58, 72.71 (7t, -CH2Ph and -PO(OCH2Ph)2), 
75.73, 76.09, 76.15, 76.55, 76.60, 76.71 (6d, inositol ring carbons), 127.54, 127.59, 
127.65, 127.74, 127.79, 127.92, 128.03, 128.16, 128.27, 128.30, 128.36, 128.41,
128.56, 128.82, 128.89, 129.02 (16d, -Ph), 135.62, 135.69, 135.88, 135.91, 135.95, 
135.99, 136.02, 137.17, 137.50 (9s, Cq, -CH2Ph and -OPO(OCH2Ph)2). 
31PNMR(CDC13, 162MHz) 6p-1.39 (lP,s ),-1.54 (IP, s ), 1.89 (IP, s).
(3 !P-^-decoupled).
MS: m/z (-ve ion FAB, rel. intensity) 1383[(M+NBA)‘, 75%].
MS: m/z (+ve ion FAB, rel. intensity) 1231[(M+H)+, 80%], 1253[(M+Na)+, 25%], 
91[(C7H7)+, 100%], 181[(2C7H7-H)+, 10%].
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Accurate mass requires (M+H)+ = 1231.392. 
Accurate mass found (M+H)+ = 1231.3933.




A solution of 110 (lOOmg, 81.3jj.mol) in ethanol-water 4:1 (50mL) was treated with 
hydrogen at room temperature over Pd/C (10%, lOOmg) at a pressure of 50psi for 20 h. 
The suspension was filtered through Celite to remove the catalyst, 2mL of TEAB buffer 
pH 8.0 was added, and the solution concentrated in vacuo at room temperature. The 
remaining residue was made up to 200mL with de-ionised water and purified by ion- 
exchange chromatography on Q Sepharose Fast Flow Resin, eluting with a gradient 
TEAB buffer (0-1M), pH 8.0. The triethylammoniun salt of 111 eluted between 400- 
500mM TEAB. Detection and quantification of the compound was by the Briggs 
phosphate assay. 244(39jimol, 48% yield).
*H NMR (D20, 400MHz)
5 3.78-3.82 (2H, m, C-3-H and C-6-H), 4.01-4.18 (C-l-H, C-4-H, C-5-H), 4.49-4.80 (m, 
C-2-H and H20).
31P (D20, 162MHz)
5P -0.06 (IP, d, J = 7.2Hz, -CH-0P032'), -0.22 (m, 2P).
MS: m/z (+ve ion FAB, rel. intensity) 102[(C2H5)3NH+, 100%], 301(20%).
MS: m/z (-ve ion FAB, rel. intensity) 97(100%), 250(85%), 419[(M)\ 68%], 516(28%), 
838[(2M)‘, 12%].
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Accurate mass requires (M-H)' = 418.9545. 
Accurate mass found (M-H)' = 418.9538.
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L-Quebrachitol (112) L-chiro inositol (113)
L-Quebrachitol (lOg, 51.5mmol) and 47% aq.hydroiodic acid (60mL) were boiled under 
reflux for 3h. The solution was carefully decanted into boiling ethanol (60mL) and the 
mixture left to cool. The white solid which precipitated out of solution was filtered, 
washed with cooled ethanol and recrystallised from hot ethanol to give the title 
compound 113 (6.50g, 36.1 lmmol 70% yield) as white crystals.
Mp: 240-244°C (from ethanol). L i t117 240°C.
'H NMR (D20 , 400MHz)
8 3.42 (2H, dd, C-l-H and C-4-H, J = 2.5, 7.3Hz), 3.57 (2H, dt, C-5-H and C-6-H, J = 
2.3,7.3Hz), 3.86 (2H, d, C-2-H and C-3-H, J = 2.2Hz).
13C NMR (D20, 100MHz)
8 71.25, 72.46, 73.56 (3d, inositol ring carbons).
7.9.2. 1 .2 :3 .4-Di-O-isopropylidene-c/nra-inositol. (T14i
L-chiro inositol (113)
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To a suspension of 113 (11.4g, 63.3mmol) in DMF (400mL), was added PTSA (0.24g, 
1.26mmol) and 2,2-dimethoxypropane (16.3mL, 132.9mmol). The mixture was stirred 
at 90°C for 2h to a clear solution. TLC (ether) showed the formation of one major 
product Rf 0.2 and two minor products, Rf 0 and Rf 0.65. Triethylamine (30mL) was 
added and the solution left to cool. The solvents were evaporated under reduced 
pressure and the residue taken up in dichloromethane and washed with sat.aq.NaHC03 
and sataq.NaCl (200mL each). The aqueous phase was separated and re-extracted with 
dichloromethane (3xl00mL). The combined organic fractions were dried over MgS04, 
filtered and concentrated to a crude solid residue. Purification by column 
chromatography (ethyl acetate-hexane 2:1) afforded the major product 114, Rf 0.35, 
(9.2g, 56%) as a white crystalline solid.
Mp: 151-154°C (from hexane).
*H NMR (CDCI3,400MHz)
6 1.35 and 1.50 (12H, 2s, 4x -CH3), 3.56 (2H, m, C-5-H and C-6-H), 3.64 (2H, s, D20  
ex., 2x-OH), 4.18 (2H, m, C-l-H and C-4-H), 4.33 (2H, m, C-2-H and C-3-H).
13C NMR (CDC13, 68MHz)
6 25.10,27.63 (2q, -CH3), 72.32, 76.23, 78.63 (3d, inositol ring carbons), 109.66 (s, Cq, 
CMe).
MS: (+ve ion FAB, rel. intensity) 59(60%), 203(20%), 245(62%), 261[(M+H)+, 
100%],283[(M+Na)+, 34%], 521[(2M+H)+, 48%], 543[(2M+Na)+, 94%].
MS: (-ve ion FAB, rel. intensity) 412[(M+NBA-H)\ 100%], 529[(M-H)\ 82%].
Accurate mass FAB requires (M+H)+ = 261.1338.
Accurate mass FAB found (M+H)+ = 261.1339.
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7 .9 .3 .1 .2 :3 .4-Di-0-isopropvlidenecvclohex-5-ene-l. 2 / 3 .4  tetrol. (115)
(114) (115)
A mixture of 114 (1.95g, 7.50mmol), triphenylphosphine (7.87g, 30.00mmol), triiodo- 
imidazole (5.0g, 11.25mmol) and imidazole (l.Og, 15.00mmol) in toluene (150mL) was 
heated under reflux for 3h to a dark red mixture. TLC (ethyl acetate) showed the 
conversion of the starting material diol 114 Rf 0.68, to a new product Rf 0.95. The 
mixture was left to cool and toluene (150mL) was added. The solution was decanted 
into a stirring solution of sat.aq.NaHC03 and stirred for 20min. before transferring to a 
separating funnel. The organic phase was separated and washed with 20% aq. sodium 
thiosulphate, sat. aq. NaHC03, water, dried over MgS04, filtered and concentrated 
under reduced pressure. The residue was dissolved in toluene (lOmL) and gently 
warmed to dissolve any triphenylphosphine oxide, and loaded onto a flash column. 
Purification of the crude residue (ethyl acetate-toluene 1:2) afforded the title compound 
115, Rf 0.55, (1.1 Og, 4.86mmol, 64%) as a thick syrup.
'H NMR (CDCl,, 400MHz)
8 1.37 (12H, s, 4x-CH3), 4.55 (4H, m, C-l-H, C-2-H, C-3-H, C-4-H), 5.72 (2H, s, =CH). 
I3C NMR (CDClj, 100MHz)
8 26.42, 27.81 (2q, -CH3), 70.22, 73.22 (2d, inositol ring carbons), 126.91 (d, =CH).
MS: (+ve ion FAB, rel. intensity) 227[(M+H)+, 82%], 279(100%), 431(88%) 
453[(2M+H)+, 65%], 476[(2M+Na)+, 20%].






To a stirred solution of 115 (1.03g, 4.56mmol) in ethyl acetate-acetonitrile 
(20mL/20mL) at 0°C was added a solution of R.UCI3.H2O (70mg, 0.34mmol) and NaI04 
(1.27g, 5.95mmol) in distilled water(8mL). The mixture was stirred vigorously for 
30min before being quenched with a solution of 20% aq.Na2S20 3. The solution was 
then filtered through a pad of Celite which was then washed with ethyl acetate 
(2x50mL). The organic phase was separated and the aqueous phase re-extracted with 
ethyl acetate (2x50mL). The organic extracts were combined and dried over MgS04, 
filtered and evaporated under reduced pressure. TLC (chloroform-acetone 30:1) before 
concentration of the solution showed two major products Rf 0.60 and Rf 0.66. 
Purification of the crude residue by flash chromatography (ethyl acetate-hexane 1:2) 
afforded the desired compound 116, Rf 0.60, (600mg, 2.30mmol, 50%) and 117, Rf 0.66 
(96mg, 0.39mmol, 8% yield).
Analytical data for 116:
Mp: 80-84°C (from hexane-ethyl acetate). Lit.269 81-82°C.
[a]D23 = +9.1° (c = 1.01, CHCI3). Lit”® [a]D25 = +8.9° (c = 1.12, CHClj)
‘H NMR (CDClj, 270MHz)
S 1.24, 1.26, 1.36, 1.42 (12H, 4s, 4x-CH3), 3.45 (2H, br.s, D20  ex., -OH), 3.60 (1H, m, 
D20  ex., C-5-H), 4.03 (1H, dd, J = 1.8, 3.6Hz, D20  ex. simplified, C-6-H), 4.18-4.28
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(2H, m, C-l-H and C-4-H), 4.32-4.36 (2H, m, C-2-H and C-3-H).
MS: m/z (+ve ion FAB, rel. intensity) 59[(OCMe2+H)+, 95%], 261[(M+H)+, 100%], 
283[(M+Na)+, 58%], 521[(2M+H)+, 45%], 543[(2M+Na)+, 42%].
Accurate mass FAB requires (M+H)+ = 261.1338.
Accurate mass FAB found (M+H)+ = 261.1336.
Analytical data for 117:
Mp: 93-95°C (from ethyl acetate-hexane)
'H NMR (CDCI3,400MHz)
8 1.36, 1.41,1.51,1.54 (12H, 4s, 4 x-CHj), 3.32-3.34 (2H, m, 2 x C-5-H), 4.33 (1H, dd, 
J = 1.4,5.8Hz, C-4-H), 4.54-4.57 (3H, m, C-l-H, C-2-H, C-3-H).
13C NMR (CDC13,100MHz)
8 24.94, 25.80, 26.44,27.39 (4q, -CH3), 39.11 (t, -CH2), 69.71, 71.32, 72.12, 74.24 (4d, 
inositol ring carbons), 108.85,109.25 (2s, Cq, CMe2), 204.33 (s, Cq, C=0).
MS: m/z (+ve ion FAB, rel. intensity) 265[(M+Na)+, 9%], 243[(M+H)+, 100%], 
227[(M-CH3)+, 81%}.
Accurate mass (FAB)+ requires (M+H)+ = 243.1232.
Accurate mass (FAB)+ found (M+H)+ = 243.1223.
7.9.5. <3//o-Inositol. 1118)
(116) alio inositol (118)
Hydrochloric acid (2mL) was added to a solution of 116 (1.50g, 5.76mmol) in ethanol 
(80mL) and the mixture was stirred at room temperature for 16h, whereupon the 
inositol 118 crystallised out of solution. The white solid was filtered off and washed 
with ethanol to give crystalline a//o-inositol 118 (l.OOg, 5.55mmol, 96%).
Mp: 270-276°C (from ethanol). L it“ 9270-280°C.
'H NMR (D 2 0 ,  400MHz)
5 3.80 (2H, br.s), 3.90 (4H, m).
7.9.6. DL-1.3.6-tri-0-benzvl-a//o-inositol (119) and an unidentified tetra-O-benzvl- 
derivative (122)7(123).
OH OH OBn
A mixture of 118 (l.Og, 5.55mmol) and dibutyltin oxide (6.22g, 24.9mmol) was 
suspended in methanol-toluene 1:10 (150mL) and stirred under reflux for 4h, using a 
Soxhlet apparatus with 3A molecular sieves to remove water. The solution was allowed 
to cool and the solvents evaporated under reduced pressure to give a crystalline tin 
complex. The residue was further dried at 130°C under reduced pressure for 3h. To the 
dry crystalline solid was added DMF (200mL) and caesium fluoride (3.37g, 22.2mmol) 
and the mixture stirred under an atmosphere of nitrogen. Benzyl bromide (3.13g, 







temperature for 8h. TLC (ether-light petroleum 2:1) showed two major products Rf 0.3 
and 0.5. The solvents were evaporated under reduced pressure, the residue taken up in 
dichloromethane (200mL), and the solution was poured into a stirring solution of 
sat.aq.NaHC03. The two-phase mixture was stirred vigorously for 30min during which 
time solid tin derivatives precipitated out of the solution. The suspension was filtered 
through a pad of Celite which was then washed with dichloromethane (2x50mL). The 
organic layer was separated and washed with water, sat.aq.NaCl, water (lOOmL each), 
dried over MgS04, filtered and concentrated. The crude residue was purified by flash 
chromatography (ether-light petroleum 2:1) to give the desired tri-Obenzylated 
analogue 119, Rf 0.3, (700mg, 1.55mmol, 28%) as a thick syrup and a tetra-0 - 
benzylated analogue whose regiochemistry of substitution was identified as either 122 
or 123, Rf 0.5, (500mg, 0.92mmol, 16%) also as a thick syrup 
Analytical data for 119:
*H NMR (CDC13,400MHz)
5 2.62 (1H, s, D20  ex., -OH), 3.40 (1H, s, D20  ex., -OH), 3.63 (1H, t, J = 3.0Hz, C-3-H), 
3.66 (1H, dd, J = 3.0, 9.2Hz, C-l-H), 3.88 (1H, br.s, D20  ex., -OH), 4.00 (1H, dd, J =
3.0, 9.2Hz, C-6-H), 4.15 (1H, m, C-5-H), 4.20 (1H, br.s, C-4-H), 4.30 (1H, br.s, C-2-H), 
4.56-4.78 (6H, m, -CH2Ph), 7.21-7.35 (15H, m, -Ph).
13C NMR (CDCI3 , 100MHz)
6 70.28, 70.77, 76.29, 79.80 (4d, inositol ring carbons), 71.14, 71.30, 71.36 (3t, 
-CH2Ph), 127.54, 127.79, 127.85, 127.99, 128.23, 128.27, 128.43, 128.52, 128.72 (9d, 
-Ph), 137.80, 137.98, 138.02 (3s, Cq, -Ph).
MS: m/z (+ve ion FAB, rel. intensity) 91[(C7H7)+, 100%], 451[(M+H)+, 30%], 
901[(2M+H)+, 75%], 923[(2M+Na)+, 60%].
MS: m/z (-ve ion FAB, rel. intensity) 449[(M-H)', 15%], 603[(M+NBA)', 100%].
Accurate mass FAB requires (M+H)+ = 451.2120.
Accurate mass FAB found (M+H)+ = 451.2139.
Analytical data for 122/123:
!H NMR (CDCI3,400MHz)
8 2.51 (1H, br.s, D20  ex., C-5-OH(122) or C-4-OH(123) ), 3.48 (1H, br.s, D20 ex., C-3- 
OH(122) or C-6-OH(123) ), 3.57 (1H, dd, J = 2.7, 9.1Hz, C-4-H(122) or C-5-H(123), 
3.70 (1H, t, J = 4.0Hz, C-2-H (122) or C-l-H(123)), 3.85-3.88 (1H, m, C-l-H(122) or 
C-2-H(123) ), 3.94 (1H, t, J = 4.2Hz, C-6-H(122) or C-3-H(123) ), 4.20 (1H, dt, J = 3.0, 
9.1Hz, C-5-H(122) or C~4-H(123) ), 4.37 (1H, br.s, C-3-H(122) or C-l-H(123) ), 4.45- 
4.80 (8H, m, -CH2Ph), 7.10-7.40 (20H, m, -Ph).
13C NMR (CDCI3, 100MHz)
8 67.92, 67.95, 76.71, 76.81, 77.12, 77.32 (6d, inositol ring carbons), 73.71, 73.86, 
74.39, 74.46 (4t, -CH2Ph), 127.52, 127.65, 127.74, 127.81, 127.85, 127.88, 128.14, 
128.40, 128.76 (9d, -Ph), 137.39, 137.59, 138.09, 138.16 (4s, Cq, -Ph).
MS: m/z (+ve ion FAB, rel. intensity) 91[(C7H7)+, 100%], 541[(M+H)+, 30%], 
563[(M+Na)+, 70%].
MS: m/z (-ve ion FAB, rel. intensity) 540[(M)\ 10%], 693[(M+NBA)\ 100%], 
1079[(2M-H)', 95%], 1233[(2M+NBA)\ 75%].
Accurate mass (FAB)+ requires (M+H)+ = 541.2585.
Accurate mass (FAB)+ found (M+H)+ = 541.2591.
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7.9.7. DL-1.3.6-tri-0-benzvl-<2//(9-inositol 2A5-tris(dibenzvlphosphateV (120)
OH OPO(OBn)2
4| OBn OH 0P0 0^Bn^
51 6Vs\^ 0Bn 51—*V\>0Bn
0H OBn (BnO)2OPO OBn
(119) (120)
To a solution of bis(benzyloxy)-Af,AT-diisopropylaminophosphine (460mg, 1.33mmol) in 
dry dichloromethane (lOmL) was added tetrazole (140mg, 2.0mmol). The mixture was
stirred at room temperature for lOmin. 119 (lOOmg, 0.22mmol) was added and the
mixture left to stir at room temperature for lh. Water (3mL) was added and stirring 
continued for 5min. before the solution was cooled to -78°C. m-CPBA (500mg, 
2.89mmol) was added and the cooling bath was removed. The solution was stirred at 
room temperature for a further 45min. before diluting with dichloromethane (50mL). 
TLC (chloroform-acetone 30:1) showed a single product Rf 0.3. The solution was 
washed with 10% aq. Na2S20 5, sat.aq.NaHC03, sat.aq.NaCl (50mL each), dried over 
MgS04, filtered and concentrated to a clear oil. Purification by column chromatography 
(chloroform-acetone 30:1) afforded the title trisphosphate triester 120, Rf 0.3, (98mg, 
0.08mmol, 36% yield).
*H NMR (CDC13,400MHz)
6 3.61 (1H, t, J = 4.0Hz, C-3-H), 3.75 (1H, dd, J = 4.0,9.8Hz, C-l-H), 4.05 (1H, dt, J =
2.0, 8.3Hz, C-6-H), 4.50-5.07 (19H, m, -CH2Ph and C-4-H), 5.18 (1H, ddd, J = 2.9, 5.9, 
8.8Hz, C-5-H), 5.42 (1H, dt, J = 4.0, 9.3Hz, C-2-H), 7.00-7.45 (45H, m, -Ph).
,3C NMR (CDCI3 , 100MHz)
6 69.01, 69.07, 69.25, 69.31, 69.36, 69.42, 69.56, 69.62, 69.65 (9t, -CH2Ph and 
-OPO(OCH2Ph)2 ), 73.55, 73.88, 73.93, 74.39, 74.45, 75.21 (6d, inositol ring carbons), 
127.13, 127.30, 127.77, 127.81, 127.90, 128.03, 128.12, 128.16, 128.19, 128.27,
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128.36, 128.40, 128.45, 128.51, 128.54 (15d, -Ph and -(-Ph)2), 135.45, 135.53, 135.62,
135.69, 136.13, 136.22,136.26, 136.92, 137.72 (9s, Cq, -Ph and -(-Ph)2.
31P NMR (CDC13,162MHz)
8 -1.52, -1.57, -1.79 (31P-'H-decoupled).
MS: m/z(+ve ionFAB, rel. intensity) 91 [(C7H7)*, 100%], 1231[(M+H)+, 65%].
MS: m/z (-ve ion FAB, rel. intensity) 1139[(M-C7H7)‘, 72%], 1384[(M+NBA+H)', 
30%].
Accurate mass FAB requires (M+H)+ = 1231.3882.
Accurate mass FAB found (M+H)+ = 1231.3876.
7.9.8. DL-fl//o-inositol 1.3.6-trisphosphate. (121)
A solution of 120 (70mg, 56.9pmol) in ethanol-water 4:1 (50mL) was treated with 
hydrogen at room temperature over Pd/C (10%, lOOmg) at a pressure 50psi for 24h. The 
suspension was filtered through Celite to remove the catalyst, TEAB buffer (2mL, pH 
8.0) was added, and the solution concentrated at room temperature under reduced 
pressure. The remaining residue was made up to 200mL with de-ionised water and 
purified by ion-exchange chromatography on Q Sepharose Fast Flow Resin, eluting with 
a gradient of TEAB buffer (0-1M), pH 8.0. The triethylammonium salt of 121 eluted 
between 390-460mM buffer, and was detected and quantified using the Briggs 





'H NMR (CD3OD, 400MHz)
8 4.10-4.20 (2H, m, 2x inositol ring protons), 4.40-4.55 (3H, m, 3x inositol ring 
protons), 4.70 (1H, dt, J = 3.1,9.5Hz, C-3-H).
31P NMR (CDjOD, 162MHz)
8 +0.60 (IP, d, J = 9.3Hz, -CH-OPO-), +0.39 (2P, d, J = 9.3Hz, -CH-OPO-). 
(31P-‘H-coupled).
MS: m/z (+ve ion FAB, rel. intensity) 255(10%), 301 (5%).
MS: m/z (-ve ion FAB, rel. intensity) 97(25%), 250(30%), 419[(M)\ 100%], 515(65%), 
578(42%), 839[(2M+H)\ 75%].
Accurate mass (FAB)' requires (M-H)' = 418.9545.
Accurate mass (FAB)* found (M-H)' = 418.9535.
















The diol 122/123 (lOOmg, 0.18mmol) was phosphitylated and oxidised to the 
bisphosphate 124/125 as described for compound 119. Purification by flash 
chromatography (chloroform-acetone 30:1), Rf 0.5 afforded the bisphosphate 124/125 
(70mg, 66.0jiimol, 36%).
*H NMR (CDCI3 ,400MHz)
5 3.71 (1H, m, C-2-H(124) or C-l-H(125) ), 3.77 (1H, m, C-l-H(124) or C-2-H(125)), 
4.00 (1H, dt, J = 4.0, 10.3Hz, C-4-H(124) or C-5-H(125) ), 4.20 (1H, t, J = 2.9Hz, C-6- 
H(124) or C-3-H(125) ), 4.40-5.11 (17H, m, -CH2Ph and C-5-H(124) or C-4-H(125), 
5.52 (1H, dt, J = 4.0,9.3Hz, C-3-H(124) or C-6-H(125), 6.96-7.36 (40H, m, -Ph).
13C NMR (CDCI3 , 100MHz)
6 69.10, 69.15,69.72,69.34,69.39,69.41,69.50, 69.70, 69.73, 69.81 (lOt, -CH2Ph and - 
OPO(OCH2Ph)2), 72.11, 72.76, 73.45, 76.91, 77.81, 79.00 (6d, inositol ring carbons), 
127.26, 127.29, 127.32, 127.45, 127.49, 127.53, 127.59, 127.63, 127.63, 127.69, 
127.79,127.92,128.11,128.14,128.22,128.63,128.69,128.71 (17d, -Ph and-(Ph)2). 
31P NMR (CDCI3 , 162MHz)
5 -1.12 (IP, m ), -1.67 (IP, sextet, J = 7.3Hz, -CH-O-P-). 31P-1H-decoupled.
MS: (+ve ion FAB, rel. intensity) 91[(C7H7)+, 100%], 181[(2C7H7-H)+, 18%], 
1061[(M+H)+, 80%].
MS: (-ve ion FAB, rel. intensity) 277(100%), 969[(M-C7H7)\ 70%], 1213[(M+NBA)\ 
84%].
Accurate mass FAB requires (M+H)+ = 1061.3794.
Accurate mass FAB found (M+H)+ = 1061.3790.
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A ppendix 1 Notes on Nomenclature
The inositols are cyclohexane-l,2,3,4,5,6-hexols. Individual inositols are differentiated 
by the use of an italicised prefix and hyphen. There are eijght possible diastereoisomeric 
inositols, of which seven are achiral meso compounds possessing an internal symmetry 
plane (scyllo, myo, neo, epi, muco, cis, alio) and the eighth (c/uro-inositol) is chiral. The 
symmetry plane may not be obvious in allo-inositol, in that the individual chair forms are 
chiral, but chair-inversion leads to the enantiomer.
Assignment of Locants (Positonal Numbers)272
Locants are assigned to the carbon atoms of the ring. The substituents above the plane of 
the ring constitute a set, and those below the plane another set. Lowest locants are 
related to one set of substituents according to a sequence of criteria which are applied 
successively until a decision is reached:
(i) to the substituents considered as a numerical series, without regard to configuration;




muco C I S alio
(iii) if the sets are equally numerous and one of them can be denoted by lower numbers, 
to that set;
(iv) to substituents other than unmodified hydroxyl groups;
(v) to the substituent first in alphabetical order;
(vi)—for meso-compounds only—to those positions that lead to an L rather than a D 
designation when the absolute configuation rule is applied to the lowest-numbered 
asymmetric carbon atom (see below).
Note: Lowest numbers are those that, when considered as a single ascending series, 
contain the lower number at the first point of difference, e.g. 1,2,3,6 is lower than
These criteria are generally applicable to cyclitol nomenclature. For unsubstituted 
inositols, only criteria (ii) and (vi) are required. Application of these criteria to 
myo-inositol, for example, gives the numbering shown below, in which the axial hydroxyl 
group is designated as the 2-position.
Derivatives of Inositols
The numberings of the parent inositols are retained for derivatives. Within this 
framework, criteria (iv) and (v) are used to decide between alternatives. These arise 
because (a) in several of the parent inositols (scyllo, n e o , m u c o , cis, chiro) there are 
two or more fully equivalent starting points (related by a Cn symmetry axis) for the 
numbering, that may not be equivalent in the derivatives, and (b) criterion (vi) does not 
apply to chiral derivatives of inositols having a symmetry plane (scyllo, myo, neo, epi, 
muco, cis, alio). The application of criteria (iv) and (v) to a pair of enantiomers gives
Above plane
myo-inositol Below plane
each a pair of mirror-related positions of the same numbering. Typically, one enantiomer 
will be numbered clockwise, the other anti-clockwise.
Absolute Configuration Rule 272
The absolute configuration of each enantiomer is specified by making a vertical Fischer 
projection of the structure with C-l at the top and with C-2 and C-3 on the front edge of 
the ring. The configuration is then designated D if the hydroxyl group of the lowest 
numbered stereogenic centre (or other substituent if no hydroxyl group is present) 
projects to the right, and as L- if it points to the left:
2-
H? O P 032- 6
o 3p o \ - ^ < ^ o h
O P 0 32-
h ? o p o 32- 4 
OH O P O
2-
2 FOhh
1 D-myo-inositol 1,3,4-trisphosphate 1 L-cb/ro-inositol 2,3,5-trisphosphate 
For mvo-inositol derivatives, this rule has the consequence that derivatives numbered 




D -m y o ln s(1 ,3 ,4 )P 3
O3P0,
Ha'
,o p o 3
'OPOi
L-/7?yolns(1.3f4 )P 3
The mere absence of a prefix D, L or DL indicates that the compound has a mesa- 
configuration (e.g. Ins( 1,3,4,6)P4) and should therefore not be omitted. However, see 
below.
Relaxation of Lowest Locant Rule
A more recent recommendation 273 allows that, when necessary, the lowest-locant rule 
may be relaxed, so that a compound that by this rule belongs to the 1L series may be 
given the i d  numbering if this shows the relationships that the author wishes to stress. 
For example, in the metabolic conversion:
lD-myo-inositol 1,3,4-trisphosphate to lD-/wyo-inositol 1,6-bisphosphate,
it may not be obvious that the step is simply a hydrolysis at C-l, but this is immediately
apparent if the conversion is written as:
LD-zwyo-inositol 1,3,4-trisphosphate to lD-wyo-inositol 3,4-bisphosphate. 
lD-myo-inositol 1,3,4-trisphosphate to lD-myo-inositol 1,6-bisphosphate 
The Symbol Ins
The recommendation 273 also allows that Ins should be taken to mean /wyo-inositol with 
the numbering of the i d  configuration unless other prefixes are explicitly added. Thus, 
lD-myo-inositol 1,4,5-trisphosphate may be symbolised as Ins(l,4,5)P3. In this thesis, d -  
and L-prefixes are often used, even when not strictly required, and the lowest locant rule 
applied, so as to emphasise particular stereochemical relationships.
Example
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1 Numbering of parent inositol:
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[ Criteria (ii) and (vi)
2 Allocate lowest numbers to phosphate groups within this framework:
H?  OPO32 6 
2 OH HoX—^ ^ 0 P032 -
OPO,
myo-inositol 1,4,5-trisphosphate
3 Determine absolute configuration:
2 FOH-i
3  WOH > 1 D-myoinositol 1,4,5-trisphosphate
[ Criterion (iv) ]
Criterion (vi) no longer 
applies, and therefore 
direction of numbering 
changes to give lowest 
locants.
(Absolute Configuration Rule
